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“One, remember to look up at the stars and not down at your feet.  
Two, never give up work. Work gives you meaning and purpose and life is 
empty without it.  
Three, if you are lucky enough to find love, remember it is there and don't 
throw it away.”  
 
― Stephen Hawking 
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Abstract - The role of cellular prion protein (PrPC) in the development of 
schwannomas and other Merlin-deficient tumours, Lucy Provenzano 
 
Neurofibromatosis type 2 (NF2) is an inherited, multiple tumour disease caused 
by loss of the tumour suppressor protein, Merlin. There are several tumours 
associated with NF2 including; ependymomas, meningiomas and 
schwannomas. Merlin loss can also occur sporadically in all of these tumours 
and is associated with upregulation of various growth factor receptors and their 
relevant signalling pathways. At present the only treatment options for NF2 are 
surgery or radiosurgery, both of which incur serious morbidity and are unable to 
prevent recurrence of tumours. Either new drug treatments, or re-profiling of 
other drugs already commercially available, are urgently needed to improve 
outcome for NF2 patients.  
Cellular prion protein (PrPC), encoded by PRNP gene, is involved in tumour 
development by altering proliferation, adhesion, and survival in some cancers 
via focal adhesion kinase (FAK) /Src/ NFκB, cyclin D1 and p53 -proteins. Our 
group previously showed a strong elevation of PRNP gene activity in 
schwannoma. I hypothesise that PrPC may contribute to schwannoma 
development.  
To study the role of PrPC in schwannoma development I have used the well-
established in vitro model of schwannoma that comprises primary human 
Schwann and schwannoma cells. I show that PrPC is upregulated in 
schwannoma as well as in Merlin-deficient meningiomas and human malignant 
mesotheliomas. In schwannoma PrPC is released both via exosomes and by α-
cleavage which forms biologically active N- and C-terminal portions of the 
protein. PrPC contributes to pathological proliferation, adhesion and survival of 
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schwannoma cells by activating ERK1/2, PI3K/AKT, cyclin D1, FAK, p53 
pathways via the 37/67kDa non-integrin laminin receptor (LR/37/67kDa) and 
CD44.  
Furthermore, schwannoma cells appear to be intrinsically drug-resistant due to 
upregulation of MDR1 protein p-glycoprotein (p-gp) expression. P-gp 
expression is dependent on PrPC thus, inhibiting PrPC may be a good potential 
new therapeutic option for schwannoma patients, either alone or in combination 
with Sorafenib and p-gp inhibitor Valspodar (PSC833). An inhibitor of 
LR/37/67kDa/PrP interaction, NSC47924, or Bortezomib, a proteasome/NFκB 
inhibitor which has been approved for the treatment of multiple myeloma, could 
also be of beneficial therapeutic effect and is something to investigate in future 
work. 
I conclude that PrPC is an interesting new therapeutic target through its 
involvement with schwannoma patholgenesis and resistance to drug treatments 
PrPC may prove to be a good therapeutic target in other NF2-related tumours 
like meningiomas and schwannomas. 
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1. Introduction 
 
Schwannomas are tumours arising from Schwann cells which occur either 
spontaneously or as part of the hereditary, multi-tumour disease 
Neurofibromatosis Type 2 (NF2). NF2-associated tumours show loss of the 
tumour suppressor protein Merlin, overactivation of key intracellular signalling 
pathways, ultimately leading to pathological increases in proliferation, cell matrix 
adhesion and resistance to apoptosis, characteristics of all tumour cells.  
Recently a large subset of tumours from a multitude of different cancers were 
shown to overexpress cellular prion protein (PrPC), included in this list are 
schwannomas. As well as playing a role in development, myelination and prion 
diseases, PrPC has been shown to activate several of the key signalling 
pathways involved in the development of schwannomas and other tumours. 
Drug resistance is one of the biggest issues facing modern cancer medicine. 
Increased PrPC has also been linked to multi-drug resistance (MDR) of 
chemotherapy agents in several cancer types via interactions with two key 
MDR-associated proteins. Firstly, p-glycoprotein, an efflux transporter which 
pumps drugs out of cells and secondly CD44, a cell surface hyaluronan 
receptor that is widely expressed on the surface of drug-resistant cells. The 
knowledge from the literature makes the study of PrPC in tumours and the 
search for a potential drug-target within schwannomas a very interesting and 
important topic.  
1.1 Neurofibromatosis type 2 and associated tumours 
Neurofibromatosis type 2 (NF2) is an autosomal dominantly inherited tumour 
predisposition syndrome characterised by multiple tumours of the nervous 
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system including bilateral vestibular schwannomas (VS). NF2 is caused by 
biallelic mutations of the NF2 gene located on the long arm of chromosome 22 
at position q12, originally cloned in 1993 (1,2). NF2 codes for the tumour 
suppressor protein Merlin, also known as schwannomin, mutations in which 
lead Merlin to be either absent from or non-functional within cells. 
Schwannomas often present with symptoms including deafness, tinnitus, 
dizziness and balance problems due to compression of the vestibulocochlear 
nerve that transmits sensory signals from the inner ear to the brainstem. As well 
as vestibular schwannomas, patients often also present with multiple other 
nervous low-grade system tumours such as subcutaneous and spinal 
schwannomas, meningiomas and ependymomas which may lead to paralysis, 
seizure, sensory problems and compression of the brainstem which can be fatal. 
Symptoms often begin to become noticeable around adolescence although they 
can appear at any age. The clinical diagnostic criteria for NF2 from the National 
Institute of Health is evidence of bilateral VS, OR a family history of NF2, plus 
any two of the following; schwannoma, meningioma, ependymoma, glioma 
neurofibroma or posterior subscapular lenticular opacities (Reviewed in (3)). In 
the UK, birth incidence of NF2 at present is estimated to be approximately 1 in 
33,000 (4).  
These NF2-associated tumours are mostly benign (WHO Grade I) so therefore 
currently existing treatment options are limited to surgery or radiotherapy,  
depending on tumour site and complexity (5). However, these techniques often 
require invasive procedures (surgery), incur serious morbidity and resection of 
the entire tumour is often incomplete, leading to recurrence. Standard 
chemotherapy is not a viable treatment option as the tumours are too slow-
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growing and therefore do not respond. NF2 patients also often present with a 
huge tumour load, with multiple Merlin-deficient tumours in different locations, 
therefore, for NF2 patients, a systemic treatment option such as a drug would 
be highly beneficial.   
As well as occurring as part of NF2, spontaneous Merlin-loss can also lead to 
the sporadic development of the same types of tumour; 50-60% of 
meningiomas, 70-80% schwannomas and 33% of ependymomas. Unlike NF2-
associated tumours, these spontaneous Merlin-deficient tumours often affect 
patients later in life (40 years+) rather than during adolescence with some 
patients often developing asymptomatic tumours which are only discovered 
during post mortem (6). Other non-brain tumour or NF2-related cancers have 
also been shown to harbour Merlin mutations including human malignant 
mesothelioma, as well as a portion of melanoma, prostate and breast cancers 
(7-10). 
1.1.1.1 Schwannomas and schwannomatosis 
Schwannomas are benign, encapsulated proliferations of the Schwann cells 
that myelinate peripheral nervous system axons and cranial nerves contributing 
to successful nerve conduction. They are slow-growing tumours and, although 
they do not invade the nerve, they are able to compress it. Thus, vestibular 
schwannomas often cause severe complications including tinnitus, deafness, 
balance problems and even death (reviewed in (11)). Peripheral neuropathies 
may also occur and can lead to altered pain and tactile sensitivity or progressive 
distal muscle atrophy (12). Unlike healthy Schwann cells which have a thin, 
elongated, bi-polar structure, schwannomas often show increased cell 
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spreading, membrane ruffling, proliferation, survival and adhesion to the cell 
matrix (Fig. 1, reviewed in (11)). 
Schwannomas are often thought of as the hallmark tumour for NF2 as it was 
originally thought that 100% of schwannoma tumours display loss of functional 
Merlin. Clinical diagnosis of NF2 requires the presence of bilateral vestibular 
schwannomas or unilateral vestibular schwannoma presenting with another 
NF2-related tumour as a minimum criteria (reviewed in (13,14)). This also made 
schwannoma the ideal in vitro model for studying NF2 with results that are able 
to be extrapolated for other Merlin-deficient tumours. However, a recent 
publication has shown that around 30% of non-NF2 (sporadic) schwannomas 
may actually be Merlin-positive (15), completely changing the face of both 
sporadic and NF2-related schwannoma research. 
 
 
Figure 1. Differences in cell shape between Schwann and schwannoma 
cells. 
Schwann cells (NF2+/+) are bipolar with a thin, elongated structure (right panel) 
whereas schwannoma cells (NF2-/-) show cell spreading, loss of contact 
inhibition, membrane ruffling and increased cell matrix adhesion through focal 
adhesions. Image taken  from (11).  
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As well as being part of NF2, schwannomas may also occur in a condition 
known as schwannomatosis. Schwannomatosis shows large clinical overlap 
with NF2 and spontaneous schwannomas but these schwannoma tumours 
arise due to germline mutations in either the SW1/SNF-related, matrix 
associated, actin-dependent regulator of chromatin, subfamily B, member 1 
(SMARCB1) gene, which contributes to ~7% of sporadic schwannomatosis 
cases (16) and ~45% of familial cases (17) or in the leucine zipper-like 
transcriptional regulator-1 (LZTR1) tumour suppressor gene, germline 
mutations of which contributes around 9.8% of sporadic cases and 48% of 
familial cases of schwannomatosis (18). NF2 is, however, also frequently 
inactivated in these tumours (19) suggesting an incredibly complex and highly 
variable genetic pattern. It was originally thought that the schwannomatosis 
occurred entirely spontaneously, but since the familial role of SMARCB1 
muttions had been outlined, studies have also shown that a variant form of the 
NF2 gene may be present in these patients which has around a 50% chance of 
being passed on genetically (20).   
 Schwannomatosis is characterised by the presence of two or more 
schwannomas in the absence of the bilateral vestibular schwannomas that are 
so often seen as part of NF2 (21). Reported incidence of schwannomatosis 
varies, with some reports suggesting that it affects only one person in 1.8 million, 
but the majority of reports suggest an incidence similar to that of NF2 at one in 
40,000  (22). Patients with schwannomatosis often have multiple schwannomas 
on peripheral nerves around the body with symptoms being dictated by the 
location of each tumour, although chronic pain is experienced by most 
schwannomatosis patients.   
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1.1.2 Meningiomas 
Meningiomas are the most common primary brain tumours, affecting around 
five  in every 100,000 individuals (23) and found incidentally in around 2-3% of 
the general population (24). Meningiomas originate from arachnoidal cap cells 
which help form part of the protective meninges that covers the brain and spinal 
cord (25) and are two-fold more common in females compared to males (26) 
with some studies linking tumour size and growth to progesterone levels (27). 
The symptoms associated with these tumours depend entirely on their location 
but common symptoms to all brain tumours include headaches and potential 
seizures. The genetics of meningiomas is a lot more complicated than other 
tumours associated with NF2. The majority of meningiomas are spontaneous 
although only a small proportion are associated with NF2 (~15%), around 50-60% 
of all spontaneous meningiomas and all NF2-associated meningiomas have 
mutations in the NF2 gene that leads to its inactivation (28). Meningiomas not 
associated with NF2 have mutations involving one of the following genes; KLF4, 
AKT1, SMO, TRAF7, Plk3CA, POLR2A or PRKAR1A (29). Each of these 
different mutations activates different signalling pathways associated with 
tumour development; SMO activates sonic hedgehog signalling and is seen in 
around 5% of meningioma cases, TRAF7 is an E3 ubiquitin ligase and TNF 
receptor associated factor 7 whose signalling affects nuclear factor κappa B 
(NFκB activation/inactivation), KLF4 mutations affect pluripotency and AKT1 
mutations alter signalling through phosphatidylinositol-3 kinase (PI3K) 
(reviewed in (29)), PI3CA, the catalytic subunit of PI3K, is able to auto-activate 
PI3K and its downstream signalling pathways (30), POLR2A is a DNA 
polymerase and PRKAR1A codes for the protein kinase cAMP-dependent 
regulatory subunit 1 (reviewd in (29)). These mutations occur mutually 
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exclusively from NF2 mutations and it is thought that there may still be more 
mutations in other genes still to be discovered as a cause of meningiomas.  
Currently there are 15 distinct histopathological subtypes of meningiomas that 
span three WHO gradings from benign, atypical to malignant. Approximately 80-
90% of meningiomas are WHO type I and benign (reviewed in (31)). They are 
the most diverse class of NF2-associated tumours and are often difficult to 
accurately diagnose without histopathological tools. To go into the various 
meningioma subtypes and their properties is beyond the scope of this thesis but 
a basic overview can be found in Table 1 which shows the various 
histopathological subtypes of meningioma and their associated grade. As with 
schwannomas, the primary treatment option for the majority of meningiomas is 
surgery or radiosurgery. 
Table 1. World Health Organisation (WHO) meningioma classifications 
WHO Grade I - Benign WHO Grade II - 
Atypical 
WHO Grade III - 
Malignant 
Meningiothelial Choroid Papillary 
Fibrous Clear cell Rhabdoid 
Transitional (mixed) Atypical Anaplastic 
Psammomatous   
Angiomatous   
Microcystic   
Secretory   
Lymphoplasmacyte-rich   
Metaplastic   
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Although this current grading system provides prognostic value, it is based 
solely on histology and ignores biomarkers. A recent comprehensive 
characterisation of meningiomas using DNA methylation status (32) has been 
shown to produce more homologous groups of meningiomas compared to the 
WHO grading system above and appear to help stratify patients for more 
personalised treatments in the future. Furthermore, the presence of TERT 
promoter mutations in these tumours has been associated with a faster 
progression rate (32) and therefore would be useful to combine with both 
histological and genetic data in order to provide a fully comprehensive 
classification of meningioma subtypes and provide more personalised therapies 
in the future.   
1.1.3 Ependymomas and other NF2-associated tumours 
Ependymomas are much rarer than either meningiomas or schwannomas, 
accounting for only 2-5% of adult intracranial neoplasms [10]. Although 
originally, as their name suggests, ependymomas were thought to arise from 
the ependymal cells lining the spinal canal, more recent work has postulated 
that they are in fact glial in origin, arising from radial glial cells (reviewed in (33)).  
Approximately 33% of ependymomas show mutations in the NF2 gene leading 
to loss of Merlin expression (11). Merlin loss appears to be more common in 
spinal ependymomas although mutations in genes other than NF2 also cause a 
significant proportion of ependymomas, including some genes coding for other 
members of the 4.1 superfamily of proteins (34).  
There are nine different ependymoma subgroups that have been described 
recently based on DNA methylation profiling and tumour location (35). This 
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method appears to be far superior to histological subtyping for assessing and 
stratifying risk for ependymoma development and grade in patients. 
1.2. NF2 gene and its protein product, Merlin 
1.2.1 NF2 gene structure, location and mutations 
The NF2 gene is 110KB in length and consists of 17 coding exons, although 
only 15 of which have been identified to harbour pathological mutations (2,36). 
Transcription of the NF2 gene can be initiated from several start points creating 
up to eight alternatively spliced isoforms, two of which are predominantly 
expressed; isoform II, the full-length gene product and isoform I which lacks 
exon 16 (37). It is thought that the diversity of the NF2 isoforms could be down 
to the presence of multiple polyadenylation sites (37).  
Normally a defect in one allele of the NF2 gene is either inherited as a germline 
mutation or occurs sporadically, before a spontaneous mutation in the other 
allele leads to the development of NF2. Approximately 50% of NF2 patients 
have de novo, spontaneous NF2 germline mutations and around one third of 
these are mosaic for the underlying disease-causing mutation, enabling 
production of the disease phenotype. The most common mutations are 
truncating mutations (including nonsense and frameshift mutations) which also 
happen to cause the most severe disease. The most frequent and well 
described NF2 mutation is a single nucleotide polymorphism (SNP) C>T that 
leads to a nonsense mutation. However, single and/or multiple exon deletions 
within the NF2 gene have also been documented (reviewed in (3)). 
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1.2.2 Merlin as a tumour suppressor protein 
Merlin, as previously mentioned, is the tumour suppressor protein product of the 
NF2 gene. It is a 586 amino acid (aa), Moesin Ezrin Radixin-like (ERM) protein 
that belongs to the superfamily of band 4.1 proteins (1,2). The ERM family 
proteins link the cytoskeleton to the cell membrane via integral membrane 
proteins or indirectly via membrane-associated proteins (38). Merlin consists of 
a C-terminal domain which lacks the canonical actin-binding motif of other ERM 
proteins, a coil segment and an N-terminal FERM domain that contains an 
actin-binding domain through which Merlin is able to interact with the 
cytoskeleton (39). 
 
 
Figure 2. Merlin loss causes activation of several signalling pathways. 
Merlin acts as a tumour suppressor by preventing activation of the 
Ras/Raf/MEK, PI3K/AKT and Rac/PAK pathways, regulating cell-cell contact at 
adherens junctions, regulating growth factor receptor, CD44 and integrin 
expression (A). Loss of Merlin causes dysregulation of this, leading to altered 
cell adhesion properties, increased proliferation and survival (B). Image adapted 
from Hanemann et.al. (11).  
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Merlin, when present, exists in one of two states; either an open state whereby 
it is able to control growth or a less-active, more-closed state. Conversion 
between these two states is mediated by p21-activated kinase (PAK). PAK is 
activated by integrin-dependent cell matrix adhesion and receptor tyrosine 
kinase activation and phosphorylates the C-terminus of Merlin at Serine 518 
(S518), causing an increase in the C-terminal-FERM interaction, maintaining 
the protein in a more closed conformation and decreasing its ability to control 
growth (40).  
There appears to be an auto-regulatory loop between Merlin and PAK as Merlin 
itself is able to inhibit activation of PAK via its binding to the PAK protein binding 
domain and also by inhibiting PAK recruitment to focal adhesions. Concurrent 
with this theory, loss of Merlin has been shown to lead to hyperactivation of 
PAK (41). De-phosphorylation of Merlin occurs via myosin phosphatase 
MYPT1-PP1δ (42), promoting growth inhibition when activated by cell-cell 
adhesion at high cell density or upon CD44-hyaluronan interaction (43,44). 
Merlin loss has been observed in a proportion of several different tumours 
including mesothelioma, glioblastoma multiforme, melanoma, breast, colorectal, 
hepatic, and prostate cancers. Merlin loss promotes oncogenic RAS-induced 
tumour formation via YAP-dependent transactivation of RAS proteins (reviewed 
in (15,45)).  
Merlin acts as a tumour suppressor through its roles in several key pathways, 
firstly via its role as a cytoskeletal linker. Although Merlin lacks the actin-binding 
site that most ERM proteins have, it does have its own unique, N-terminal actin 
binding motif, meaning Merlin still interacts with actin although in a weaker and 
more dynamic way than other ERM proteins (46,47). Merlin indirectly links F-
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actin with transmembrane receptors and effectors including receptor tyrosine 
kinases, small GTPases, mammalian target of rapamycin (mTOR), 
phosphatidylinositol 3-kinase (PI3K)/AKT pathway and HIPPO pathway, 
enabling it to act as a tumour suppressor protein by controlling cell proliferation 
and survival (48) (Fig. 2). Merlin has been shown to regulate activity of ERK1/2 
and c-Jun-NH2-kinase (JNK) as Merlin-loss leads to a maintained elevated 
activation via of both ERK1/2 and JNK pathways, providing evidence of Merlin’s 
role both as an effector of Rac and a sensor of Rac signalling (49) (Fig. 2).  
A major tumour suppressor role of Merlin is thought to involve the role of 
CRL4(DCAF1), a nuclear cullin-ring E3 ubiquitin ligase. The more-open, growth 
inhibitory form of Merlin translocates to the nucleus where it binds and 
suppresses activity of the E3 ubiquitin ligase CRL4(DCAF1) (50), preventing 
excessive growth and proliferation of cells (51).  
Research using Drosophila Melanogaster have shown that Merlin functions 
together with other band 4.1 proteins to block the endocytosis of several 
signalling receptors, including receptor tyrosine kinases, causing their 
accumulation at the plasma membrane (52), this was also demonstrated in 
mammalian cells (reviewed in (53)). Merlin is activated to suppress cell 
proliferation and growth upon formation of cell-cell contacts in a process known 
as ‘contact inhibition’, loss of which is a hallmark of invasive cancers (54). When 
performing normally upon contact inhibition Merlin down-regulates several key 
growth factor receptors (55), suppresses Rac recruitment to cell matrix 
adhesion points at the cell membrane to inhibit mitogenesis (56) (Fig. 2).  
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1.2.3 Merlin and integrin-related signalling 
An interaction between Merlin and integrin β1 was first demonstrated in 
Schwann cells in 1998 (57). Loss of Merlin is associated with an upregulation in 
the expression of integrins, including integrin β1 at both the protein (58) and 
mRNA level (59). Integrin activation and increased cell-matrix adhesion has 
been shown to activate small membrane GTPases Rac1 and Cdc42 which, in 
turn, activate PAK. As well as its role in phosphorylating Merlin, PAK is also 
able to activate stress protein kinases SAPK and JNK, which translocates to the 
nucleus and leads to alterations in inflammation, proliferation and cell survival 
(reviewed in (60)) and regulates activity of the p53 tumour suppressor protein 
and transcription factor pathway (61). Thus, Merlin loss in schwannoma has 
been shown to hyperactivate this integrin/Rac/PAK/JNK axis and suppress p53 
levels (62-64).  
As well as activating the small molecule GTPases and the Rac/PAK/JNK axis, 
integrin activation also regulates focal adhesion kinase (FAK). FAK is a non-
integrin receptor tyrosine kinase with key roles in adhesion and migration (65). 
FAK has been shown to have key roles in cancer initiation and progression and 
is upregulated in several cancer forms and in schwannoma where it signals via 
both PI3K/AKT and Raf/MEK/ERK pathways to promote schwannoma 
proliferation, adhesion and survival (66-68). FAK is commonly phosphorylated 
at two distinct tyrosine phosphorylation sites; the autophosphorylation tyrosine 
Y397 site and Src phosphorylation site tyrosine Y925, activation at both of 
which are increased in schwannoma compared to Schwann cells (67,68). In 
schwannoma cells FAK is able to localise to the nucleus, suggesting that it may 
be able to regulate cell proliferation without requiring the presence of Merlin (68).  
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Integrins also promote activation of cyclin D1, a cell cycle marker protein 
important in the transition from G1 to S phase, that is upregulated in ~50% of 
human breast cancers (69), marking a potentiation of the cell cycle and a 
subsequent increase in proliferation. Although the most well-known role for 
cyclins is in cell cycle progression, they also play a role in migration, metastasis 
and gene transcription (69). Cyclin D1 expression control via integrins appears 
to occur via mTOR, activation of which has been linked to increased cell 
survival and resistance to apoptosis (70). mTOR expression is Merlin-
dependent in both meningioma and schwannoma cells (71).    
1.2.4 Receptor tyrosine kinase signalling and Merlin 
Merlin normally functions to promote clearance and recycling of growth factor 
receptors and other receptor tyrosine kinases (RTKs) from the cell surface, 
regulating receptor accumulation and signalling in Schwann and schwannoma 
cells, inhibiting the export of epidermal growth factor receptor (EGFR) and other 
RTKs to the plasma membrane (55). It has also been suggested that Merlin 
negatively regulates the transcription and thus the expression of RTKs via 
CRL4DCAF1 (72). Unsurprisingly,  loss of Merlin both in these cells and in other 
cell types has been shown to lead to an accumulation of EGFR, (73), ErbB2, 
ErbB3, insulin-like growth factor receptor (IGF1-R), vascular endothelial growth 
factor receptor (VEGFR) and platelet-derived growth factor receptor β 
(PDGFRβ) (55). Merlin also functions independently of the actual RTKs at the 
plasma membrane to regulate growth signals by inhibiting activation of their 
downstream signalling molecules such as Ras and Rac (74). All of these 
mechanisms contribute to Merlin’s function as a tumour suppressor protein, 
regulating growth factor signalling.  
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1.3. Cellular prion protein (PrPC) 
In 2006, a gene microarray comparison between schwannoma and healthy 
Schwann cells highlighted a significantly increase in expression in schwannoma 
compared to Schwann cells of PRNP, the gene located at 20p13 that codes for 
cellular prion protein (PrPC) (59,75). 
1.3.1 Prion protein and its role in prion diseases 
Prion protein (PrP) is a membrane-bound glycoprotein most commonly known 
for its involvement in the development of prion diseases such as Creutzfeldt- 
Jacob disease (CJD), Gerstmann-Sträussler-Scheinker disease (76), kuru and 
fatal familial insomnia (FFI (77)). Prion diseases, also known as transmissible 
spongiform encephalopathies, are a family of rare, progressive 
neurodegenerative disorders characterised by fast-onset dementia (as little as 
six weeks) although, for a small subset of patients, symptoms can appear over 
a number of years. Unlike a number of other neurodegenerative disorders such 
as Alzheimer’s disease or Parkinson’s disease, prion diseases are highly 
heterogeneous and affect both humans and animals. These disease are among 
a small subset of recently-defined proteinopathies - diseases caused by 
proteinaceous particles that contain amino acids but not nucleic acids, RNA or 
DNA (78). Prion diseases can occur sporadically through point mutations, be 
acquired (external inoculation) or be inherited. For example, a familial form of 
CJD accounts for 10-15% of all human prion diseases and is associated with 
around 40 different missense mutations in the PRNP gene (reviewed in (79)).  
In healthy adults, the normal, cellular form of prion protein (PrPC) is particularly 
highly expressed in the nervous system in both neurons and glial cells, although 
levels of PrPC in the peripheral nervous system (PNS) are lower than in the 
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CNS (reviewed in (80)). In the CNS PrPC is thought to play a role in 
neuroprotection, signalling functions and regulation of circadian rhythm (81). 
This normal cellular, protease-sensitive form of PrPC that is seen throughout the 
CNS in healthy patients is not the same form of PrPC that causes prion 
diseases (82).  In prion disease conformational change of PrPC to PrPSc occurs, 
either via infection with the disease-associated scrapie form of the protein 
(PrPSc) or through conversion of PrPC to PrPSc, which can arise either by a 
dominant point mutation in the PRNP gene, creating PrPC that is more readily 
converted to PrPSc, or sporadically as a result of a random event that causes a 
PrPC to PrPSc conversion (83). PrPres is another term used to describe misfolded 
PrP that is resistant to degradation by proteinase K, although this encompasses 
PrPSc form of the protein it has been suggested that not all PrPres are infectious, 
therefore producing a confusing gap in the nomenclature.  
Although the 253 amino acid primary amino acid structure of PrPC and PrPSc/ 
PrPres are identical, the secondary structure of PrPC is mainly made up of alpha 
helices whereas for PrPSc it is beta sheets (84). It is this increased proportion of 
beta sheets that makes PrP more stable and form aggregates which, in turn are 
capable of forming peptide aggregates known as amyloid fibrils. Parts of these 
fibrils are thought to be able to break off and act as a template for the 
recruitment of other PrPC molecules which can be converted to PrPSc (85). The 
exact mechanism of conversion of PrPC to PrPSc through inoculation is not fully 
understood but there are two main competing theories as to how prion 
propagation occurs. Firstly Prusiner (86) describes the template-directed 
replication of prions in which PrPSc induces the conformation change in PrPC, 
secondly Lansbury and Caughey (87) suggest that prion propagation occurs 
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when an oligomeric form of PrP acts as a nucleus or seed from which 
polymerisation of PrPC occurs, as opposed to a single-molecule conformational 
change. This theory may help to explain why not all exposed cells take up PrPSc 
and become infected (88). 
To further confuse things, PrPC has now been shown to exist in healthy human 
brains in insoluble dimeric and oligomeric forms (termed insoluble PrPC or iPrPC) 
as well as in the traditional monomeric form and accounts for between 5-25% of 
the PrPC expressed in the CNS. At high levels these proteins, like PrPSc, can 
also be resistant to degradation by proteinase K and iPrPC associates with gene 
5 protein (g5p) and sodium phosphotungstate, something that PrPSc but not 
monomeric PrPC does. This suggests that these aggregates may function as 
dormant ‘silent prions’ which could be activated and lead to prion diseases (89).   
1.3.2 Structure and regulation of PRNP  
The PRNP gene that codes for PrPC has been mapped to the short arm of 
chromosome 20 in position p12 in humans (75).  PRNP comprises a 134bp 
untranslated exon 1, followed by a 12,696bp intron 1 and a 2.35kb exon 2 which 
contains the entire 759bp open reading frame (ORF) that encodes the 253 
amino acid (aa) PrPC protein (90).  A novel 99bp ‘exon-like’ sequence was also 
found beginning 2303bp downstream of exon I (91).  
PRNP has previously been described as a “housekeeping gene” due to the 
absence of a TATA box, presence of CpG islands and the presence of several 
Sp1 binding sites (92). However, the fact that transcription of PRNP depends on 
chromatin structure (93) and that the promoter region contains binding sites for 
several transcription factors that are yet to be identified (94), suggests that 
PRNP expression is likely to depend on several cellular factors. Other aspects 
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of the PRNP gene also appear to regulate promoter activity; exon II has been 
shown to play a role in regulation of PrPC expression and intron I is required for 
full activity of the bovine PRNP promoter (95). Regulation of PrPC expression is 
complex and appears to be able to be modified in several different ways.  
As well as PRNP, there are three other members of the prion protein gene 
family that include PRND, PRNT and SPRN. Two of these genes, PRND and 
PRNT, share the same chromosome 20 gene locus as PRNP but are located 
further downstream, SPRN, however is located completely separately on 
chromosome 10 (Figure 4). A brief overview of the structure and function of 
these proteins can be found in the section entitled ‘Other members of the prion 
protein family’ but to fully and extensively review these proteins would be 
outside of the scope of this thesis.  
1.3.3 PrPC Structure, biogenesis and degradation 
1.3.3.1 PrPC biosynthesis and cleavage 
The mammalian PRNP gene encodes a protein approximately 250aa in length 
that contains several distinct domains; an N-terminal signalling peptide, 5 
proline-rich octapeptide repeats, a central, highly-conserved hydrophobic region 
and a C-terminal hydrophobic region which is the site of glycosylation  and to 
which the glycosylphosphotidylinositol (GPI) anchor is attached (reviewed in 
(96), see Fig. 3). PrPC is initially synthesised in the nucleus as a pre-pro-PrP 
which contains a leader peptide of 22aa which resides at the N-terminal and a 
C-terminal GPI anchor signalling peptide (termed GPI-PSS) (reviewed in (97)).  
The N-terminal lead peptide translocates the PrP into the endoplasmic reticulum 
(ER) where it is co-translationally transported and synthesised. In the ER, PrPC 
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associates with lipid rafts and undergoes cleavage of the N-terminal leader 
signal peptide to generate pro-PrP. PrP also undergoes glycosylation with the 
addition of two oligosaccharides (discussed further in chapter 1.3.3.3), 
formation of a single disulphide bond between two cysteine molecules within the 
C-terminal (reviewed in (98)).  
Healthy pro-PrP is then trafficked to the Golgi apparatus where it undergoes 
cleavage of the GPI signal molecule (GPI-PSS) and addition of the GPI anchor, 
modification of the oligosaccharide attachments and addition of a sialic acid 
molecule to both the carbohydrate attachments and to the core of the GPI 
anchor, the latter making the PrPC GPI anchor unusual compared to other 
proteins (99). The majority of mature PrPC is then trafficked either directly or 
within endosomes (reviewed in (100)) to the cholesterol-rich domains of the 
outer leaflet of the cell membrane, where it binds via the GPI anchor. PrPC does 
not remain on the cell surface for very long, undergoing recycling between the 
plasma membrane and endocytic compartment of cells (101). 
 In neuroblastoma cells in culture, PrPC molecules take approximately 60 
minutes to cycle from the cell membrane through the endosomes and back to 
the membrane again, each time this occurs, 1-5% of the PrPC undergoes α-
proteolytic cleavage directly or indirectly by ADAM8,  ADAM10, ADAM17 and 
ADAM9 9 (reviewed in (102), see Fig. 3), within a segment of 24 hydrophobic 
amino acids between residues 110/111 or 111/112 (103). This α-cleavage of 
PrPC, also known as ‘normal’ PrPC cleavage (104) and can be stimulated by 
agonist of the protein kinase C pathway (105) and forms a  bioactive, C1 
fragment which has been linked to apoptotic signalling (106), that has been 
shown to accumulate at the plasma membrane via its GPI anchor (103).   
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Figure 3. PrPC can undergo α or β-cleavage and be shed from the cell 
surface by the ADAM family of proteases. 
The post-translationally modified PrPC (B) undergoes two significant types of 
cleavage at the cell membrane. Firstly, the whole PrP molecule can be shed 
completely via cleavage of the GPI anchor (C), this can occur via ADAM’s 9 and 
10 or, in vitro, with the use of phosphatidylinositol phospholipase C (PIPLC). 
Alternatively, PrPC can undergo α-cleavage which cleaves PrP molecule just 
after the octapeptide repeat region and produces two PrPC fragments (Ai and 
Aii); N-terminal fragment which contains the octapeptide repeat region and a C-
terminal fragment that contains the hydrophobic segments, glycosylation sites 
and GPI anchor. PrPC can also undergo β-cleavage which occurs just 
downstream of alpha cleavage. β-cleavage of PrPC (not shown) is less common 
and little is known about the mechanisms surrounding it.  
 
Α-cleavage also produces a 10kDa N-terminal fragment (N1) of PrP that spans 
amino acids 23-110, which may serve as a biologically active ligand with a 
neuroprotective function (107). It has been demonstrated that it is within this 
endocytic recycling pathway that PrPSc acquires its protease resistance as the 
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region cleaved, between aa109-122, is thought to be involved in key 
conformational changes underlying the conversion of PrPC to PrPSc (108).   
There is debate as to whether this α-cleavage occurs entirely within the 
endosomes (96) or at the plasma membrane. Initially it was hypothesised that α 
cleavage of PrPC occurred within lipid rafts residing in the plasma membrane 
(109) but more recent data suggests that α-cleavage in fact occurs within the 
late compartment of the endocytic pathway (110). Other research suggests that 
cleavage to produce C1 likely occurs in an acidified environment such as within 
lysosomes as α-cleavage can be blocked by inhibitors of lysosomal degradation 
(111). 
PrPC can also be cleaved by an event mediated by reactive oxygen species 
(ROS) known as β-cleavage (not shown in Fig. 3). This cleavage event occurs 
adjacent to the octapeptide repeat region to produce a 19kDa GPI-anchored C-
terminal portion termed C2 and a 7kDa N-terminal fragment known as N2 ((112), 
reviewed in (110).) and has been shown to be essential in the resistance of 
neuroblastoma cells against oxidative stress (113) thus making β-cleavage a 
potentially important stage of PrPC processing in cancer cells. 
1.3.3.2 GPI anchoring and shedding of PrPC 
A portion of PrPC is localised and tethered to the cell membrane via a C-
terminal glycosylphosphatidylinositol (GPI) anchor (114). The GPI anchor of 
PrPC has been shown to be highly flexible and is key to maintaining the protein 
a set distance (9-13 Ǻngström (Ǻ)) from the membrane surface (115). Although 
a large portion of the membrane-bound PrPC undergoes endocytic recycling, 
some of the membrane bound PrPC also undergoes a second cleavage within 
the GPI anchor by a cell surface phospholipase (116) (Fig. 3). This cleavage 
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releases an almost full-length PrPC into the extracellular medium in a process 
known as ‘shedding’. Shed PrPC has been demonstrated in supernatant of 
cultured cells as well as in human cerebrospinal fluid (117-119).  A disintegrin 
and metalloprotease-containing protein (ADAM)s 9 and 10 have been 
demonstrated as functionally relevant enzymes in PrPC shedding in vivo (120). 
ADAMs 9 and 10 cleave between residues Gly228 and Arg229 (121), both of 
the full length PrP peptide and the C1 fragment produced by α-cleavage (122). 
This study supports the idea that metalloproteases, such as members of the 
ADAM family, cleave membrane bound PrPC as metalloprotease inhibitors were 
able to reduce shedding of PrPC.  Phosphatidylinositol phospholipase C (PIPLC) 
has been shown to evoke PrPC shedding in vitro (117). In some studies, full-
length soluble PrPC released from cells which is then able to be converted to 
PrPSc has been proposed as one of the mechanisms responsible for the 
intercellular transfer of prions and thus the dissemination of prion diseases 
(119). However, others have reported that PrPC shedding is concurrent with a 
reduction in PrPSc formation (123) thus the physiological consequences of PrPC 
shedding from the cell membrane remain elusive.  
The importance of the GPI anchor can further be questioned as studies in 
human neurons show that anchorless PrPC is present in small quantities in 
healthy human brains (124). In healthy brains it is thought that there is still a 
signalling role for GPI-anchorless PrPC as studies have shown that PrPC does 
not require the GPI membrane anchor in order to protect cells against apoptosis 
(125,126). 
The fact that PrPC is cycled to and from the membrane and undergoes 
endocytosis via clathrin-coated pits suggests that one function of PrPC is to 
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serve as a receptor for one or more extracellular ligands. However, as a GPI-
anchored membrane protein PrPC lacks a cytoplasmic domain that is able to 
directly interact with signalling adapter proteins and clathrin (98)  it is, as most 
GPI-anchored molecules, excluded from coated pits and instead internalised via 
caveolae (127). The proposed mechanism by which the GPI-anchored PrPC 
may still be internalised by clathrin coated pits is via the several PrPC interacting 
partners or putative PrPC ‘receptors’ able to recruit clathrin which have been 
hypothesised, including 37/67kDa non-integrin laminin receptor (LR/37/67kDa) 
(128), stress-inducible protein 1 (STI-1) (129) and copper ions (130). 
1.3.3.3 PrPC glycosylation  
Glycosylation is a post-transcriptional modification process for many proteins. It 
has many different important functions within cells; regulating protein-protein 
interactions as the sugars can act as ligands for various receptors, regulating 
attachments (131) and even used to monitor protein folding and affect the 
solubility of proteins  (132) making the glycosylation process key for determining 
the activity of certain proteins. PrPC is a sialo-glycoprotein which undergoes 
glycosylation in the Golgi apparatus by the addition of N-linked high-mannose-
type oligosaccharide chains to a portion of the C-terminal of the protein, as well 
as undergoing glycosylation of the GPI anchor, an event that is uncommon in 
mammalian GPI anchors (133). N-glycans have been shown to play a critical 
role in quality control and folding of proteins in the endoplasmic reticulum, 
particularly in the unfolded protein response (UPR) and ER associated 
proteasomal degradation (ERAD) (134). The attachment of these N-linked 
sugar chains also modulates the function of cell surface proteins involved in 
migration, adhesion and myelination, all important in schwannoma development, 
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they also affect transport of proteins through the Golgi apparatus and sorting of 
secreted proteins such as prions (reviewed in (135). This makes glycosylation 
of PrPC interesting to look at with regards to schwannoma development.  
To the newly synthesised PrPC, oligosaccharide chains are added at two C-
terminal asparagine residues at Asn181IleThr, located in one of the α-helix 
regions and Asn197PheThr, located in a loop region of PrPC in humans, during 
post translational modification in the ER and before addition of the GPI anchor 
(115,136), leading to the ability of three glycoisoforms of PrPC to be produced – 
di-, mono- and un-glycosylated. It appears that glycosylation of PrPC is 
dependent on membrane topology and tethering, as only PrP with a C-terminus 
anchored by a GPI anchor or transmembrane section and not soluble PrP was 
glycosylated in the ER, even though both proteins have a structurally identical 
C-terminal (137). More than 50 sugar chains have been identified as able to 
glycosylate PrP (138) and some studies have shown a shift in the proportion of 
glycans between the normal cellular prion protein and PrPSc; with PrPSc 
containing more complex tri- and tetra-antennary glycans compared to PrPC 
(139). Upon translocation to the Golgi apparatus, the N-linked oligosaccharides 
undergo further processing into more complex sugar types, which have had a 
sialic acid residue attached and become resistant to digestion by 
endoglycosidase H (140).  
Glycosylation appears to be an important step in the formation of the protease 
resistant forms of PrP too; inhibiting glycosylation of PrPC using tunicamycin 
has been shown to predispose PrPC to convert to PrPSc and made PrP more 
resistant to protease degradation (141,142). Non-glycosylated 26kDa PrP has 
been detected in N2a neuroblastoma cells expressing PrPC which may be the 
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result of a failure to N-glycosylate the protein in the first place or suggests that 
the PrPC has been deglycosylated in the cytosol of the cells by N-glycosidase 
(143). 
1.3.3.4 Different topological isoforms of PrP- CtmPrP NtmPrP 
As well as the cleaved C1/2 and N1/2 PrPC fragments generated by 
endoproteolytic α- and  β-cleavage (described above), several other topological 
isoforms of PrPC have also been described that correspond to specific secreted 
and transmembrane forms of the prion protein SecPrP, CtmPrP and NtmPrP (144). 
Upon synthesis, PrPC is translocated, via the N-terminal signal sequence, and 
inserts itself into the ER membrane in order to be able to undergo the first stage 
of post-translational modifications. Is has been shown, however, that the C-
terminal hydrophobic region (TM2) can also function as a signal sequence, 
yielding a C-terminal transmembrane form of the prion protein (CtmPrP) of which 
the C-terminus is directed towards the ER lumen (145)). CtmPrP spans the 
membrane once via the hydrophobic region between residues 111 and 134 and 
undergoes the addition of the GPI anchor and N-glycosylation in the same way 
as full length PrPC (137). CtmPrP is able to accumulate in the ER and can 
contribute to neurotoxicity and cell death via mechanisms involving ER stress 
(146,147). In fact, it has been suggested that CtmPrP is the main effector of 
neurodegeneration in prion diseases and that PrPSc only functions to increase 
levels of CtmPrP although this is still not widely accepted (148). 
The other topological isoform NtmPrP which also traverses the cell membrane 
between residues 111-134 has the N-terminal directed towards the ER lumen 
(Reviewed in (144)). NtmPrP lacks the GPI anchor and N-linked glycosylatation 
seen in both PrPC and CtmPrP (137), it has been shown to have no role in any of 
 
39 | P a g e  
 
the prion diseases and has only been demonstrated in transgenic animals and 
cell culture models (reviewed in (144).  Finally, a third topological isoform of 
secreted PrP (SecPrP), not associated with the lipid bilayer, is the predominant 
form of PrPC produced. From the lumen of the ER SecPrP can then be 
translocated to the secretory pathway where it is able to travel via the Golgi 
apparatus and endosomal vesicles (149). It is suggested that relative 
proportions of the three topological isoforms of PrP are determined by currently 
unknown accessory proteins which are present during translation or a region of 
nine hydrophilic acids adjacent to the transmembrane domain of PrP (reviewed 
in (150)), although more work is required to understand the precise mechanism 
by which the PrP transmembrane variants arise. 
1.3.3.5 PrPC degradation  
During PrPC synthesis in the ER, several forms of misfolded or mutated PrP are 
recognised, ubiquitinated and sent for ER-associated protein degradation 
(ERAD). This has been demonstrated in cell cultures where proteasome 
inhibitors such as MG132 have been shown to increase levels of PrPC. It was 
initially thought that ERAD degradation was specific to PrPSc although further 
research has shown that approximately 10% of all newly generated PrPC is 
diverted to degradation via ERAD (151) . 
There is evidence of PrP degradation by a different pathway – lysosomal 
degradation. Lysosomal degradation is a degradation process carried out by 
acidified spherical vesicles known as lysosomes that contain >60 different 
hydrolytic enzymes, as well as maintaining a low pH, to break down their 
contents. Lysosomal degradation can occur alone or via autophagy which 
initially involves the material to be degraded being engulfed in an 
 
40 | P a g e  
 
autophagasome before being targeted to lysosomes. A lot of the evidence that 
PrP is degraded via lysosomal degradation comes from studies looking into the 
abnormal form of PrP - PrPSc (152-154), suggesting at the very least that 
lysosomal degradation is a key pathway via which levels of PrPSc are regulated 
in infected brains.  
 
Knockdown and pharmacological blockade of key components of the autophagy 
pathway, including Rapamycin, an inhibitor of the mTOR pathway, increase 
PrPSc levels reviewed in (155), whereas chemical stimulation of autophagy in 
infected cells has been shown to decrease levels of PrPSc (156). One rapalogue 
(an analogue of Rapamycin known as Tacrolimus) was even shown to decrease 
levels of PrPC in an anti-prion screen (157). This suggests that autophagy is  
the main route by which PrPSc and, potentially also PrPC, are targeted and 
transported for lysosomal degradation in chronically infected cells (156). 
Although, other data has shown that PrPSc can also be a substrate within the 
Golgi quality control (QC) pathway - a pathway involved in non-autophagy 
dependent lysosomal degradation (155). This points to the fact that lysosomal 
degradation of PrPSc is a key process in regulating PrPSc levels but this process 
can occur either with, or independently of, autophagy. Thus, two major 
clearance pathways – both proteasomal and lysosomal degradation- appear to 
be involved in PrP clearance, this complicated any findings that can be drawn 
from PrP intracellular levels, making it impossible to deduce information about 
degradation rate of PrP solely based on intracellular levels but making both 
proteasomal and lysosomal degradation important therapeutic targets to reduce 
PrP expression, both of PrPSc and PrPC.  
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1.4 Other members of the prion protein family 
1.4.1 PRND and doppel (Dpl) 
PRND was the first discovered of three other genes related to PRNP. Discovery 
of the PRND gene was rather indirect. Upon creation of Npu and Zrch 1 
PRNP0/0 mice which are homologous for the inactivated PRNP gene due to 
disruptions in the open reading frame (ORF) of PRNP, animals to show no overt 
phenotypical differences to their wild-type counterparts aside from a slight 
alteration in circadian rhythm. Upon generation of the next generation of 
PRNP0/0 mice (Ngs and Zrch II), not only was the ORF disrupted but also the 
flanking regions, including the splice acceptor site of the third exon (reviewed in 
(158)). This unexpectedly allowed expression of PRND, located just 16kB 
downstream of PRNP, to be put under the control of the PRNP promoter when, 
normally, its expression in the CNS would be blocked and expression would be 
restricted to the testes (159). This led the Nagasaki mice to demonstrate 
cerebellar Purkinje cell loss leading to late onset cerebellar ataxia.  
PRND encodes a 179-aa long prion-like protein called Doppel (Dpl). PRND 
shares 24% coding sequence homology with PRNP and, like PRNP is highly 
expressed during embryogenesis (Fig. 4). During embryogenesis PRND has a 
role in development of both the testes and ovaries and plays a role in male 
fertility (160) but, due to its location in the gonads of both sexes and the fact 
that it lacks the N-terminal octapeptide repeat domain, key for PrPC  PrPSc 
conversion, Dpl has never been linked with prion diseases (reviewed in (161)).  
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Figure 4. Gene and protein structure of the prion protein family PRNP/PrPC, 
PRND/Dpl, PRNT and SPRN/Sho. 
PRNP, PRND and PRNT are all located within the same gene cluster on 
chromosome 20. PRNP consists of just two exons. Located just downstream of 
PRNP are PRND and PRNT which are under control of the PRNP promoter (A). 
The final Prion Protein member, SPRN, is located elsewhere on chromosome 
10 but, like the majority of other prion protein members, only consists of two 
exons (A). All four genes have the open reading frame contained within a single 
exon. All three of the major prion protein family are GPI-anchored glycoproteins. 
Protein structures of PrPC and Dpl are similar whereas Sho only shares a 
loosely similar repeat region, hydrophobic domain and only has one 
glycosylation site (B). Figure modified from (160).  
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The structure of PrPC and Dpl are similar with both containing three α-helices, 
Dpl also undergoes the same post-translational modifications as PrPC leading to 
the production of a GPI-anchored membrane glycoprotein with two N-
glycosylation sites (162) and a disulphide bond (Fig. 4B). However, the PRND 
gene does not appear to contain a classical GPI recognition sequence (159) 
and there is evidence that more than one disulphide bond exists (162).  
There is also data to suggest an antagonistic interaction between the two 
proteins. PrPC has been shown to rescue neuroblastoma cells and astrocytes 
from Dpl-induced apoptosis via a direct interaction with Dpl in detergent-
resistant domains of the cell membrane (163) and a physical interaction has 
been demonstrated by way of immunoprecipitation in Fischer rat thyroid (FRT) 
epithelial thyroid cells (164). 
 
1.4.2 PRNT and PRT 
PRNT is the hypothetical third and most recently described member of the prion 
protein superfamily, it belongs to the same gene cluster as PRNP and PRND 
and is located approximately 3kB downstream of PRND ((165) see Fig. 4), 
appearing to be specifically expressed only in  primate populations (166). The 
PRNT gene consists of two exons and has three distinct alternatively spliced 
transcripts, none of which have any homology to PrPC or Dpl. The protein 
product of PRNT, PRT, is expressed exclusively in adult testes, the major site of 
Dpl expression (165) suggesting that, although not homologous, PRT and Dpl 
are functionally related (166). The open reading frame of PRNT is predicted to 
encode a 94 residue protein (Fig. 4B), although no evidence of this protein has 
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yet been found and some are unsure whether PRNT represents a genuine 
human gene at all (167). 
1.4.3 SPRN and shadoo 
Shadow of Prion Protein (SPRN) is a 3.9kB gene located on chromosome 
10q26.3 that encodes the prion-like protein Shadoo (Sho) (Fig. 4A, bottom 
panel). Sho is a 150aa, 14kDa highly-conserved protein seen in many 
organisms from mammals to fish (168).  The protein sequence of Sho is closely 
related to PrP and Dpl, it contains a highly conserved N-terminal signal 
sequence, an Arginine-rich basic region, a 20-residue hydrophobic region highly 
homologous to PrP, a less well conserved C-terminal domain containing a 
conserved glycosylation motif and a C-terminal signal sequence peptide for 
GPI-anchor attachment (168) (Fig. 4B). Unlike PrP, Sho is both a glycoprotein 
and a lipoprotein as it undergoes both glycosylation and lipidation and there are 
mixed results about whether Sho expression is essential for completion of 
embryogenesis; some research suggests that Sho is not essential for 
embryonic development and others suggesting Sho knockout leads to 
embryonic lethality (169,170). Bioinformatic data suggests that a very primitive, 
early form of prion protein was related to SPRN, with PRNP and PRND evolving 
later (168). Sho has been shown to have neuroprotective functions similar to 
PrPC and has been shown to rescue PRNP0/0 cerebellar granular neurons from 
the cytotoxic effects of Dpl (171). Reduced expression of Sho in prion diseases 
has been described (171) and polymorphisms in the SPRN signal peptide have 
been linked to development of sporadic CJD (172).  
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1.5 Significant biological functions of PrPC  
Unlike PrPres, function of the ‘normal’ PrPC was, unknown for many years as 
PRNP-null mice initially appeared phenotypically normal [10-12], aside from a 
few defects in their circadian rhythm. Conservation of parts of the PrPC 
sequence throughout evolution and the presence of PrPC in species from yeast 
to mammals suggest it does, however, have an important biological role [13]. 
Global PrPC expression begins during embryogenesis but in the adult it is 
predominantly expressed in the central nervous system (CNS) and has been 
linked to several key roles that may be relevant in tumourigenesis which are 
discussed in more detail in the following subchapters.  
1.5.1 PrPC in cell adhesion 
PrPC has been implicated in adhesion in both healthy and tumour cells [17]. In 
melanoma, pro-prion protein (an incompletely processed form of PrPC) binds to 
filamin A, facilitating the interaction with integrin β1 (173). Binding of PrPC to 
filamin A disrupts its normal function leading to altered adhesion of cells but 
also to changes in cytoskeletal organisation and signal transduction pathways, 
allowing cells to grow more aggressively (174). PrPC has also been shown to 
control β1 integrin-mediated adhesion in human monocytes, mediated by RhoA, 
cofilin and ERM-mediated membrane cytoskeletal linkage (175) in which Merlin 
is known to play an important role.  
The N-terminus of PrPC has a neuronal cell adhesion molecule (NCAM) binding 
site (176) providing further evidence for PrPC as a mediator of cell adhesion. 
Other reports suggest that NCAM acts as a neuron-specific receptor for PrPC 
(177) to not only affect cell adhesion but also regulate downstream signalling 
pathways involved in development and tumourigenesis as NCAM itself is 
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expressed in an array of cancers from brain tumours to acute myeloid 
leukaemia (AML (178)). 
Finally, PrPC has been shown to interact with another cell adhesion molecule E-
cadherin. During development PrPC regulates the stability of adherens junctions 
and, thus, cell adhesion by modulation of E-cadherin transport to and from the 
plasma membrane (179,180) and that downregulation of PrPC actually modifies 
and impairs the formation of adherens junctions (181). PrPC may also play a 
role in modulating focal adhesions (FA) as PrPC overexpression leads to the 
formation of new FA-like structures, whereas downregulation of PrPC leads to 
reduced FA numbers as well as activation of Src and FAK (182) which is known 
to be upregulated and over-activated in schwannoma and contribute to 
schwannoma increased adhesion (183).   
1.5.2 PrPC in survival and neuroprotection 
It is well known that the aggregated and misfolded forms of PrPC, PrPSc and 
PrPres lead to neuronal cell death on a huge scale, as seen in the prion 
diseases. However, in more recent years a role for the cellular form of PrP in 
neuroprotection and cell survival has been established, with PrPC protecting 
cells from oxidative stress [15], from the pro-apoptotic effects of another form of 
cellular prion protein, Dpl [16] and protecting cells from Bax-mediated apoptosis 
[14]. This is thought to occur through Bcl-2-dependent apoptotic pathways 
where Bcl-2 was upregulated and, consequently, p53 and Bax downregulated in 
gastric cancer cells (184). 
Resistance to apoptosis provided by PrPC is regulated by its glycosylation state 
as inhibition of N-linked glycosylation of PrPC eliminated the ability of both oral 
squamous cell carcinoma (HSC-2) and colon adenocarcinoma (LS 174T) cell 
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lines to resist oxidative stress, leading to a decrease in viability of these cells 
(185). In the same colon adenocarcinoma cell line, PrPC also helped resist 
against doxorubicin-induced apoptosis (186), further suggesting a protective 
role for PrPC.  
In serum deprived neuronal cells, PrPC was able to prevent apoptotic neuronal 
cell death and the mitochondrial dysfunction that often leads to oxidative stress 
(187) and depletion of PrPC led cells to have increased levels of programmed 
cell death as well as increased levels of apoptotic proteins such as p53, BAX, 
caspase-3, Poly(ADP-ribose) polymerase (PARP) and cytochrome C upon 
starvation, again suggesting a role of neuroprotection for PrPC that may occur 
via the aforementioned pathways.   
1.5.3 PrPC in cell proliferation and tumorigenesis 
Transcription of PRNP is upregulated in several cancer cell lines (188) and 
PrPC itself has been shown to play a role in cell proliferation both in cancer cells 
and in other cell populations. In gastric cancer patients PrPC was shown to 
promote G1/S transition, in part via the activation of the PI3K/AKT, as well as by 
activating levels of cyclin D1 both at the mRNA and the protein level (189). PrPC 
has also been demonstrated in the nucleus of proliferating intestinal epithelial 
cells, where it interacts with the Wnt signalling pathway including alternative 
downstream pathway members of the HIPPO family such as Yap (190), a 
pathway that regulates organ size, proliferation and survival and which have 
been shown to be involved in tumourigenesis of many different types of cancers 
including breast, pancreatic and colorectal cancers (191).  
Under normal development, PrPC plays a role in the CNS, regulating neuronal 
cell and glial cell precursor cell proliferation (192,193) suggesting a role for PrPC 
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in proliferation way before it becomes involved in tumourigenesis and that 
increased proliferation of tumour cells may, in some cases be caused by a 
dysregulated expression of PrPC.   
Previous work has shown PrPC to be involved in the promotion of 
tumourigenesis and metastasis in several different cancer types including 
gastric, colorectal and breast cancers (194-196). One of the main phenotypes of 
cancer cells is their ability to resist apoptosis, this contributes not only to tumour 
growth but also the metastatic and drug-resistance potential of these cells. 
Resistance to apoptosis can be the result of several different cellular events 
including overexpression of anti-apoptotic proteins or a downregulation of pro-
apoptotic proteins which may be caused by the expression of oncogenes, 
epigenetic modification or loss of tumour-suppressor proteins such as in the 
case of NF2 (reviewed in (197)).  
PrPC expression may also increase the invasiveness of certain tumour types 
such as gastric cancer (198) where PrPC was able to promote the invasive, 
adhesive and metastatic capabilities of these cells in culture via activation of the 
MEK/ERK pathway and matrix metalloprotease 11 (MMP11). It has been 
reported that PrPC activates several of the key signalling pathways known to be 
involved in schwannoma development including p53 [24], AKT [25], [26] and 
phospho-ERK1/2 (pERK1/2) [27]. 
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1.6 In search of a receptor for PrPC  
1.6.1 P75NTR and the NFkB signalling axis 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) is a 
transcription factor with roles in inflammation (reviewed in (199)), immunity and 
cell survival (reviewed in (200)). NFκB belongs to a class of transcription factors 
known as ‘Rapid-Acting Transcription Factors’ which are present in an inactive 
form within cells and are subsequently activated, rather than relying on new 
protein synthesis to have their effect. NFκB activity is regulated by a set of 
inhibitory cytoplasmic factors known as IκB. IκBα binding to NFκB inhibits its 
translocation to the nucleus thus forcing it to remain inactive. Activation of 
kinases IKKα and IKKβ phosphorylate IκBα causing it to undergo proteasomal 
degradation, freeing NFκB and allowing its translocation to the nucleus. In the 
nucleus NFκB acts to trigger transcription of various target genes, including 
inhibitory factor IκBα, in turn temporarily suppressing the NFκB response 
(reviewed in (201)).  
NFκB has been linked to both tumour initiation as well as cancer progression by 
regulating proliferation, resistance to apoptosis, epithelial to mesenchymal 
transition (EMT) and metastasis (202-205). Recently, increases in NFκB levels 
in cancer patients undergoing chemotherapy or radiotherapy have been shown 
to cause resistance of tumour cells to apoptosis, giving NFκB a role not only in 
tumour development but also in drug and treatment resistance through its 
control of transcription of the MDR1 gene (206), making it an interesting 
potential therapeutic target in schwannoma and other tumours. Similarly, NFκB 
has been shown to regulate transcription of other key genes relevant to 
schwannoma including; CD44 (207), p53 (208) and cyclin D1 (203).  
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NFκB is essential in Schwann cell developmental biology and injury repair 
(209,210). Dilwali et.al. (211) recently showed using pathway analysis that 
aberrant NFκB activation appears to be one of the major causes of increased 
proliferation in VS and demonstrated that use of NFκB inhibitors such as 
BAY11-7082 can decrease schwannoma proliferation and survival in vitro 
(reviewed in (212)). Previous work by myself and others in our research group 
showed that NFκB is also activated downstream of the AXL/Gas6 growth factor 
axis in schwannoma and that NFκB overexpression seen in schwannoma 
contributes to increased expression of survivin, cyclin D1 and FAK, leading to 
increased schwannoma proliferation, adhesion and survival (213). 
One of the major modulators of NFκB expression is the cell-surface growth 
factor receptor p75 neurotrophin receptor (p75NTR) (201). P75NTR can act both 
independently or in conjunction with tropomyosin-related kinase (Trk) receptors 
modulating Trk-ligand interactions, augmenting their binding capabilities to 
neurotrophins and pro-neurotrophins as well as altering their signalling 
capabilities either to promote cell survival or cell death depending on the co-
receptor that its coupled with (reviewed in (214)). p75NTR is known to play an 
important role in both Schwann cell migration during development and in 
Schwann cell pathology after injury (215,216) and was in the list of upregulated 
genes found in schwannoma compared to Schwann cells (59). 
Signalling of p75NTR has been linked to activation of c-Jun transcription, a 
master regulator of Schwann cell regeneration and proliferation that is 
upregulated in schwannoma, leading to increased tumour proliferation and 
survival (217,218). P75NTR activates NFκB via JNK-independent pathways in VS 
to provide a pro-survival response which likely contributes to their ability to 
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survive even in the absence of axons (219). Merlin is a key mediator of 
p75NTR expression and signalling in Schwann cells, this expression is highly 
upregulated in VS due to inactivation or loss of Merlin (220) (reviewed in (212)). 
Research in a mouse neuroblastoma cell line has implicated p75NTR activation 
of NFκB as the cause of cell death mediated by the prion protein fragment 106-
126, suggesting that p75NTR acts, either alone or in complex with other Trk 
receptors, to act as a receptor for PrP (221). Other research has shown that 
p75NTR is upregulated in schwannoma and produces a pro-survival response 
due to activation of NFκB (220) and PrPC has also been shown to have a 
neuroprotective role and contribute to cell survival.  
1.6.2 Laminins and their receptors 
Interaction between tumour cells and the extracellular matrix and basement 
membrane is a key step in tumourigenesis as most tumour cells show increased 
cell matrix adhesion, adhesion to the basement membrane also plays a role in 
tumour invasion and metastasis (222).  Laminins (LAs), a group of 
approximately 11 isoforms of large, non-collagenous glycoproteins, formed from 
two polypeptide chains joined by disulphide bonds. LAs were found to be one of 
the key components of the basement membrane and thus, a key component in 
mediating tumour invasion and metastasis (223). Further studies have shown 
the fragments of LA are able to exert opposing effects on tumour cells; some 
fragments enhance the metastatic activity of tumours (224) whereas others 
inhibit the metastatic activity of some malignant cells (225,226); this may be due 
to actions at different laminin receptors on the cell surface. Two families of 
laminin receptors have been discovered; the integrins and the non-integrin 
laminin receptors.  
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Integrins are transmembrane, cell surface receptors heavily involved in cell 
adhesion that are composed of an alpha and beta subunit. So far 19 alpha and 
8 beta subunits have been described (227) of which several heterodimers serve 
as receptors for LA, these include alpha 1 beta 1, alpha 2 beta 1, alpha 3 beta 1, 
alpha 6 beta 1, alpha 7 beta 1 and alpha 6 beta 4 (228) . Integrins regulate a 
wide range of cellular functions critical for the initiation, progression and 
metastasis of solid tumours. They are key to several integrin-mediated signal 
transduction processes, transducing signals across the membrane upon ligation 
with ligands such as laminin and fibronectin (reviewed in (229)), pathways 
known to play important roles in tumourigenesis and are known to be involved 
in schwannoma development as previously described. Overexpression of 
several key integrins (alpha 6 beta 1 and alpha 6 beta 4) has previously been 
demonstrated in schwannoma and been attributed to the increased pathological 
adhesion seen in these cells (58).   
The first of the non-integrin laminin receptors to be discovered was the 67kDa 
non-integrin laminin receptor (230-232) which, later on, was found to arise from 
a 37kDa laminin receptor precursor (LRP).  Evidence of this precursor laminin 
receptor protein led to the protein being named as 37/67kDa non-integrin 
laminin receptor (LR/37/67kDa) (233,234). However, this precursor was shown 
not to be a homodimer of 37kDa and that instead may be formed by heparin 
sulphate proteoglycan (HSPG) binding to the 37kDa LR (235). A separate group 
from a different field of research also identified the same protein and named it 
p40. This 37kDa protein was found to bind to the 40S ribosome where, although 
it does not function here as a laminin receptor, it instead plays a role in gene 
transcription (236), hence why LR/37/67kDa is also known as ribosomal protein 
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SA (RPSA). LR/37/67kDa is formed by transcription of the 5.8Kbp RPSA gene 
on chromosome 3p22.2 which consists of seven exons and six introns (237). 
Many tumours show increased expression of LR/37/67kDa including colorectal 
and breast carcinomas, melanoma and acute myeloid leukaemia (238-241). 
LR/37/67kDa expression has been demonstrated to be important in tumour cell 
proliferation, survival, adhesion, migration, invasion, angiogenesis and 
intracellular signalling (242-246). Furthermore, LR/37/67kDa may be a novel 
potential therapeutic target for treating tumours as studies have shown that 
using siRNA to reduce LR/37/67kDa expression leads to cell cycle arrest by 
reducing levels of cyclins, cyclin-dependent kinases and resistance to apoptosis 
by increasing levels of survivin and p21 (245). No studies have, thus far, 
commented on the expression and role of LR/37/67kDa in schwannoma.  
1.6.2.1 37/67kDa non-integrin laminin receptor protein as a ‘receptor’ for PrPC 
In 1997, a group first identified the existence of a prion protein receptor of 
around 66kDa by complementary hydropathy -a practice that uses the 
hydrophobic properties of amino acid side chains to determine protein 
properties and predict protein interactions (247). After this, another group (248) 
showed in a yeast two-hybrid system that the 37kDa LRP is able to interact with 
PrPC and further verified this interaction in mammalian COS-7 cells suggesting 
that LR/37/56kDa could act as a receptor for PrPC.  In 2001 LR/37/67kDa was 
shown to act as a cell surface receptor for PrPC in neuroblastoma cell lines (128) 
via PrPC/LRP binding domain 1 (amino acids (aa) 144–179) as a direct and 
PrPC/LRP binding domain 2 (aa 53–93) as an indirect, HSPG-dependent LR 
binding site on PrPC, as both LR and PrPC have been shown to bind HSPG’s 
(249,250).  A second direct PrP-binding domain on LRP was also found 
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between aa 161 and 179 (235).  LR/37/67kDa appears to be an interesting 
potential receptor, upregulated in many tumour types, via which PrPC acts to 
contribute to pathological proliferation, invasion, adhesion and survival of 
tumour cells and may prove to be a novel therapeutic target in schwannoma 
cells. 
1.7 Multi-drug resistance 
1.7.1 P-glycoprotein and multi-drug resistance in cancer cells 
In recent years, PrPC has been shown to be upregulated in multi-drug resistant 
cancer cells compared to parent cell lines [176]. Multi-drug resistance (MDR) is 
the most common reason why cancer patients stop responding to 
chemotherapy regimens as cancer cells become resistant to the cytotoxic effect 
of chemotherapy drugs over time. This can occur through several mechanisms: 
Decreased drug uptake, increased drug export, decreased drug activation, 
increased drug de-activation, decreased formation of drug-target complexes 
and increased repair of drug damage (251). MDR cell lines were first isolated in 
1968, but it was almost another decade later until high expression of phospho-
glycoprotein (p-gp) in such cell lines was demonstrated to be the cause of the 
MDR phenotype (252,253). Since its initial discovery in drug-resistant Chinese 
hamster ovary cells and its purification, p-gp expression has been shown to 
confer an MDR phenotype in several human cancer cell lines and is a well-
established cause of drug-resistance in many tumours today.  
P-gp, also known as ATP binding cassette sub-family B member 1 (ATPB1), is 
a transmembrane ATP-dependent efflux pump which functions to actively 
extrude toxins, xenobiotics and chemotherapeutic agents as well as a wide 
variety of other small molecules out of cells and plays a significant role in 
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regulating drug absorption and deposition. Although 48 ABC-binding cassette 
transporter subfamily genes exist, it appears that only three are associated with 
chemoresistance in vivo, these are; P-gp/MDR1, ABCG2 also known as Breast 
Cancer Resistance Protein (BCRP) and ABCC1/ Multi-drug resistance protein-1 
(MDRP-1) (Reviewed in (254)). Of these, p-gp is most well-known and thus the 
most researched.  
 
 
Figure 5. Schematic structure of p-glycoprotein (p-gp). 
P-gp consists of 12 transmembrane domains split into two similar halves. The 
two halves form together to make a transmembrane pore through which 
substrates are extruded from the cell upon binding of ATP to the ATP-binding 
domains. These two ATP-binding domains present in p-gp also double up as 
the p-gp nucleotide binding domains (NBD1 and NBD2). The glycosylation site 
of p-gp contains three potential glycosylation points, the overall result is a large, 
highly complex transmembrane protein which forms a pore through which drugs 
are extruded in an energy-dependent manner. Image adapted from (255).  
 
 
P-gp has a molecular weight of around 170kDa and is thought to contain two 
similar transmembrane segments with 63% homology to each other (256), each 
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containing six transmembrane domains and an intracellular loop containing an 
ATP-binding site, which form a channel through which drugs can be exported 
(257) (Fig. 5). P-gp is initially transcribed as a 140kDa precursor but undergoes 
glycosylation at its three N-linked glycosylation sites at amino acids 91, 94 and 
99 to form the 170kDa mature p-gp. Complete glycosylation of p-gp is key to 
formation of the cellular MDR phenotype, after glycosylation p-gp must then 
undergo phosphorylation to enable it to form an effective efflux pump (258).   
 
1.7.1.1 P-gp isoforms, gene variants and mutations 
The MDR1 gene is located on chromosome 7q21.12 and consists of 209,691bp, 
forming 28 exons, although many different polymorphisms have been reported 
(259).  One of p-gp’s most important physiological roles is cytoprotective -to 
limit cellular uptake of drugs and other toxic moleules from the circulation 
through the blood brain barrier into the CNS. However, this significantly limits 
the bioavailability of anti-cancer (257) and anti-retroviral drugs (260). As well as 
being present at high levels in the brain, p-gp is also present in several other 
tissues including adrenal cortical cells, pancreas excretory ducts, testicles and 
placenta which may explain why these organs are particularly resistant to 
uptake of cytotoxic, chemotherapy drugs.  Some tumours deriving from tissues 
with high base levels of p-gp are more likely to have an intrinsic MDR 
phenotype (251) although, most often, MDR phonotype is acquired, arising after 
long-term exposure to anti-cancer agents. 
1.7.1.2 P-glycoprotein sub-cellular localisation and function 
P-gp is known as an energy-dependent plasma-membrane-based efflux 
transporter, where it resides within the plasma membrane, forming a pore 
through with substrates can be transported. A substrate binds to the binding site 
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on the inner leaflet of the plasma membrane, upon ATP binding and being 
reduced to ADP, the substrate is expelled from the cell and the process can 
begin again (Fig. 5).  
There has recently been evidence suggesting that p-gp is also located in 
subcellular organelles. Molinari et.al. (261) show that, in MDR MCF-7 breast 
cancer cell line, there are significant levels of p-gp in the Golgi apparatus, 
suggesting a role for p-gp in the sequestration and vesicular transportation of 
drugs out of the cells, another mechanism by which p-gp is able to produce an 
MDR phenotype. Another group showed, in doxorubicin-resistant MCF-7 cells, 
that p-gp is expressed in the mitochondria where it has an efflux function within 
these organelles (262), this suggests a role for p-gp in protecting the 
mitochondria from the effects of harmful molecules. 
As well as being located on the plasma membrane to export drugs out of cells 
and within cytoplasmic organelles, there is strong evidence that p-gp is also 
located in the nuclear envelope of MDR cells. This would act as an extra 
defence mechanism of these cells against cytotoxic agents such as 
chemotherapy drugs (263), protecting the cell’s DNA  and preventing them from 
inhibiting cell replication. 
1.7.2 PrPC and multi-drug resistance 
PrPC has been reported to be upregulated in several drug-resistant cancer cell 
lines from breast, gastric and colon cancers. This includes increased PrPC 
expression in adriamycin-resistant gastric cancer (SGC7901/ADR) cells 
compared to the parental cell line (SGC7901) where PrPC is not only 
ubiquitously expressed but confers resistance to both phospho-glycoprotein (p-
gp) related and non-p-gp related drugs on these cells, preventing apoptosis 
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(184). The group also show that inhibition of PrPC in these cells using RNAi led 
to a reduction in MDR phenotype and that overexpression of PrPC led to an 
increase in p-gp expression.  
Finally, another group (264) show a novel interaction of p-gp and PrPC in 
Paclitaxel-treated breast cancer cells, with paclitaxel facilitating p-gp/PrPC 
cluster formation in caveolar domains at the cell surface and again inhibiting 
apoptosis of these cells. This also, for the first time, provides evidence for a 
physical interaction between PrPC and p-gp. Contrarily, in a different breast 
cancer cell line, oestrogen receptor-negative MDA-MB-435, silencing of PrPC 
was shown to enhance doxorubicin resistance, partially via the ERK1/2 pathway 
(265). 
These studies suggest an important role of PrPC overexpression in p-gp-related 
drug resistance so several of the key chemotherapeutic agents (including 
adriamycin, paclitaxel and doxorubicin) in cancer cell lines. There has, however, 
been little research into PrPC expression and its contribution to MDR in primary 
tumour samples.  
1.7.3 Adhesion-mediated drug resistance 
Adhesion of tumour cells to extracellular matrix (ECM) components such as 
fibronectin (FN) via β1 integrin has previously been shown to contribute to 
resistance to a host of chemotherapy agents (266) in what has been termed cell 
adhesion-mediated drug resistance (CAM-DR), a novel form of drug resistance. 
The interaction between FN and β1 integrin is already known to influence 
survival, cell growth and proliferation of schwannoma cells. This is particularly 
important as β1 integrin has been previously shown to be upregulated in 
schwannoma compared to healthy Schwann cells (58).  
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MDR-associated protein MGr1-Ag has been shown to be upregulated in drug-
resistant gastric cancer cells compared to the parental cell line (267). The same 
group later found this MDR-associated MGr1-Ag to be identical to the 37Kda 
laminin receptor precursor (37LRP) (268). It is thought that this MGr1-Ag/37LRP 
is also capable of inducing CAM-DR via signalling through FAK/PI3K and MAPK 
pathways (269). As previously described, PrPC has been shown to interact with 
the 37kDa LRP in the N2a neuroblastoma cell line (248), more recently, 
overexpression of both PrPC and MGr1-Ag/37LRP has been shown to be a 
marker of poor prognosis and even resistance to chemotherapeutic 
interventions in gastric cancer (270). These experiments make the PrPC/37LRP 
interaction interesting to examine with regards to potential cell adhesion-
mediated drug-resistance in schwannoma cells.   
 
1.8 Cluster of differentiation 44 (CD44) 
1.8.1 CD44 structure and function 
There have been several studies that link expression of both CD44 and PrPC in 
different tumours. CD44 expression has been associated with various tumour 
types, cancer stem cells (CSCs) and drug resistance although these aspects 
will be discussed fully in chapters 8.1.2-4. CD44 is encoded by a single copy of 
the CD44 gene located on the short arm of chromosome 11 that spans 
approximately 50kb of DNA (reviewed in (271)). It is an extremely complex gene 
made up of 21 exons with at least 12 alternatively spliced exons (272). Out of 
the 21 exons, 10 are ubiquitously expressed and produce a heavily glycosylated 
85–90 kDa isoform known as standard form CD44 (CD44s) where exon 5 is 
spliced directly to exon 16 (Fig. 6A). The other exons are able to be alternatively 
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spliced in various combinations, these splice variants incorporated into the 
polypeptide backbone encoded by the standard form exons to produce a huge 
range of CD44 isoforms (CD44v, Fig. 6A) which are differentially expressed in 
various tissues (273-275). 
The encoded CD44 protein forms a single-chain, cell surface glycoprotein also 
known as homing cell adhesion molecule (HCAM) involved in cell-cell 
interaction, signalling, cell adhesion and migration. The CD44 molecule consists 
of an N-terminal extracellular domain, made up of exons 1-5, that is related to 
several hyaluronate binding proteins (276,277) and contains docking sites for 
various ligands (Fig. 6B). 
The primary ligand for CD44 is hyaluronan (HA), although binding of CD44 to 
β1 integrin, laminin, growth factors, metalloproteases and cytokines also occurs. 
CD44 contains a small, variable, membrane proximal stem region, encoded by 
part of exon 5, 16 and 17 (plus any included variable exons), with binding sites 
for metalloproteases ADAM10, ADAM17 and disintegrin. This proximal stem 
region separates the extracellular loop from the plasma membrane, through 
which the transmembrane section, encoded by part of exon 18, runs (reviewed 
in (278)). On the other side of the transmembrane domain, at the inner surface 
of the plasma membrane, there is a gamma secretase cleavage site. This 
cleavage site allows the cytoplasmic tail of CD44 to be cleaved and 
translocated to the nucleus where it is able to act as a transcriptional regulator 
(279).  
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Figure 6. Protein and gene structure of CD44 and its variants. 
CD44 is a complex cell surface receptor which consists of between 10 and 20 
exons that are differentially spliced depending on the CD44 variant (A). The 
standard CD44 isoform (CD44s) is coded by 10 exons (A, S1-10), seven of 
which form the complex extracellular loop region, one forms the transmembrane 
region and two form the C-terminal cytoplasmic portion (CP) that contains the 
ERM- and ankyrin-binding domains (B). All the isoforms of CD44 share this 
similar pattern but also contain up to 10 extra, variant isoforms (A, V1-10) 
inserted at the end of the extracellular loop (B, teal region), just before the 
transmembrane region. Image adapted from (283). 
 
The C-terminal cytoplasmic domain is subject to alternative splicing via different 
variant of exons 19 and 20 generating either a short, 3 amino acid or long, 70 
amino acid version (reviewed in (274)). The C-terminal domain  plays an 
important role in intracellular signal transduction with binding sites for signalling 
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molecules including; Rho GTPases (280) and members of the Src family 
kinases including Src, Lck, Fyn and Lyn (281). There are also binding sites for 
key cytoskeletal elements such as Ankyrin and the ERM family of proteins (282), 
making CD44 a key molecule in cytoskeletal organisation and intracellular 
signalling to affect pathways involved in cell adhesion, survival, proliferation (Fig. 
7). 
The structural variability of CD44 is further complicated by post-translational 
modifications; N- linked and O-linked glycosylations as well as 
glycosaminoglycan (GAG) attachments which contribute to a doubling of the 
molecular weight of CD44 from 37kDa to a heavily-glycosylated form at 90kDa 
(these glycosylation sites are shown in Fig. 7B). There is conflicting evidence on 
the effects of glycosylation on HA binding to CD44, however. Inhibiting N-linked 
glycosylation has been shown to both enhance (284,285) and inhibit (286) HA 
binding, whereas inhibiting O-linked glycosylation can either enhance (287) or 
have no effect (285) on HA binding.  
Various CD44 isoforms are expressed in a wide range of tissues; including the 
skin, lung, stomach, intestine, oesophagus, bladder and cervical epithelium, 
glandular epithelial cells including that of the pancreas, sweat glands, bile ducts, 
prostate gland and mammary glands and endothelial cells, fibroblasts and white 
matter of the brain (in particular perivascular astrocytes), as well as in tumours 
arising from these tissues (288).  
1.8.2 CD44 in cancer 
CD44 has been shown to be expressed and involved in enhanced 
tumourigenicity in several cancer types including melanoma (289), colorectal 
carcinoma (290), non-Hodgkin’s lymphoma (291) and some gliomas (292). 
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Often CD44 expression level correlates with the grade of the tumour and poorer 
prognosis. Some tumours (such as glioma) express only the standard CD44s 
variant which lacks the entire variable region and is also expressed in normal 
cells, whereas other cancers, including gastric, bladder, cervical and breast 
cancers express variants of CD44 (CD44v1-10) as well as CD44s. It appears 
that not all CD44 isoforms act in the same way within cancer cells; involvement 
of variants CD44v4-v7 and CD44v6-v9 in tumour progression have been 
confirmed for various different tumour types in multiple clinical studies. In 
contrast, downregulation of the standard CD44 isoform (CD44s) has been 
shown to increase tumourigenesis in colon cancer cells. The mechanism for this 
is thought to be due to stromal-derived hepatocyte growth factor (HGF) 
production and release stimulating synthesis of MT1MMP, a matrix 
metalloprotease that is able to induce shedding of CD44 variants which, in turn, 
promotes invasion in both colon and prostate cancer cells (reviewed in (293)).  
Silencing of the appropriate CD44v (depending on cancer type) inhibits tumour 
cell adhesion to the cell matrix in vitro and prevents in vivo tumour cell invasion, 
blocking the HA/CD44/PI3K signalling axis that induces invasiveness (294).  
As well as CD44 itself, hyaluronan (HA), the primary ligand of CD44 which is a 
key component of the extracellular matrix and a glycosaminoglycan that, like 
PrPC, is more abundant during development compared to in mature adults (295) 
may play an important role in tumour formation and progression. CD44 (296) 
and HA (297) are both known to be aberrantly expressed in schwannoma (296). 
HA expression is increased in a variety of cancers including breast, prostate, 
colorectal and gastric (298). Its interaction with CD44 can promote migration, 
invasion, inflammation, angiogenesis and cell proliferation (293,299); all key 
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features of tumourigenesis (300).  Further to this, animal models have shown 
that interfering with CD44-ligand binding with the use of specific antibodies is 
able to inhibit growth a metastatic spread of the tumours (reviewed in (274)) 
making CD44, HA and their interaction a set of promising therapeutic targets in 
various neoplasms.  
1.8.3 CD44 in schwannoma and other Merlin-deficient tumours 
As previously stated, expression of both CD44 (standard isoform as well as 
CD44 variants, specifically CD44v6) and its primary binding partner HA are 
known to be aberrantly expressed in schwannoma.Oligodendrocyte and 
Schwann cell-specific CD44-overexpressing mice show widespread CNS 
dysregulated myelination and progressive demyelination (301), thus, CD44 
overexpressed by these myelinating cells, such as in the case of schwannoma 
(302), may contribute to de-differentiation of Schwann cells and thus 
demyelination. The CD44 ligand, HA, has also been shown to accumulate in 
glial cells of CD44 overexpressing mice (303).  
Immunoprecipitation of the CD44 cytoplasmic tail in embryonic hamster kidney 
cells showed that CD44 is associated with ERM family proteins, which include 
Merlin, that link cell surface proteins with the actin cytoskeleton (305). Merlin 
has been shown to co-localise and co-immunoprecipitate with CD44 in cultured 
cells (306) and has been shown to  mediate contact inhibition and growth via 
interactions with CD44, ezrin and moesin by acting as a molecular switch to 
arrest growth at high cell density (307). Furthermore, knockdown of Merlin, 
using siRNA, from healthy primary Schwann cells in culture caused an 
upregulation in levels of CD44 (308). As well as its role in mediating contact 
inhibition, CD44 is essential to mediate many other elements of tumourigenesis 
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including cell proliferation, cytoskeletal reorganisation, migration, angiogenesis 
and cell survival/resistance to apoptosis by several pathways known to be 
involved in schwannoma development, these are outlined in Figure 7. 
 
 
Figure 7. Overview of CD44 signalling pathways and their resulting effects 
on cells. 
Signalling via CD44, either alone or via interaction with a co-receptor, activates 
several key pathways already previously described to be involved both in 
schwannoma development and the development of other tumours. This 
includes activation of PI3K/AKT, NFκB, β-catenin and Ras/Rac/ERK1/2 
pathways which, overall, lead to the activation of the inflammatory response, 
increased cell proliferation, invasion and angiogenesis as well as cytoskeletal 
rearrangement. Image adapted from (304).  
 
1.8.4 CD44 in multi-drug resistance 
CD44 is a cell surface glycoprotein with major roles in cell adhesion, 
proliferation, angiogenesis and migration and recently has been linked to roles 
in drug-resistance (271). Cancer stem cells (CSCs) are subpopulations of 
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tumour cells which are more resistant to treatment that their surrounding 
counterparts, therefore successful treatment is dependent on removal of these 
specific subpopulations as well as the main tumour mass, failure to do so leads 
to relapse in patients. CSCs have very similar properties to tumour initiating 
cells which have previously been described in the brain (309)– they have the 
capacity for self-renewal, the potential to develop into any cell in the overall 
tumour population, have proliferative abilities to drive expansion of malignant 
cells and are a major cause of cancer aggressiveness (310). CSCs also 
express high levels of proteins associated with efflux of anti-cancer drugs, 
protecting the cancer cells from the chemotherapy agents. These proteins 
involved in the efflux of anti-cancer drugs include members of the ATP Binding 
Cassette (ABC) family of transporters, to which p-gp (MDR1) belongs  (311).  
CD44, in particular CD44v isoforms, have been described as the most common 
cell surface markers of CSCs either alone or alongside other markers such as 
CD24, CD133 and CD34 (reviewed in (310)) where it integrates signalling 
between normal stem cell, CSC’s and pre-metastatic niches (312). Furthermore, 
CD44 plays a large role in tumour initiation and progression as discussed earlier, 
making them not only a good therapeutic target but also a potential biomarker to 
identify aggressive forms of cancer. The role of CD44 on these cells is thought 
to involve communication of CSCs with the microenvironment and surrounding 
stromal cells as well as regulating ‘stemness’ properties  (310). CD44 binding 
regulates CSC survival, self-renewal, maintenance, and chemoresistance, 
which helps explains the importance of CD44 for disseminated cancer cells to 
adapt to new environments (313) and why CD44 is required for metastatic 
colonisation (314).  
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As well as traditional MDR-related proteins, it has been suggested that CD44 
can induce drug resistance independently of p-gp (315) Interactions between p-
gp and CD44 (both standard and variant isoforms, depending on the cancer 
type) have been well documented in cancer cells (316) and appear to promote 
migration and invasion as well as mediating MDR (317). This makes CD44 
protein that requires a much further investigation in order to fully appreciate the 
interplay between LR/37/67kDa, PrPC, p-gp and MDR in schwannoma.  
1.8.5 CD44 and its interaction with PrPC 
CD44 has been associated with CSCs; CD44-positive CSCs that express PrPC 
contribute to colon cancer metastasis which was inhbited by using RNAi to 
knockdown PrPC (318) suggesting that both CD44 and PrPC may act as 
biomarkers on CSCs to identify particularly aggressive or metastatic tumours 
and suggesting a previously untapped role for PrPC in CSCs and tumour 
initiation.  
A more direct interaction between PrPC and CD44 has been demonstrated by 
Cheng et.al. (2014) who show that PrPC and CD44 both physically and 
functionally interact within an adriamycin-resistant breast cancer cell line (319) 
and that knockdown of either PrPC or CD44 was able to abolish cell migration, 
proliferation and invasion. The group concluded that the interaction between 
PrPC and CD44 affects the response to neoadjuvant chemotherapy and 
enhances malignancy in breast cancer. There is some evidence that the 
interaction between PrPC and CD44 could also involve a third member – MDR-
associated protein p-gp which has also been shown to interact with PrPC in 
drug-resistant breast cancer cell lines. Thus, the interaction between these 
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three proteins appears to be a novel and interesting point of study in order to 
gain insight both within the realms of MDR and CSCs.  
1.9 Aims and objectives 
The aims of this research project are: 1) to investigate the expression patterns 
of PrPC in schwannoma and other Merlin-deficient tumours in comparison to 
normal tissue, 2) to look at the role of PrPC in schwannoma pathological 
proliferation, adhesion and survival via the key pathways already well-known to 
be involved in schwannoma development, 3) to investigate whether altered 
glycosylation, degradation or aberrant protein folding of PrPC may contribute to 
schwannoma pathology, 4) to check whether PrPC is released from 
schwannoma cells and is able to act in an autocrine or paracrine manner to 
further trigger downstream signalling pathways, 5) to investigate previously 
identified potential receptors, including LR/37/67kDa, P75NTR and CD44, via 
which PrPC may act in schwannoma cells and 6) to check whether LR/37/67kDa, 
P75NTR and CD44 receptors or other PrPC-interacting partners could be involved 
in schwannoma drug resistance or whether intrinsic drug resistance may play a 
role instead.  
The findings of this study should begin to elucidate whether PrPC is a good 
novel potential therapeutic target for the treatment schwannoma and other 
Merlin-deficient tumours and also whether it may be able to function as a 
biomarker to aid diagnosis and help evaluate tumour load of patients.  
1.10 Brief summary of main findings 
 
I show that upregulation of glycosylated PrPC occurs in schwannomas in a 
Merlin-dependent manner and contributes to the increased pathological 
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adhesion, survival and proliferation seen in these cells. This occurs via 
activation of key signalling pathways ERK1/2, P13K/AKT, FAK and cyclin D1 
downstream of both LR/37/67kDa and CD44. Finally, I show that p-gp is 
upregulated in schwannoma downstream of both Merlin and PrPC, making PrPC 
a potential new therapeutic target, not only for schwannomas, but also other 
Merlin-deficient tumours.    
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Chapter 2: Materials and methods 
2.1 Sample collection and cell culture 
2.1.1 Primary human cells 
Primary human tumour samples were used for the majority of the experiments 
in this project to reduce the limitations of using a cell culture model and to 
bridge the gap between the bench and the bedside, allowing the work done 
within this project to be more clinically translatable.  
2.1.1.1 Clinical sample collection and ethics 
Schwann cells were isolated from post-mortem donors at Derriford Hospital with 
informed consent from next of kin and after ethical approval under the Research 
Ethics Committee (REC) number REC6/Q2103/123. Schwannoma samples 
were collected after informed consent from patients at both Derriford Hospital, 
Plymouth and Bristol Southmead Hospital under local R&D approval Plymouth 
Hospitals NHS Trust: R&D No: 14/P/056 and North Bristol NHS Trust: R&D No: 
3458. A subset of the schwannomas and all the meningiomas used were 
collected under the Molecular Targets (MOT) project again involving both 
Derriford and Southmead Hospitals. The project was granted full ethics 
approval by the South West research ethics committee (REC number 
14/SW/0119). All tumours used in this project were classified as WHO grade 1.  
2.1.1.2 Schwann cell collection and culture 
Human nerve samples were isolated from the sural nerve in the lower leg, 
samples were dissected and the fascicles removed from the nerve sheaths. 
Individual fascicles were then digested with a mixture of type IIA collagenase 
and dispase as well as undergoing mechanical digestion by pipetting. The 
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individual Schwann cells were then cultured in a growth factor medium (GFM): 
DMEM; 100U/ml pen/strep; 2.5 µg/ml Insulin (Thermofisher Scientific, MA, USA); 
0.5µM forskolin (Tocris, Bristol, UK); 10% FBS, 2.5µg/ml amphotericin (Sigma, 
MO, USA); 10nM β1 heregulin; 0.5mM 3-isobutyl-1-methylxanthine (IBMX, Bio-
Techne, MN, USA) and maintained in a humidified atmosphere of 10% CO2 at 
37ºC, on plates coated with both poly-L lysine (Sigma) and laminin 
(Thermofisher Scientific).  Immunofluorescent staining with S100 marker was 
routine to ensure a pure Schwann cell population devoid of fibroblasts, as 
previously described ((320) and (321)). 
2.1.1.3 Schwannoma cell collection and culture 
Cells were isolated by digestion using a mixture of collagenase, dispase and 
mechanical digestion by pipetting.  Once digested cells were cultured in growth 
factor medium (GFM): DMEM, 10% FBS, 100U/ml pen/strep; 0.5µM forskolin; 
2.5µg/ml amphotericin; 2.5 µg/ml Insulin; 10nM β1 heregulin, maintained in a 
humidified atmosphere of 10% CO2 at 37ºC on plates coated with both poly-L 
lysine and laminin. 
2.1.1.4 Meningioma cell collection and culture  
Meningioma cells were again isolated using a mixture of collagenase, dispase 
and mechanical digestion by pipetting.  Once digested cells were cultured in a 
simple medium of DMEM, 10% FBS and 100U/ml pen/strep.  
2.1.2 Cell line culture 
2.1.2.1 Human meningeal cell (HMC) culture 
Foetal-derived, human meningeal cells from ScienCellTM were maintained in the 
manufacturer’s recommended media (meningeal cell media, ScienCellTM) at 
37⁰C, 5% CO2. Cells were split when confluent and plated on uncoated plates.  
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2.1.2.2 Ben-Men-1 benign meningioma cell culture 
BenMen-1 (abbreviated to BenMen in this report) are a benign meningioma cell 
line originally created by Pϋttmann et.al. in 2005 (322)  via a telomerase reverse 
transcriptase (hTERT)-mediated immortalisation of benign meningioma cells. 
Cells were routinely cultured in DMEM with the addition of 10% FBS and 
100U/ml pen/strep at 37⁰C at 5% CO2. BenMen cells were used in this project 
as a control for grade 1 meningioma results and also as a tool for directly 
comparing between meningioma samples and HMC without use of primary cells.  
2.1.2.3 Human malignant mesothelioma cell (HIB and TRA) culture 
The characteristics of the HMM cell lines HIB (Merlin-positive) and TRA (Merlin-
deficient), reported previously (323). Cells were seeded on uncoated cell culture 
dishes at a density of 10,000 cells/cm2 and maintained in medium consisting of 
RPMI, 10% FBS, 100 U/ml pen/strep, in a humidified atmosphere of 5% CO2 at 
37 °C. 
2.1.2.4 HEK293FT cell culture 
Human Embryonic Kidney HEK293FT cells (Thermofisher Scientific) were 
maintained on uncoated cell culture dishes in a simple medium of DMEM, 10% 
FBS, 100U/ml Pen/Strep at 37ºC, 5% CO2 and passaged when confluent. 
293FT cells were used for the production of lentiviral particles, see section 
2.5.2.1 for further information.  
 
2.2 Chemicals, peptides & antibodies 
2.2.1 Chemicals 
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Table 2: Table of chemicals and peptides used  
Chemical Company 
Catalogue 
Number 
Use 
Treatment 
Protocol 
TCS Prion 
Inhibitor 13 
(TCS) 
Insight 
Biotechnology, 
Wembley, UK 
3238 Inhibition and 
reduction of 
PrPC 
20, 100 and 
500μM for 72h, 
37ºC 
Cycloheximide 
(CHX) 
Sigma-Aldrich, 
Gillingham, UK 
C7698 Inhibitor of 
protein 
synthesis 
1μM, 24h, 37ºC 
Actinomycin D 
(Act D) 
Sigma-Aldrich, 
Gillingham, UK  
A9415 Inhibitor of 
transcription 
10nM, 24h, 
37ºC 
Proteinase K 
(PK) 
Sigma-Aldrich, 
Gillingham, UK  
P2308 Protease 
enzyme 
5% in lysis 
buffer, 2h, 
37ºC 
PMSF Sigma-Aldrich, 
Gillingham, UK  
P7626 Inhibitor of 
proteinase K 
10ug/ml, 10’, 
RT 
MG132 Sigma-Aldrich, 
Gillingham, UK  
M8699 Proteasomal 
degradation 
inhibitor 
1μM, 24h, 37ºC 
10’ then RT 1hr 
DAPI Sigma-Aldrich, 
Gillingham, UK  
D9542 Nuclear stain 1:500, 30’ 
H2O2 (30% w/w 
solution) 
Sigma-Aldrich, 
Gillingham, UK  
H1009 Apoptosis 
inducer 
500μM, 12h, 
37ºC 
GI254023X Sigma-Aldrich, 
Gillingham, UK  
SML0789 ADAM10 
Inhibitor 
10µM, 3h. 
37⁰C 
Choloroquine 
(CQ) 
Sigma-Aldrich, 
Gillingham, UK  
C6628 Lysosomal 
degradation 
inhibitor 
12.5μM, 24h, 
37ºC 
PIPLC Sigma-Aldrich, 
Gillingham, UK  
P5542 Cleaves GPI-
membrane-
bound proteins 
0.2U/ml, 3h, 
37⁰C 
PNGaseF Promega, 
Southampton, 
UK 
V4831 De-glycosylase 
enzyme 
As per 
manufacturer 
protocol. 
P-glycoprotein 
blocking peptide 
Insight 
Biotechnology, 
Wembley, UK 
BS-0563P Show 
unspecific 
binding of the 
P-gp antibody 
As per 
manufacturer 
protocol. 
Protamine 
Sulfate  
Sigma-Aldrich, 
Gillingham, UK  
P3369 Facilitates 
gene/DNA 
transfection. 
8µg/ml 
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Chemical Company 
Catalogue 
Number 
Use 
Treatment 
Protocol 
PSC833 
(Valspodar) 
Biotechne, 
Abingdon, UK 
#4042 P-gp inhibitor 4µg/ml, 20 
minute pre-
treatment 
Puromycin Sigma-Aldrich, 
Gillingham, UK  
P9620 Antibiotic used 
for selection. 
4µg/ml 
Blasticidin Sigma-Aldrich, 
Gillingham, UK  
15205 Antibiotic used 
for selection. 
10µg/ml 
SN50  Merck Millipore, 
Feltham, UK 
41480 Prevents 
nuclear 
translocation of 
NFκB 
8μg/ml, 24h, 
37ºC 
PrP Peptide 
(Central Portion) 
BioRad, 
Watford, UK 
7672-5509 KTNMKHMAG
AAAAGAC 
AA105-120 
4μM, 1-72h, 
37ºC 
 
2.2.2 Antibodies  
Table 3: Table of antibodies used and their application 
Antibody Type Company Cat. Number Dilution 
PrP 12F10  Mouse 
Monoclonal 
Antibody 
Sigma-Aldrich, 
Gillingham, UK  
No longer 
available 
1:1000 (IHC) 
PrP 6D11 Mouse 
Monoclonal 
Antibody 
Insight 
Biotechnology, 
Wembley, UK 
Sc-58581 1:500 (WB) 
1:100 (ICC) 
PrP 
[EP1802Y] 
Rabbit 
Monoclonal 
Antibody 
Abcam, 
Cambridge, UK 
ab52604 1:500 (WB) 
PrP 8H4 Mouse 
Monoclonal 
Sigma-Aldrich, 
Gillingham, UK  
P0110 1μg in 1mg 
lysate (IP) 
GAPDH Mouse 
Monoclonal 
Antibody 
Merck Millipore, 
Feltham, UK 
MAB374 1:10,000 (WB) 
Merlin D1D8 Rabbit 
Monoclonal 
Antibody 
New England 
Biolabs, Hitchin, 
UK 
#6995 1:500 (WB) 
Phospho 
MerlinS518 
Rabbit 
Polyclonal 
Antibody 
New England 
Biolabs, Hitchin, 
UK 
#9163 1:500 (WB) 
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Antibody Type Company Cat. Number Dilution 
CD63 
(RFAC4) 
Mouse 
Monoclonal 
Merck Millipore, 
Feltham, UK 
CBL553 1:500 (WB) 
Ki67 (MIB-1) Mouse 
Monoclonal 
Antibody 
Agilent 
Technologies Ltd., 
Stockport, UK  
M7240 1:100 (ICC) 
c-Jun (60A8) Rabbit 
Monoclonal 
Antibody 
New England 
Biolabs, Hitchin, 
UK 
#9165 1:100 (ICC) 
1:500 (WB) 
Cleaved 
caspase-3 
(Asp175) 
Rabbit 
Polyclonal 
Antibody 
New England 
Biolabs, Hitchin, 
UK 
#9661 1:100 (ICC) 
1:200 (WB) 
NFκB p65 Rabbit  
Polyclonal 
Antibody 
Abcam, 
Cambridge, UK 
ab16502 1:100 (ICC) 
1:500 (WB) 
IκB Rabbit  
Monoclonal 
Antibody 
Abcam, 
Cambridge, UK 
ab32518 1:100 (ICC) 
1:500 (WB) 
VPBRP (C-8) 
(DCAF1) 
Mouse 
Monoclonal 
Antibody 
Insight 
Biotechnology, 
Wembley, UK 
sc-376850 1:250 (WB) 
Cyclin D1 Rabbit  
Polyclonal  
Antibody 
New England 
Biolabs, Hitchin, 
UK 
#2922 1:1000 (WB) 
P44/42 MAPK 
(137F5) 
(Total 
ERK1/2) 
Rabbit  
Monoclonal 
Antibody 
 
New England 
Biolabs, Hitchin, 
UK 
#4695 1:2000 (WB) 
Active MAPK 
(pTEpY) 
(pERK1/2) 
Rabbit 
Polyclonal  
Antibody 
Promega, 
Southampton, UK 
#V803A 1:1000 (WB) 
Pan AKT 
(C67E7) 
Rabbit 
Monoclonal 
Antibody 
New England 
Biolabs, Hitchin, 
UK 
#4691 1:500 (WB) 
Phospho 
AKTS473 
Rabbit 
Monoclonal 
Antibody 
New England 
Biolabs, Hitchin, 
UK 
#9271 1:500 (WB) 
Total FAK Rabbit  
Polyclonal 
Antibody 
New England 
Biolabs, Hitchin, 
UK 
#3285 1:500 (WB) 
Phospho 
FAKY397 
Rabbit 
Polyclonal 
Antibody 
New England 
Biolabs, Hitchin, 
UK 
#3283 1:500 (WB) 
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Antibody Type Company Cat. Number Dilution 
p53 (B-P3) Mouse 
Monoclonal 
Antibody 
Insight 
Biotechnology, 
Wembley, UK 
sc-65334 1:500 (WB) 
LR/37/67kDa Rabbit 
Polyclonal 
Serum 
Biotechne, 
Abingdon, UK 
Nb110-74761 1:500 (WB) 
1μg in 1mg 
lysate (IP) 
Anti 67kDa 
Laminin 
Receptor 
Rabbit  
Polyclonal 
Antibody 
Abcam, 
Cambridge, UK 
ab137388 1:500 (WB) 
1μg in 1mg 
lysate (IP) 
P-glycoprotein 
(F4) 
Mouse 
Monoclonal 
Antibody 
Sigma-Aldrich, 
Gillingham, UK  
P7965 1:1000 (IHC) 
1μg in 1mg 
lysate (IP) 
P-glycoprotein  Rabbit 
Polyclonal 
Antibody 
Abcam, 
Cambridge, UK 
ab129450 1:500 (WB) 
HCAM 
(DF1485) 
(CD44) 
Mouse 
Monoclonal 
Antibody 
Insight 
Biotechnology, 
Wembley, UK 
sc-7297 1:500 (WB) 
1:100 (ICC) 
CD44s Rabbit 
Polyclonal 
Serum 
Biotechne, 
Abingdon, UK 
NBP1-31488 1:1000 (WB) 
Phalloidin Alexafluor 
488 
New England 
Biolabs, Hitchin, 
UK 
#8878 1:500 (ICC) 
Goat anti-
mouse 
488 Thermofisher 
Scientific, Paisley, 
UK 
A11001 1:500 (ICC) 
Goat anti-
mouse 
594 Thermofisher 
Scientific, Paisley, 
UK 
A11005 1:500 (ICC) 
Goat anti-
rabbit 
488 Thermofisher 
Scientific, Paisley, 
UK 
A11008 1:500 (ICC) 
Goat anti-
rabbit 
568 Thermofisher 
Scientific, Paisley, 
UK 
A11011 1:500 (ICC) 
Goat anti-
mouse 
HRP-
conjugated 
BioRad, Watford, 
UK 
#170-6516 1:20,000 (WB) 
Goat anti-
rabbit 
HRP-
conjugated 
BioRad, Watford, 
UK 
#172-1019 1:20,000 (WB) 
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2.3 Immunohistochemistry and immunocytochemistry 
2.3.1 Immunohistochemistry (IHC) 
Formalin-fixed, paraffin embedded, thin tissue sections (4µm) were taken from 
samples collected during surgery or post mortem with patient or family informed 
consent. Sections were then baked onto slides at 60⁰C for 10 minutes. Slides 
underwent de-waxing and rehydration through xylene (Thermofisher Scientific) 
and 100% ethanol (VWR) respectively before undergoing a methanol and 
hydrogen peroxide (3%) block to quench excess peroxidase activity. This was 
followed by antigen retrieval using a pre-treatment with citrate buffer pH6.0 
(during p-gp staining) or EDTA buffer for 30 minutes under heat (for PrPC 
staining). Slides were incubated overnight with anti-PrPC 12F10 (Bioquote, York, 
UK) at a dilution of 1:1000 or anti-p-gp (Sigma) at 1:500. Detection was 
performed with the Vectastain Universal Elite ABC kit (Vector Laboratories, 
Peterborough, UK). 3’3’-Diaminobenzidine (DAB (Sigma)) was used to visualise 
with Mayer’s haematoxylin (Sigma) used as a nuclear counterstain. Slides were 
de-hydrated through ethanol and xylene before being mounted using DPX 
(Sigma). Slides were imaged on a bright field light microscope and images 
taken using an attached camera.  
2.3.2 Immunofluorescence and confocal microscopy 
2.3.2.1 Fluorescent immunocytochemistry (ICC) 
Pre-treated cells were fixed using 4% paraformaldehyde and permeablised 
using 0.2% Triton X-100 before being blocked using 10% normal goat serum. 
Cells were then incubated with primary antibodies overnight at a concentration 
of 1:100. Localization various proteins was performed using anti-human-PrPC, 
anti- 37/67kDa non-integrin laminin receptor, anti-p-glycoprotein, anti-CD44 
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antibodies. Secondary antibodies goat anti-Mouse 594, goat anti-Mouse 488, 
goat anti- rabbit 594 and goat anti- Rabbit 488 (Invitrogen) were used and Alexa 
Fluor 488-labeled phalloidin was used to visualize actin filaments (1:100; 
Molecular Probes, Eugene, OR). DAPI was used to visualise cell nuclei.  
2.3.2.2 Immunofluorescence proliferation and survival assays 
Cells were treated as required then fixing agent (4% PFA) applied directly into 
the cell culture medium rather than washing cells first. All other elements of the 
protocol were carried out as described above. Anti-Ki67 was used as a marker 
or proliferating cells (324) and anti-cleaved caspase-3 was used as a marker or 
cells undergoing apoptosis. Again, AlexaFluorTM secondary antibodies goat-anti 
mouse 594 and goat-anti rabbit 488 were used and DAPI applied as a nuclear 
stain. 
2.3.2.3 Confocal microscopy 
Multitrack imaging was performed using a Zeiss Confocal LSM510. Co-
localisation experiments were all carried out using z-stack techniques. Apart 
from proliferation and survival assays which were carried out using a 20x air 
objective, all other experiments were imaged using a 40x oil pH2 objective. The 
appropriate Zeiss image manipulation software (ZEN) was used for editing.  
2.4 Quantifying PrPC release from cells 
2.4.1 Culture medium collection and concentration 
Both Schwann and schwannoma cells were cultured for a minimum of seven 
days in growth factor medium containing exosome-free FBS (Gibco). Medium 
from cells was collected before being concentrated 10x using Amicon Ultra 
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centrifugal filters (Millipore). Concentrated media samples were then run using 
ELISA (see below). 
2.4.2 Exosome isolation 
Cell culture medium was collected and incubated overnight at 4⁰C with Total 
Exosome Isolation Kit (cell culture medium version, Invitrogen). The next day 
exosomes were pelleted by centrifugation at 13,000rpm, 4⁰C for 30 minutes 
before being re-suspended in 50µl PBS. Samples were either subject to ELISA 
(see section 2.4.4) or Western blotting for quantification where anti-CD63 was 
used as a marker for exosomes. 
2.4.3 Quantifying PrPC cleavage by PIPLC and ADAM10  
Schwannoma cells were cultured in normal cell growth medium (GFM) until 
confluent before being treated either with phosphatidylinositol phospholipase C 
(PIPLC) 0.2U/ml or ADAM10 inhibitor GI254023X 5µM for 24h at 37⁰C. Cell 
medium was collected for ELISA and cells were lysed as described below (see 
chapter 2.4.4), before being subjected to Western blotting (refer to chapter 
2.4.1). Untreated cells in GFM or GFM cell culture medium were used as a 
control. 
2.4.4 Analysis by enzyme-linked immunosorbent assay (ELISA) 
Samples were collected as described above (section and 100µl sample loaded 
into each well of a Prion Protein (PRNP) ELISA kit (CUSABIO from Antibodies-
online, ABIN821046) for an overnight incubation at 4⁰C to detect PrPC release 
from cells. The remainder of the protocol was carried out according to the 
manufacturer’s manual and the plate was read on a microplate reader (Genios) 
at 450nm to quantify the results. Results were adjusted based on the fold-
concentration of the medium where required.  
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2.5 Viral infections of Schwann and schwannoma cells in culture  
2.5.1 Adenoviral re-introduction of Merlin into schwannoma cells 
Merlin (NF2) wild type (recombinant adenovirus AdNF2) and control GFP-
containing vector adenoviruses were a kind gift from J. Testa [39]. Confluent 
(70%) schwannoma cells were incubated with virus for 48 hours and then 
incubated with fresh GFM for additional 24 hours prior to lysis with RIPA buffer. 
Successful viral infection was determined by the presence of GFP within the 
cells and backed up with quantification of Merlin levels using Western blotting. 
2.5.2 Lentiviral knockdown of PRNP in schwannoma cells  
2.5.2.1 Homemade TRC PRNP shRNA lentiviral particles 
TRCN0000083488 hairpin-pLKO.1 construct, part of a TRC (The RNAi 
Consortium) PRNP shRNA, glycerol set (GE Dharmacon, IL, USA) was used to 
produce lentiviral particles. The plasmid was amplified using DH5α E.Coli cells, 
plasmid DNA was then transfected into 293FT cells in a low-antibiotic, high-
serum medium along with packaging plasmid dR8.2 and envelope plasmid 
VSV-G using Fugene6 (Promega). Medium was collected and spun down to 
remove cellular debris before being applied to cells (see below for full protocol). 
Viral titre and multiplicity of infection (MOI) was unable to be determined for the 
homemade viruses, through a series of different dilutions I found that sufficient 
knockdown of a well of 70,000 schwannoma cells could only be achieved with 
2ml viral particles (unconcentrated) with 1ml GFM.  
2.5.2.2. Pre-made PRNP shRNA lentiviral particles 
Alongside the homemade PRNP shRNA the following commercially available 
shRNA PRNP shRNA lentiviral particles and control shRNA particles (Santa 
Cruz) that consist of a pool of three to five expression constructs each encoding 
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a different, target-specific 19-25nt region of PrPC plus a hairpin shRNA were 
used to knock down PRNP expression. The pre-made tubes contain 1.0x106 
infectious units of virus (IFU) in DMEM with 25mM HEPES pH7.3. The 
manufacturer recommends using 10-20µl of virus per 70,000 cells, I found that 
10µl of pre-made viral particles per well of a 6 well plate was sufficient for a 
significant knockdown.   
2.5.2.3 Lentiviral infection of schwannoma cells with PRNP shRNA  
Schwannoma cells were seeded at a high density (minimum 70% confluency) 
before being incubated with medium containing lentiviral particles or a scramble 
control (sc-108080, Insight Biotechnology, Wembley, UK) plus protamine 
sulphate (8µg/ml) and incubated at 37°C for 72 hours. Infected cells were 
selected with puromycin for a minimum of 72 hours before being lysed or fixed 
and subjected to Western blotting or immunocytochemistry respectively.  
2.5.3 PRNP overexpressing clone 
2.5.3.1 Production of the PRNP overexpressing clone  
The coding region of PRNP (NCBI gene ID: 5621) was synthesised on request 
by Life Technologies, it was then PCR cloned and ligated into pENTR11 entry 
vector before being gateway cloned into the pLenti6.2/V5-DEST vector (Fig. 9). 
The pLenti6.2/V5-DEST-PRNP DNA was transfected into 293FT cells alongside 
a viral packaging mix (Life Technologies) and virus-containing medium was 
collected from cells after 48 hours, spun down and frozen at -80°C. A 
pLenti6.2/V5-GFP containing lentivirus was also made at the same time to act 
as a control.  
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2.5.3.2 Infection of Schwann cells with PRNP overexpressing clone 
Schwann cells were cultured until confluent then split at a high density. The 
following day lentiviral particles containing pLenti6.2/V5-DEST-PRNP (Fig.8) or 
pLenti6.2/V5-DEST-GFP were applied to the Schwann cells with the addition of 
protamine sulphate ((8µg/ml) Sigma) and incubated at 37°C for 48 hours. 
 
Figure 8. PRNP overexpressing clone structure. 
The PRNP coding region was PCR cloned into a pLenti6.2/V5-DEST vector that 
uses a CMV promoter to drive overexpression of the target gene. The above 
vector was transfected into HEK293FT cells alongside the appropriate 
packaging vectors and the cell culture medium containing the viral particles was 
collected. Viral titre was determined by a series of dilution experiments before 
the virus was used to infect Schwann cells. Image courtesy of SnapGene®. 
 
Virus-containing medium was removed and replaced with GFM containing the 
selective antibiotic blasticidin and incubated for 72 hours or until all uninfected 
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cells in a control culture were killed. Cells were then lysed then subjected to 
Western blotting or immunofluorescence as described. 
2.5.4 Knockdown of 37/67kDa-non-integrin laminin receptor  
Pre-made RPSA (the gene coding for LR/37/67kDa) shRNA lentiviral particles 
was purchased (Santa Cruz). Schwannoma cells were seeded at a minimum of 
700,000 cells per well and, the day after splitting were infected with 20µl virus 
per well with the addition of protamine sulphate (8µg/ml). Cells were incubated 
with the viral particles for 72 hours before the medium was replaced with 
selection medium containing GFM and puromycin for a further 48 hours. After 
this, cells were starved by changing to medium containing only DMEM and 
puromycin before being subject to treatment with PrP peptide for either 1 hour 
or 24 hours and then lysed. Cell lysate was used for Western blotting and 
scramble control shRNA viral particles were used as a control (Insight 
Biotechnology, Wembley, UK). 
2.5.5 Knockdown of CD44/HCAM  
Pre-made CD44 shRNA lentiviral particles were purchased (Santa Cruz). 
Schwannoma cells were cultured, infected, selected and treated with PrP 
peptide exactly the same as described above for LR/37/67kDa shRNA, except 
with the addition of the CD44 shRNA lentiviral particles instead. Cell lysate was 
used for Western blotting and scramble control shRNA viral particles were used 
as a control (Santa Cruz).  
2.6 Co-immunoprecipitation 
Tumour cells were lysed in a low-salt Triton X-100 buffer (50mM Tris-HCl pH8, 
30mM NaCl, 10% glycerol, 1% Triton X-100 in d.H2O) with 5% complete 
protease inhibitor and 1% phosphatase inhibitors. Cell debris was removed by 
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centrifugation. 1mg cell lysate was incubated overnight at 4°C with pre-washed 
Upstate fast flow Protein G beads (GE Healthcare) along with either 1µg 
primary antibody (PrPC, CD44 (Santa Cruz), 37/67kDa laminin receptor (Novus 
Biologicals), p-gp (Abcam)), or 1µg normal IgG of the same species (Santa 
Cruz) as a negative control. Beads were thoroughly washed before adding twice 
concentrated reducing sample buffer and boiling. Samples were then subject to 
Western blotting on a 15% acrylamide gel for SDS-PAGE (see chapter 2.8) 
where schwannoma cell lysate from the same patient was used as an input 
control. Where noted, frozen schwannoma tumour samples were used instead 
of cultured cells, tumour samples were homogenised in the same buffer and 
then subject to the same treatment as cell lysate.  
2.7 Other functional assays 
2.7.1 Proteinase K sensitivity assay  
In order to check whether the PrPC present in the cell samples was the cellular 
form of the protease-resistant form, Schwann and schwannoma cells were 
lysed either as normal (see below) but either with the addition of 5% complete 
protease inhibitor or without the protease inhibitor and instead with the addition 
of 5% proteinase K (Sigma). Lysates were incubated at 37°C for 10 minutes 
then left to stand at room temperature for 1 hour. Proteinase K was inactivated 
using PMSF for 10 minutes at room temperature before lysates were spun 
down and run as normal on SDS-PAGE (see Chapter 2.8). 
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2.7.2 De-glycosylation assay 
Both Schwann and schwannoma cells were lysed in radioimmunoprecipitation 
(RIPA) buffer then treated with 5% sodium dodecyl sulphate (SDS), 1M 
Dithiothreitol (DTT), 0.5M Sodium phosphate buffer (pH7.5), 10% Triton X-100 
and either PNGase F (Promega) or distilled milliQ water as a control. Samples 
were incubated at 37ºC for 1-3 hours before being run on SDS-PAGE. 
2.7.3 Adhesion assay 
Suspended schwannoma cells were seeded (2000 cells/well) onto pre-coated 
96-well plates (325) and incubated at 37°C in 10% CO2 for three hours using 
different conditions: DMEM and 20µM, 100µM and 500µM TCS prion inhibitor 
13. For knockdown adhesion assays PRNP shRNA and their controls were 
treated, selected and counted prior to being plated and incubated only in GFM. 
After 3 hours cells were washed to remove any un-adhered cells, fixed and 
stained with DAPI before total cell number was counted using an Olympus 
fluorescent microscope.  
2.7.4 MTS viability assay 
Schwann or schwannoma cells were seeded onto pre-coated 96-well plates and 
grown until confluent. Cells were treated (only with treatments lasting >12 
hours) before adding the recommended mix of MTS (3-(4,5-dimethylthiazol-2-
yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) and 
PMS (phenazine methosulfate) from the kit (Promega) to each well (1:10 final 
concentration). Cells were incubated for 3-6 hours, in the dark, checking 
periodically before being read on a microplate reader at a wavelength of 490nm. 
MTS is a good fast way of getting a preliminary idea of cell viability but it is 
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difficult to determine whether changes in readings are due to a reduction in 
proliferation or an increase in apoptosis, thus more detailed assays are required 
for a better understanding (e.g. immunocytochemical proliferation and survival 
assays (Chapter 2.3.2.2)).  
2.8 Western blotting 
2.8.1 Sample lysis 
2.8.1.1 Cell lysis 
Cells were cultured on pre-coated plates to at least 70% confluency before 
being lysed on ice by both chemical and mechanical lysis by cell scraping. RIPA 
buffer was used as the chemical lysis agent (50mM Tris/HCl, 0.1% SDS, 1% 
NP-40, 150mM NaCl, 1mM EDTA, 0.5% sodium deoxycholate) with added 5% 
complete protease inhibitor (Roche) 1% phosphatase inhibitors B and C (Santa 
Cruz Biotechnologies). Lysates were centrifuged at 4ºC, 13,000rpm for 15 
minutes to remove cell debris and supernatant stored at -80ºC. Protein 
estimation was carried out using a colorimetric Pierce BCA Protein Assay Kit 
(Thermofisher Scientific). 
2.8.1.2 Tissue lysis 
Frozen schwannoma samples were manually homogenised in RIPA buffer on 
ice, the volume used was dependent on the size of the tumour piece. Lysate 
was stored at -20⁰C to improve protein extraction before being centrifuged at 
4ºC, 13,000rpm for 15 minutes to remove cell debris. Collected supernatant 
was then stored at -80ºC. Protein estimation was carried out using a 
colorimetric Pierce BCA Protein Assay Kit (Thermofisher Scientific). 
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2.8.2 SDS-PAGE and transfer to PVDF membrane 
10% polyacrylamide resolving gels topped with a 4% polyacrylamide stacking 
gel were made according to the protocol supplied with the 40% acrylamide 
solution (BioRad). A 15% polyacrylamide gel was used for running co-
immunoprecipitation samples. Cell lysate was loaded on the gel at a 
concentration of 20μg where possible. Before loading, samples were mixed with 
4x concentrated reducing buffer (250mM Tris-HCL [pH6.8], 8% SDS, 40% 
glycerol, 200mM DTT and 0.4% bromophenol blue (all Sigma)) and boiled for 5 
minutes at 90oC. A dual-colour protein ladder (BioRad) was used for molecular 
weight guidance. Proteins were separated according to size via sodium dodecyl 
sulphate – polyacrylamide gel electrophoresis (SDS-PAGE) at a constant 
voltage of 200v for 60 minutes at room temperature. Co-immunoprecipitation 
samples were run at a constant voltage of 150v for 120 minutes at room 
temperature.   
Proteins were transferred to a PVDF membrane (BioRad) in a transfer buffer 
made from 25 mM Tris, 19.2 mM glycine and 20% methanol (10% methanol 
was occasionally used in the transfer buffer for transfer and detection of very 
small proteins) at a constant amperage of either 250mA and 100V for 90 
minutes at 4ºC or 175mA and 85V overnight at 4ºC.  
2.8.3 Immunoblotting  
Unspecific binding to the membranes was prevented using 5% skimmed milk 
powder (Sigma) with 2% bovine serum albumin (BSA) in TBS-T (Tris buffered 
saline with 0.1% Tween) for 60 minutes at room temperature. Membranes were 
then incubated overnight with primary antibodies (see Table 3, Chapter 2.2.3 for 
detailed list). 
Application of primary antibodies was followed by incubation with the 
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appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies 
(goat anti-mouse, goat anti-rabbit, BioRad). Enhanced chemiluminescence 
(Pierce) was used for detection and GAPDH (Merck Millipore) was used as a 
loading control. Densities of bands were quantified using FluorS-Multi-Imager 
(Biorad) and all values, adjusted to GAPDH values before being determined as 
a percentage of basal or control where possible.  
2.9 Data analysis 
For statistical analysis student’s two-tailed t-tests and ANOVA with post-hoc 
tukey tests were used where group size was bigger than two. Experiments were 
performed in at least triplicate using at least three different batches of cells from 
different individuals where possible. The p-value was used to determine 
significance of the results; ns (not significant) p>0.05, * p<0.05, **p<0.01, 
***p<0.001. In figures mean ± SEM is given. 
  
 
89 | P a g e  
 
3. Results 
3.1 PrP expression and structure 
3.1.1 Different anti-PrPC antibodies show different staining patterns in 
schwannoma cells 
The PrP antibody used at the start of the project (PrP 6D11 (mouse) Insight 
Biotechnology, Wembley, UK) was initially thought to be specific to full-length 
PrP, however, due to its application specificity and species reactivity another 
antibody had to be used for immunoprecipitation and immunocytochemistry 
(PrP [EP1802Y] (rabbit) Abcam, Cambridge, UK). Even though both antibodies 
showed the exact same Western blotting pattern (size of band, molecular 
weight of band, etc.), the Abcam antibody that was specific to the C-terminal 
region of PrP, showed much more nuclear staining than the previous ‘full length’ 
PrP 6D11 antibody from Insight Biotechnology, which showed localisation 
throughout the cytosol and in the cell membrane of schwannoma cells when 
using the same fixation and staining protocol.  
To investigate fully, I purchased two new antibodies that were specifically 
designed to target either the C-terminal (Nbp1-92285) or N-terminal (Nbp2-
38508) portion of the protein. These antibodies confirmed my hypothesis that N-
terminal-specific PrPC antibodies localised mainly to the cytosol and membrane 
with only some nuclear staining (Fig. 9A) whereas C-terminal PrP localised only 
to the nucleus of most schwannoma cells (Fig. 9B). These findings mean that 
the antibody specificity must be taken into account when drawing conclusions 
from the results discussed below, particularly co-localisation and 
immunoprecipitation results, as different antibodies may have given a slightly 
different result.   
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Figure 9. N-terminal PrP is localised throughout the cytoplasm and cell 
membrane whereas C-terminal PrP is primarily localised to the nucleus. 
Schwannoma cells were fixed in 4% PFA, permeabalised with 0.2% Triton X-
100 then blocked with 10% NGS to prevent unspecific binding before being 
incubated either with the PrP antibody specifically recognising the N-terminus 
(A) or the C-terminus (B) of PrP (green staining). After incubation overnight, 
cells were washed before havng secondary antibodies and DAPI (blue staining) 
applied. Immunocytochemical staining demonstrates that different staining 
patterns occur between the two antibodies with the C-terminal portion only 
being picked up within the nucleus of schwannoma cells whereas the antibody 
recognising the N-terminal portion of the protein picked up PrP staining 
throughout the cells (n=3) PrPC is in green and DAPI is shown in blue. 
 
Upon discovery of the differences in PrP antibody specificity in 
immunocytochemical staining, I produced a table of the different antibodies 
used, what they were used for and the staining pattern I see. Certain antibodies 
had to be used for different techniques due to their suitability for that technique, 
thus, the terminal specificity was only taken more into consideration post-hoc. 
For further information please see Table 4.  
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Table 4: Table of PrP antibodies used and their staining pattern. 
Experiment Antibody Recognition site Observations using 
immunoflurescence 
IP (as bait)  PrP (Sigma) 
(Mouse, IP-specific 
antibody) 
C-terminal  C-term-specific 
antibodies show mainly 
nuclear staining. 
IP (blot) 
Western Blotting 
PrP (Abcam) 
(Rabbit) 
C-terminal C-term-specific 
antibodies show mainly 
nuclear staining. 
Western blot results are 
no different to N-
terminal PrP. 
ICC/ Immuno-
fluorescence 
PrP (Santa Cruz 
(Mouse)) 
Unspecified Cytosolic and 
membrane staining. 
IHC PrP 12F10 
(Mouse) 
C-terminal 
(aa142-160) 
Cytosol and some 
nuclear staining in 
tissues.  
 
PrP antibodies used for each experiment reflect the table above, any 
differences in antibodies used are noted. Due to pressures with time and 
resources, antibodies for both C-terminal and N-terminal were not used for each 
experiment, although this should be investigated fully in the future.  
3.1.2 PrP is overexpressed in schwannoma compared to Schwann cells 
Firstly I checked whether the PRNP gene upregulation previously described in 
schwannoma (59) translates to an increase in protein levels of PrP. 
Immunofluorescence using anti-PrP (N-T) antibody shows an increase in 
expression of PrP in schwannoma compared to Schwann cells (Fig. 10A) and 
that the PrP in schwannoma is localised throughout the membrane and cytosol 
but not in the nucleus (Fig. 10A, right panel, white arrows). 
Western blotting also shows that PrP is upregulated 3-4-fold in schwannoma 
compared to Schwann cells (Fig. 10B) and immunohistochemistry also 
 
92 | P a g e  
 
demonstrates an up-regulation of PrP in schwannoma with a similar expression 
pattern to that seen in vitro (Fig. 10C, right panel) compared to both normal 
nerve (Fig. 10C, left panel) and a a traumatic neuroma (Fig. 10C, central panel). 
Immunohistochemical staining was carried out by Dr. David Hilton’s team in the 
Neuropathology department of Derriford hospital.  
 
 
Figure 10. PrP is overexpressed in schwannoma cells and tissue. 
Immunofluorescence shows overexpression of PrP (red staining) in 
schwannoma (A, NF2-/-, right panel) compared to Schwann cells (A, NF2+/+, 
left panel) (n=5), particularly in membrane ruffles of schwannoma cells (A, right 
panel, white arrows). Western blotting which showed a significant increase in 
PrP expression in schwannoma (NF2-/-, B) compared to Schwann cells 
(NF2+/+, B) (n=5). Immunohistochemistry further demonstrated increased PrP 
expression (DAB, brown staining) in schwannoma tissue (C, right panel, n=10) 
compared to both normal nerve (C, left panel, n=5) and traumatic neuroma (C, 
central panel, n=5). *p<0.05. GAPDH was used as a loading control. 
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3.1.3 PrP is also overexpressed in meningioma and in Merlin-deficient 
mesothelioma cell line, TRA cells 
My research also aims to make these finding more widely applicable to other 
NF2-related tumours and other non-NF2, Merlin-deficient tumours. 
Immunohistochemical staining of meningioma (Fig. 11A) shows that PrPC is 
strongly over-expressed in these tumours (Fig. 11A panel ii and iii) compared to 
normal meninges (Fig. 11A, panel i, bottom) although PrPC is still more highly 
expressed in normal brain tissue (Fig. 11A, panel i, top). As meningiomas are 
more histologically diverse than schwannomas, I looked at both Merlin-positive 
(as judged by fluorescent in situ hybridisation (FISH, carried out by Dr. David 
Hilton, Derriford Hospital Neuropathology Department) as having an intact 
chromosome 22q) and Merlin-deficient (from NF2 patients) meningiomas and 
saw no difference in PrPC expression levels between the two tumour types (Fig. 
11A, ii and iii). Western blotting mirrored immunohistochemistry observations 
and showed a significant increase in PrPC expression between Merlin-deficient 
grade I meningioma samples and Merlin-positive human meningeal cells (HMC) 
(Fig. 11B and C).  Although HMC are not as good as normal human meninges 
as a control, they were the best available and provided consistent results.  
A subset of Human Malignant Mesothelioma (HMM) cells are also Merlin-
deficient, two HMM cell lines were used; Merlin-positive HIB cells and Merlin-
deficient TRA cells. I show a significant difference in PrPC expression between 
the two cell lines, with much higher PrPC expression in the Merlin-deficient TRA 
cells than in the Merlin-positive HIB cells (Fig. 11D).  
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Figure 11. PrP is overexpressed in Merlin-negative meningiomas and 
human malignant mesothelioma cells. 
Immunohistochemistry (n=10 of each sample type) shows that PrP expression 
is high in normal brain (Ai, top) but shows hardly any expression in normal 
meninges (Ai, NF2+/+, bottom). PrP expression is increased in both Merlin-
positive (Aii, NF2+/+) and Merlin-deficient (Aiii, NF2-/-) meningioma samples 
compared to normal meninges (Ai). No primary antibody control (Aiv) 
demonstrates specificity of staining. (B) Western blotting was used to quantify 
PrP protein expression and showed a significant overexpression of PrP in 
Merlin-negative meningiomas compared to human meningeal cell line (HMC, B, 
n=8). Images from each of the NF2-/- Western blot repeats are shown in (C). A 
significant increase in PrP expression was also seen between Merlin-deficient 
HMM cells, TRA, compared to Merlin-positive HMM cells, HIB (D, n=3). 
**p<0.01, GAPDH was used as a loading control. 
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3.1.4 The PrP expressed in schwannoma is the same di-glycosylated, protease-
sensitive form seen in Schwann cells 
I aimed to verify whether the PrP present in schwannoma is the protease-
sensitive form of the protein and not PrPres, the form associated with the 
development of prion diseases, which is resistant to degradation by proteinase 
K. To investigate this, cells were lysed either normally in the presence of a 
protease inhibitor cocktail or in the presence of proteinase K. Upon treatment 
with proteinase K there is a strong reduction in PrPC expression (Fig. 12A) 
suggesting that the PrP present in schwannoma is the cellular, protease-
sensitive form of the protein.  
In order to check the glycosylation status of the PrPC in both Schwann and 
schwannoma cells, cells were either treated with the de-glycosylation enzyme 
PNGaseF or with water as a control. Upon treatment with PNGaseF both 
Schwann and schwannoma cells display two lower bands on the gel (Fig. 12B 
bottom arrows), suggesting the presence of both a mono- and un-glycosylated 
form of the protein whereas the control lysates displayed a higher band around 
the 30kDa mark, indicating that the PrP present normally in both cell types is 
the di-glycosylated form (Fig. 12B, top arrow). Schematic diagrams of the 
different PrPC glycosylation states are shown in Fig. 12C to help visualisation of 
what occurs upon PNGase F treatment of cell lysates. 
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Figure 12. PrP in schwannoma is the cellular, fully glycosylated form of 
the protease-sensitive protein. 
The PrP present in schwannoma was sensitive to degradation by proteinase K 
(A), unlike protease-resistant forms of the protein (n=3). Treatment with 
glycosydase enzyme PNGaseF demonstrated the presence of de-glycosylated 
PrPC bands in both Schwann and schwannoma cells (B, n=3), suggesting the 
PrPC present in schwannoma is in the mature, fully di-glycosylated state. 
Schematic diagrams of the different PrPC glycosylation states are outlined in (C). 
Ns p>0.05, *p<0.05. GAPDH was used as a loading control. 
 
3.1.5 PrPC overexpression in schwannoma and TRA is Merlin-dependent but not 
in meningioma 
Next I looked into whether the PrP overexpression in all three of these tumour 
types is due to loss of the tumour suppressor protein Merlin. There was earlier 
suggestion that PrP expression in schwannoma is Merlin-dependent, as PrP is 
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only upregulated in schwannoma and not the Merlin-positive traumatic neuroma 
(Fig. 10C, central panel). In order to fully investigate whether PrPC expression is 
Merlin-dependent, I overexpressed the NF2 gene using an adenoviral 
reintroduction. Indeed, it appears that PrPC expression is dependent, at least 
partially, on Merlin as reintroduction of the NF2 gene into schwannoma causes 
a significant reduction in the expression of PrPC (Fig. 13A).   
 
 
Figure 13. PrPC overexpression is Merlin-dependent in schwannoma and 
mesothelioma but not significantly so in meningioma. 
Either the NF2 gene or a GFP control construct were introduced into 
schwannoma (A, n=5), meningioma (B, n=3) and TRA mesothelioma cells (C, 
n=3) using an adenoviral system and incubated for 24-48h until a significant 
number of cells showed GFP expression. Upon reintroduction of Merlin to 
schwannoma (A) and TRA mesothelioma cells (C), levels of PrPC significantly 
reduced. Re-introduction of Merlin into Merlin-deficient meningioma cells had no 
significant effect on PrPC levels (B).  Ns p>0.05, *p<0.05, **p<0.01, GAPDH 
was used as a loading control. 
 
Unlike in schwannoma, there appeared to be no difference in PrP expression 
between Merlin-positive and Merlin-negative meningiomas (Fig. 11A ii and iii), 
giving an early indication that other factors may be regulating PrPC 
overexpression in these tumours. In line with that I find no significant difference 
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in PrPC expression upon re-introduction of Merlin into Merlin-deficient 
meningioma samples (Fig. 13B). Finally, NF2-reintroduction into Merlin-deficient 
TRA cells does also significantly reduce PrPC (Fig. 13C), again suggesting that 
the PrPC overexpression in these cells compared to Merlin-positive HIB cells 
(Fig. 11D) is due, at least in part, to loss of Merlin.  
 
3.1.6 PrP expression and structure – discussion 
PrP mRNA is overexpressed in schwannoma (Fig. 10A-C), as initially 
determined from the mRNA microarray analysis (59). PrPC protein 
overexpression is seen in many other cancer cell lines (83) where it is present 
mainly in the membrane, where PrPC is known to reside within lipid rafts (326), 
and cytosol (Fig. 10A). In several tumours including breast (327) and colorectal 
(328) cancer, however, PrPC has been demonstrated in the nucleus. Based on 
the initial findings of the differential localisation of C and N-terminal PrP (Fig. 9) 
it could be that these cancers show an elevated expression of C-terminal PrP in 
the nucleus. Upon further investigation, I found that these previous research 
papers did use a C-terminal epitope of PrP antibody in their experiments. 
Similar PrPC overexpression patterns have been shown previously in neurons 
and some cancers such as neuroblastoma (reviewed in (97)). This could 
suggest several different things: Firstly, that the majority of PrPC in the 
membrane and cytosol of schwannoma cells is actually lacking the C-terminus 
but it could also mean that very little of the full-length PrP with the N-terminal 
makes it to the nucleus, this is odd because several nuclear localisation signals 
have been shown to be present within the N-terminal region of PrPC (329). 
There is some evidence in the literature of C-terminal PrP in the nucleus but it 
has mainly been shown in prion-infected animal models (reviewed in (329)), 
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however, the presence of multiple bands when probing with PrPC antibodies in 
my data (see Fig. 16A and C), could be indicative of the presence of several 
species or glycoisoforms of PrPC present in the same population.  
 
 
Figure 14. Loss of Merlin leads to overexpression of the di-glycosylated, 
cellular form of prion protein. 
I show that overexpression of PrP in schwannoma is primarily caused by loss of 
the tumour suppressor protein Merlin. The form of prion protein present in these 
cells is the cellular, fully glycosylated form and not the protease-resistant form 
associated with prion diseases.  
 
PrPC appears to also be upregulated in Merlin-deficient meningiomas compared 
to normal meningeal tissue and cells (Fig. 11A-C) and in the Merlin-deficient 
mesothelioma cell line TRA compared to the Merlin-positive HMM cell line HIB 
(Fig 11D). This is the first time levels of PrP have been investigated in these 
brain tumour subtypes and, whilst there is evidence in the literature that the 
prion protein homologue Dpl is upregulated in meningioma (reviewed in (330)) 
there is nothing in the literature regarding PrPC expression. These data suggest 
not only that PrPC may be overexpressed in a variety of NF2-related tumours 
but also that PrP overexpression may be caused by loss of the tumour 
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suppressor protein Merlin and so PrP overexpression may extend to other 
Merlin-deficient tumours. There are already a number of cancer types reported 
to show increased levels of PrP, a small fraction of which are deficient in Merlin 
including breast, prostate, colorectal cancers and glioblastoma multiforme 
(GBM) (83,331) providing a potential link between these two proteins.  
PrP expression in schwannoma appears to be Merlin-dependent as IHC 
staining shows no upregulation of its expression in the non-Merlin-deficient 
Schwann cell proliferation known as a traumatic neuroma compared to normal 
nerve tissues whereas Merlin-deficient schwannoma cells show clear increased 
expression of PrP compared to controls (Fig. 10C). Importantly however, not all 
tumours overexpressing PrPC are Merlin-deficient (e.g gastric cancers). This 
suggests that there must be other regulatory proteins and pathways involved in 
PrPC expression in tumour cells besides Merlin. These other important 
regulatory pathways could also contribute a small amount to PrPC 
overexpression in schwannoma, as Merlin re-introduction failed to decrease 
PrPC levels (Fig. 13) by the same amount as they are increased in schwannoma 
compared to Schwann cells (Fig 10).  
Adenoviral reintroduction shows PrPC to be Merlin-dependent only in 
schwannoma (Fig. 13A) and TRA cells (Fig. 13C) but not in meningioma (Fig. 
13B). The likely reason behind the lack of Merlin-dependent expression in 
meningioma may be, in part, down to the complexity of these tumours, there are 
many more subtypes, other mutations and grades (reviewed in (332)) as well as 
other variables such as additional mutations that are involved in these tumours 
that may contribute to regulation of PrPC. 
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I also investigated whether the PrP present within schwannoma samples was 
the ‘normal’ cellular form of prion protein (PrPC). I found the PrP in schwannoma 
to be the di-glycosylated, cellular form PrPC as presence of PrP protein was 
completely abolished upon treatment with proteinase K (Fig. 12A). This would 
not have occurred in the PrP present was the scrapie or resistant form (PrPSc or 
PrPres). Differences in glycosylation state of PrP may have accounted towards 
its accumulation within cells due to under or over-processing (333). However, I 
show that in both Schwann and schwannoma cells in culture PrP is present in 
the di-glycosylated, fully post-translationally modified form (Fig. 12B and C).  
 
3.2 Control of PrPC expression 
3.2.1 PrPC overexpression in schwannoma is due to increased gene transcription 
and not due to altered protein degradation  
Next I investigated the mechanisms by which PrPC overexpression may occur; 
whether it is solely due to the increased gene expression as previously 
described (59), or whether altered degradation is causing intracellular 
accumulation of the protein. In order to investigate gene expression, I used two 
inhibitors – Actinomycin D (Act. D), an inhibitor of transcription, and 
cycloheximide (CHX), an inhibitor of protein synthesis. Upon treatment of 
schwannoma cells with both Actinomycin D (Fig. 15A) and cycloheximide (Fig. 
15B) there is a significant reduction in PrPC expression suggesting that high 
PrPC levels in schwannoma are largely associated with increased PRNP gene 
expression and translation. The half life of GAPDH (8h (334))  also differs from 
that of PrPC (2.6h (335)), suggesting that PrPC can be degraded more rapidly 
than GAPDH upon treatments with actinomycin D and cycloheximide, allowing 
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for a stable GAPDH band even though PrPC levels are seen to decrease 
significantly. Protein estimation took into account for any smaller differences the 
actinomycin D and cycloheximide may have had on GAPDH protein expression 
to ensure the same amount of total protein was loaded onto the gel at the start 
of the experiment. 
 
Figure 15. PrPC in schwannomas is increased due to enhanced gene 
transcription and is degraded by both proteasomal and lysosomal 
degradation. 
Inhibition of schwannoma gene transcription using the inhibitor Actinomycin D 
(Act D, A), significantly reduced expression of PrPC (n=3), as did inhibition of 
protein synthesis using the translation inhibitor cycloheximide (B, n=5). 
Inhibition of proteasomal (Mg132) and lysosomal (Chloroquine, CQ) 
degradation was able to significantly increase levels of PrPC (C, n=5). *p<0.05, 
**p<0.01, GAPDH was used as a loading control. 
 
There are several pathways by which cellular proteins are degraded but the 
most common are lysosomal degradation and proteasomal degradation. Prion 
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proteins have been previously described to be degraded via both of these 
pathways (151,336,337). In schwannoma cells treatment with proteasomal 
degradation inhibitor MG132 (Fig. 15C) and lysosomal degradation inhibitor 
chloroquine (CQ, Fig. 15C) cause significant increases in PrPC levels. These 
results suggest that overexpression of PrPC in schwannoma is not due to 
alterations in the degradation pathways that would likely lead to protein 
accumulation and instead is purely due to gene upregulation and increased 
transcription of PRNP. 
3.2.2 PrPC expression is not regulated by DCAF1 
As PrPC expression in schwannoma is mainly regulated by gene transcription I 
wanted to investigate the role of two transcription factors – CRL4DCAF1 (a broad-
range transcriptional regulator potentially acting epigenetically) and NFκB, 
which have well-defined roles in schwannoma development and pathology 
(72,213) – to see whether they regulate  PrPC expression and thus may be 
involved in PrPC overexpression in schwannoma. Firstly, I used a shRNA 
construct to knock down expression of DCAF1 in schwannoma. Upon DCAF1 
knockdown there was no difference in PrPC expression (Fig. 16A). I also wanted 
to see whether PrPC in schwannoma could, instead, reside upstream of DCAF1, 
potentially regulating its transcription. However, upon knocking down of PrPC 
expression there was no significant difference in expression of DCAF1 (Fig. 
16B).  
3.2.3 PrPC overexpression in schwannoma may be regulated by NFκB   
NFκB has been widely described as a transcription factor, regulating expression 
of many genes including those involved in cell survival (including BAX, Bcl-2 
and XIAP (338-340)) adhesion (such as CD44 and N-CAM (341,342)) and 
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inflammation (e.g. COX2 (343)). I have previously shown that NFκB expression 
is upregulated in schwannoma compared to healthy cells (213). 
 
Figure 16. Transcriptional regulation of PrPC occurs via NFκB but not 
DCAF1. 
Upon knockdown of DCAF1 expression using DCAF1 shRNA PrPC levels were 
not affected (A, n=3). DCAF1 expression was also not altered upon PrPC 
knockdown using PRNP shRNA (B, n=3). Inhibition of NFκB with SN50 
significantly reduced PrPC expression (C, n=5) but knockdown of PrPC was also 
able to significantly increase NFκB p65 expression (D, n=4). Ns p>0.05, 
*p<0.05, **p<0.01, GAPDH was used as a loading control. 
 
Using an NFκB small molecule inhibitor; SN50 (previously successfully used in 
schwannoma cells (213)), to inhibit the transcription factor activity of p50/p65 
NFκB (the canonical NFκB pathway) by preventing p50 translocation to the 
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nucleus. (213)Lentiviral knockdown using shRNA for NFκB was not possible as 
the lentiviral particles I had did not sufficiently reduce NFκB expression and 
therefore could not be used. Upon treatment of schwannoma cells with SN50 
(8µg/ml) for 24 hours, levels of PrPC significantly decreased (Fig. 16C) 
suggesting that NFκB plays a role in regulating PrPC expression in 
schwannoma. Interestingly, I also checked NFκB expression in cell lysates 
treated with PRNP shRNA even though there is no evidence of PrPC as a 
transcriptional regulator, I found that reducing PrPC in schwannoma also 
increases NFκB expression (Fig. 16D). 
 
3.2.4 Control of PrPC expression – Discussion 
From the gene array analysis between schwannomas and Schwann cells (59) it 
appeared that upregulation of PrPC occurred at the genetic level, with 
alterations in the transcription of PRNP. However, I wanted to check whether 
the overexpression of PrPC at the protein level was solely due to alterations in 
transcription or whether alterations in the normal protein degradation pathway 
were affecting PrPC levels. I show using transcription inhibitor actinomycin D 
and translation inhibitor cycloheximide (Fig. 15) that by reducing global levels of 
transcription in schwannoma cells in culture, expression of PrPC can be reduced. 
This suggests that increased PrPC expression in schwannoma is due to the 
increased transcription and translation of PRNP. It is not the first time that 
higher PrP mRNA levels have been shown to be present in tumours; in breast 
cancer (327) and colon cancer PrP mRNA was shown to be upregulated via 
microarray analysis (344). To fully quantify the PRNP gene expression 
difference between Schwann and schwannoma cells, quantitative real-time 
polymerase chain reaction (qRT-PCR) would need to be used. 
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There are several known nuclear proteins that may act as transcription factors 
which are upregulated in schwannoma and involved in schwannoma 
pathological signalling that may be regulating PRNP transcriptional upregulation. 
One of the most well-known is the nuclear E3 Ubiquitin Ligase CRL4DCAF1 
(DCAF1) which in healthy Schwann cells is negatively regulated by Merlin (50). 
However, upon shRNA knockdown of DCAF1 expression, there was no 
alteration in PrPC expression (Fig. 16A) suggesting either that DCAF1 is not in 
control of PRNP transcription or that compensatory mechanisms are able to 
take over to maintain the high levels PrPC expression. 
 
 
Figure 17. Overexpression of PrPC in schwannoma is due to increased 
gene activity, not altered protein degradation and appears to involve NFκB. 
Overexpression of PrPC is likely due to increased gene activity of PRNP as 
seen previously (59) rather than decreased degradation. PrPC degradation in 
schwannoma can be blocked by both inhibitors of proteasomal and lysosomal 
degradation suggesting that PrPC in these cells is degraded via both pathways. 
Finally, transcriptional control of PrPC could be via NFκB but does not appear to 
involve CRL4DCAF1. 
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Another transcription factor potentially in charge of regulating PRNP 
transcription is NFκB which is upregulated in schwannoma (213) and known to 
regulate other key proteins associated with schwannoma pathology including c-
Jun (345) and AKT (346). Two NFκB inhibitors (BAY11-7082 and Curcumin) 
were found to significantly reduce VS proliferation in culture (211) suggesting 
that, targeting NFκB could make for a beneficial therapeutic target in 
schwannoma cells, although small molecule inhibitors can be unspecific and 
have multiple off-target effects. Circumin, for example also inhibits phorbol 
ester-induced protein kinase C (PKC), production of inflammatory cytokines, 
EGFR, cyclooxygenase 2 (COX2), lipoxygenase and IκB kinase as well as 
NFκB (347). I used the small molecule inhibitor SN50 to inhibit NFκB 
translocation to the nucleus and found the action of this drug was able to 
significantly reduce PrPC expression levels (Fig. 16C). ER stress, a common 
mechanism by which PrPC is upregulated in cells (327), also causes 
upregulation of NFκB (348). This suggests that PrPC may be under direct 
control of NFκB in schwannoma cells. What’s more, PrPC appears to be able to 
reciprocate this activation of NFκB transcription as knockdown of PRNP using 
shRNA significantly increases expression of NFκB (Fig. 16C), suggesting some 
kind of reciprocal interaction between these two proteins. No data has, thus far, 
demonstrated a role for PrPC as a transcription factor but PrPC has been shown 
to reside in the nucleus of some cancer cell types (97), uncovering a potentially 
interesting new role for PrPC as a transcriptional regulator in cancer cells.   
I then discovered that the increased expression of PrP in schwannoma was 
purely down to the aforementioned upregulation in PRNP gene activity rather 
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than alterations or complete defects in the PrP degradation pathways, as 
inhibitors of proteasomal (MG132) and lysosomal (CQ) degradation further 
increased PrPC expression (Fig. 15C). PrPC has been demonstrated widely to 
be degraded by autophagy and lysosomal degradation (349) and no deficits in 
either of these pathways have thus far, been demonstrated in schwannoma. In 
fact, increased autophagic activity has been described in schwannoma before 
(350) and my own unpublished data showed increased levels of LAMP-1 and 
LC3, both autophagy-related proteins, in schwannoma compared to Schwann 
cells (Supplementary Fig. 1).  
 
3.3 PrPC release from schwannoma cells 
3.3.1 PrPC is released from schwannoma cells via exosomes 
It is well known that prions can be released from cells, propagating prion 
diseases by interacting with surrounding cells. I originally hypothesised that 
PrPC was also released from schwannoma cells and acts in both an autocrine 
and paracrine manner to stimulate surrounding cells. Firstly, I used an ELISA to 
check the release of PrPC from Schwann and schwannoma cells into the cell 
culture medium. I show for the first time, that PrPC is released from both 
Schwann and schwannoma cells but significantly more from the tumour cells 
(Fig. 18A).  I wanted to check whether the PrPC released from schwannoma 
cells is released as free peptides via cleavage from the cell membrane or 
exocytosis, or, whether the PrPC was being released via exosomes, as this 
could affect how the PrPC may act on neighbouring cells. I used an exosome 
isolation kit (Invitrogen) to extract the exosomes from cell culture medium and 
ran this on a Western blot alongside both total cell medium and the leftover cell 
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medium after the exosome isolation (termed ‘supernatant’). Concentrated 
growth factor medium (GFM) from the bottle was used as a negative control and 
was made with exosome-free FBS throughout the exosome isolation 
experiments.  
 
 
Figure 18. PrPC is released from schwannoma cells via exosomes. 
PrPC is more highly released from schwannoma cells compared to Schwann 
cells (ELISA, A, n=3). Upon exosome isolation, it is clear that a large portion of 
the PrPC released from schwannoma cells occurs via exosomes (B, dark grey 
bar, n=3, ELISA). Western blotting demonstrated that PrPC was present in the 
exosome fraction although at a much lower level than the PrPC expressed 
intracellularly (C, n=3, top panel), CD63 was used as a late endosome/exosome 
marker (C, bottom panel). Immunofluorescent staining shows co-localisation of 
PrPC and CD63 within schwannoma cells suggesting that PrPC travels through 
cells in late endosomes before being released via exosomes (D, n=3). *p<0.05, 
**p<0.01, ***p<0.001.  
 
The results indicate that the majority of the PrPC released from schwannoma 
cells into the culture medium (Fig 18B, light grey bar ‘medium’) is via exosomes 
(Fig.18B, dark grey bar ‘Exo’) and only a small amount is released as free 
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peptide in the ‘supernatant’ fraction (Fig. 18B, black bar, ‘Sup’). This is further 
demonstrated by Western blotting (Fig. 18C) in which PrPC is only visible in the 
exosome fraction and is present in too small a quantity in the supernatant to be 
picked up as Western blotting is much less sensitive a technique compared to 
ELISA. CD63 is used as an exosome marker to validate the isolation (Fig. 18C, 
bottom panel). Using immunocytochemistry, I show co-localisation between 
PrPC and CD63 (late endosome/exosome marker) within the tumour cells (Fig. 
18D) suggesting that PrPC is transported through schwannoma cells within 
endosomes to the plasma membrane and is released to the extracellular matrix 
via exosomes. 
 
3.3.2 Non-exosome PrPC release is not regulated by GPI anchor cleavage  
Next I wanted to ascertain the mechanism behind how ‘free’ PrPC in the culture 
medium is released from cells. PrPC has been previously demonstrated to be 
released from cells in vitro via cleavage of the GPI anchor using 
phosphatidylinositol phospholipase C (PIPLC). However, in schwannoma there 
is no difference in PrPC expression or localisation upon treatment with PIPLC, 
as shown by immunofluorescence (Fig. 19A) and no significant difference in the 
amount of PrPC released from schwannoma cells into the culture medium, as 
shown using ELISA (Fig. 19B). Thus, in schwannoma, free PrPC is released by 
mechanisms other than cleavage of the GPI anchor.  
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Figure 19. PrPC is released from schwannoma cells by cleavage by 
ADAM10 but not by GPI anchor cleavage by PIPLC. 
GPI anchor cleavage of PrPC using PIPLC did not alter intracellular PrPC 
expression judged by immunofluorescence (A, n=3), or the PrPC released from 
cells into the culture medium (B, ELISA, n=3). Inhibition of α-cleavage by 
ADAM10 significantly increased intracellular PrPC level (C, n=5), E-cadherin 
was used as a positive control as it is known to be cleaved by ADAM10 at the 
cell surface (351). Inhibition of ADAM10 also significantly decreased the amount 
of PrPC released from schwannoma cells as judged by ELISA (D, n=6). Ns 
p>0.05, *p<0.05, **p<0.01, GAPDH was used as a loading control. 
 
3.3.3 PrPC is released from schwannoma by α-cleavage by ADAM10 
Upon discovering that PrPC did not appear to be cleaved and released from the 
membrane by PIPLC, I investigated potential other mechanisms of PrPC 
cleavage. The most well-documented is α-cleavage just after the octapeptide 
repeat of PrPC by the membrane metalloproteases ADAM9, ADAM10 and 
ADAM17, a process also known as ‘ectodomain shedding’ (102,352). I decided 
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to investigate the role of ADAM10 in PrPC cleavage as this was the enzyme 
most well-documented in the literature (353).  
Schwannoma cells were incubated for both with GI254023X, a specific 
ADAM10 inhibitor at a final concentration of 20µM for 24 hours. Cell lysate was 
collected before being subject to Western blotting in order to analyse PrPC 
levels. Data shows that there is a 1.5-2-fold increase in the amount of PrPC 
within cells upon treatment with the ADAM10 inhibitor (Fig. 19C) suggesting that 
ADAM10 plays a small role in the normal regulation of PrPC expression and 
release of the N-terminal fragment in schwannoma cells (reviewed in (354)). 
Although a small amount of full length PrPC can be secreted from cells (PrPSec), 
the majority of uncleaved PrPC remains in the cell. Cell culture medium was 
also run using the PRNP ELISA which demonstrated a significant decrease in 
PrPC release from schwannoma cells upon treatment with ADAM10 inhibitor 
(Fig. 19D).  
 
3.3.4 PrPC release from schwannoma cells – Discussion 
I show for the first time that PrPC is released from schwannoma cells and at a 
higher rate than is released from Schwann cells (Fig. 18A). Although exosomes 
have been shown to be released from tumour cells in various previous studies 
(355) and both cellular and scrapie forms of PrP have been shown to be 
released via exosomes in ROV cells (derived from RK-13 rabbit kidney cells 
overexpressing PrP) and MOV cells (derived from mouse neuroglial cells 
overexpressing PrP) (356,357), the two together have never been shown in 
tumour cells. I show using ELISA, Western blotting and immunofluorescence 
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that PrPC is released from schwannoma cells in association with exosomes 
(Fig. 18B-D).  
 
Figure 20. PrPC is released from schwannoma cells via exosomes and by 
cleavage by ADAM10. 
PrPC is known to be transported through the cytosol of cells via late 
endosomes, my data shows that these PrPC-containing late endosomes are 
released from cells as exosomes which may then be able to activate cells in a 
paracrine or autocrine manner. I also show that PrPC can be cleaved and 
released from the schwannoma cell membrane by the matrix metalloprotease 
ADAM10, although other ADAMs such as ADAM9 and ADAM17 may also play 
a role.  
 
From the exosome isolation ELISA experiments, it was clear that a small portion 
of the PrPC detected in the ELISA was not exosome associated (Fig. 18B), thus 
I investigated other mechanisms of PrPC release from these cells. Initially 
investigating whether PrPC could be released via cleavage of the GPI anchor 
(358), a process referred to as ‘shedding’. However, it was clear that cleavage 
of the GPI anchor using PIPLC is insufficient to cause release of PrPC from 
schwannoma cells (Fig. 19A and B). This raises the question as to whether 
PrPC is even membrane-anchored in these cells in the first place or whether it is 
just trafficked through vesicles and recycled at the cell surface.  
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I then wanted to investigate whether PrPC was released instead via its α-
cleavage by one of the several metalloproteases that have been reported to be 
able to cleave PrPC (102). One of the most widely reported of these 
metalloproteases is ADAM10, which cleaves PrPC between Gly228 and Arg229 
(121). I found that inhibition of ADAM10 did indeed cause an accumulation of 
PrPC to build up within schwannoma cells and reduce the amount of PrPC 
released from these cells suggesting that PrPC is cleaved and released from 
schwannoma cells via α-cleavage and not via ‘shedding’ (Fig. 20).  
This has many implications for the treatment of tumours. Recently another 
tumour suppressor protein shown to be downregulated in schwannoma, p53 
(359) has been shown to have ‘prion-like’ tendencies. Data has suggested that 
mutant p53 is able to aggregate and turn healthy p53 into oncogenic, mutant 
p53 in cancer cells (360). If PrPC has similar oncogenic  prion tendencies within 
these tumour cells it could make investigating PrPC release from schwannoma 
cells, and its action on neighboring healthy cells, an avenue that would be 
interesting to investigate further.  Furthermore, it could also make PrPC a very 
interesting potential biomarker to consider if PrPC-containing exosomes could 
be detected in patient blood (PrPC and PrPSc have previously been described in 
human blood plasma samples (361)) and could help predict re-growth or tumour 
size and burden for patients in a relatively un-invasive and inexpensive manner 
when compared to scans and surgeries.  
3.4 PrPC in schwannoma proliferation, adhesion and survival  
In order to further evaluate the role of PrPC in schwannoma development I 
wanted to look at the effects of knocking down levels of PrPC. I used two 
methods to reduce expression of PrPC in schwannoma cells, lentiviral particles 
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containing PRNP shRNA both homemade TRC lentivirus (Fig. 21Aii) and a pre-
made pool containing 5 different shRNA constructs (Fig. 21Ai).  
 
Figure 21. Knockdown of PrPC using PRNP shRNA and TCS prion inhibitor 
13. 
Both pre-made PRNP shRNA (Ai) and home-made PRNP shRNA viral particles 
made using a TRC gene set (Thermofisher) (Aii) significantly reduce expression 
of PrPC as well as cyclin D1 and pERK1/2, as determined by Western blotting 
(n=5 for each lentivirus). Results from both the pre-made and homemade 
viruses were combined due to time restraints on making more of the homemade 
virus. At both 100μM and 500µM concentrations of TCS prion inhibitor 13 PrPC 
levels were significantly reduced in a dose-dependent manner (n=6) therefore 
TCS prion inhibitor 13 was also used in further experiments to reduce PrPC 
expression in schwannoma cells.  Ns p>0.05, *p<0.05, **p<0.01, GAPDH was 
used as a loading control.  
 
I also used TCS prion inhibitor 13, originally designed to inhibit PrPSc 
accumulation (362), which I show to also affect total PrPC levels (Fig. 21B), all 
three methods (shRNA and TCS prion inhibitor) significantly reduced 
expression of PrPC in schwannoma cells (Fig. 21Ai, ii and B). As results from 
the two types of PRNP shRNA were identical, I combined the results and 
continued using mainly the pre-made viral particles due to time constraints and 
due to limited primary tumour material. 
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3.4.1 PrPC contributes to increased schwannoma proliferation and survival  
Firstly, I wanted to investigate whether reducing PrPC levels in schwannoma 
affects the pathological hallmarks of these tumours – increased proliferation, 
resistance to apoptosis and increased cell matrix adhesion. Reducing PrPC 
levels significantly reduces the number of proliferating schwannoma cells in 
GFM medium. This was judged by the decreased presence of Ki67 in the 
nucleus of schwannoma cells upon treatment both with PRNP shRNA (Fig. 22C) 
and TCS prion inhibitor 13 (Fig. 22D), this is further demonstrated in the 
immunofluorescence images (Fig. 22A and B, red arrows).  
Apoptosis of schwannoma cells was judged by expression of cleaved caspase-
3, the executioner caspase with a major role in apoptosis (ref?). Numbers of 
cleaved caspase-3-positive cells increases as PrPC is reduced (Fig. 22E and F), 
seen both using immunofluorescence (Fig. 22A and B, green arrows) and 
Western blotting (Fig. 22G and H). Data suggests a role of PrPC in 
schwannoma proliferation and survival as an increase in schwannoma 
apoptosis and a reduction in proliferation can be observed as PrPC levels 
diminish. 
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Figure 22. PrPC is involved in schwannoma proliferation and resistance to 
apoptosis. 
Knockdown of PRNP leads to a reduction in Ki67-positive cells (A, red arrows 
and quantified in C, n=3) as does inhibition of PrPC using TCS (B, red arrows, 
quantified in D, n=3). PRNP knockdown also increases the number of cleaved 
caspase-3-positive cells (A, green arrows, quantified in E, n=3) as does 
inhibition of PrPC using TCS (B, green arrows, quantified in F, n=3) also 
observed using Western blotting using both PRNP shRNA (G, n=4) and TCS (H, 
n=5). Ns p>0.05, *p<0.05, **p<0.01, ***p<0.001. GAPDH was used as a loading 
control. 
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3.4.2 PrPC in schwannoma protects against free radical-induced apoptosis but 
not Bax-mediated apoptosis  
There are several mechanisms by which PrPC is thought to exert 
neuroprotective effects, thus contributing to cell survival; namely preventing Bax 
or free radical-mediated apoptosis.  
 
Figure 23. Protection of Bax and free radical-mediated schwannoma 
apoptosis by PrP. 
Treatment of schwannoma cells with H2O2 to stimulate free radical-induced 
apoptosis significantly reduced cell viability, quantified using MTS assay (B) but 
pre-treatment with PrP peptide led to a significantly reduced cell viability (B, 
light grey bars, n=3). Staurosporine (denoted as ‘S’) was used to induced Bax-
mediated apoptosis in schwannoma cells (A), but pre-treatment of cells with PrP 
was unable to protect them from staurosporine-induced cell death, quantified 
using MTS assay (B. light grey bars). Treatment of schwannoma cells with H2O2 
induced activation of caspase 3 (C, green arrows) but pre-treatment of these 
cells with PrP peptide prevents this increase in cells expressing cleaved 
caspase-3 (C, bottom right panel). Ns p>0.05, *p<0.05, **p<0.01. Where the 
SEM is very low the error bar cannot be depicted.  
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I show using MTS assays that pre-treatment with a central portion of the PrP 
peptide chain (aa105-120, AbD Serotec) protects schwannoma cells from 
oxidative stress induced by hydrogen peroxide treatment (H2O2, Fig. 23A) but 
not against staurosporine-induced BAX-mediated apoptosis (Fig. 23B).These 
results mirror what has previously been reported in the literature regarding PrPC 
protecting against free-radical mediated cell death via activation of caspase-3 
and PKCδ (363), and give a glimpse of the potential mechanisms of PrPC-
mediated schwannoma survival that is seen in this primary cell culture model, 
therefore providing further potential therapeutic targets to investigate. 
 
3.4.3 PrPC plays a role is schwannoma pathological cell matrix adhesion 
 
Figure 24. PrPC plays a role in schwannoma pathological cell matrix 
adhesion. 
Schwannoma cells were infected and selected with either scramble (scr) shRNA 
or PRNP shRNA before being plated in equal numbers for three hours at 37ºC. 
Knockdown of PRNP significantly reduced the number of schwannoma cells 
that adhered to the pre-coated culture plate within this time frame (A, n=3). For 
the TCS prion inhibitor experiment cells were split and treated with the inhibitor 
just before being plated then incubated for three hours. Again, in a dose-
dependent manner, reduction of PrPC significantly reduced schwannoma cell 
matrix adhesion (B, n=3). *p<0.05, **p<0.01, ***p<0.001.  
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Aberrant cell matrix adhesion is one of the pathological hallmarks of 
schwannoma cells in vitro and is thought to be due to overexpression of 
adhesion proteins such as FAK, integrins and their associated ligands such as 
insulin-like growth factor binding protein -1 (IGFBP-1) (183). Reducing levels of 
PrPC significantly reduced the adhesive properties of schwannoma cells in 
culture after three hours post-plating, seen both using PRNP shRNA (Fig. 24A) 
and TCS prion inhibitor 13 (Fig. 24B). 
3.4.4 PrPC affects schwannoma proliferation, survival and cell matrix adhesion by 
signalling via cyclin D1, ERK1/2, PI3K/AKT, FAK and p53 
To further investigate the role of PrPC in schwannoma proliferation, survival and 
cell matrix adhesion I then investigated relevant signalling pathways 
downstream of PrPC. The pathways I investigated have all been shown to be 
key for schwannoma development. Cyclin D1 controls proliferation via 
regulation of cell cycle progression through G1/S phase, cyclin D1 is 
upregulated in schwannoma (364) but levels are significantly reduced upon 
treatment of cells both with PRNP shRNA (Fig. 25A, left panel) and TCS prion 
inhibitor 13 (Fig.25A, right panel). Another pathway over-activated in 
schwannoma that regulates proliferation is the Raf/MEK/ERK pathway (365). 
ERK1/2 catalyses phosphorylation of nuclear transcription factors including 
FOXO3 and STAT1 which then activate genes involved in cell division  (366). 
Levels of both total and phosphorylated, active ERK1/2 are decreased using 
PRNP shRNA (Fig. 25B, left panel, darker bars), levels of both total and 
pERK1/2 are decreased upon treatment at high concentrations with TCS prion 
inhibitor 13 (Fig.25B, right panel). 
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Figure 25. PrPC acts via key pathways involved in schwannoma  
proliferation, survival, adhesion and tumourigenesis.  
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Figure 25. PrPC acts via key pathways involved in schwannoma 
proliferation, survival, adhesion and tumourigenesis. 
Both PrPC shRNA and TCS prion inhibitor were able to reduce expression of 
cyclin D1 (A, n=3). Levels of both total and pERK1/2 were reduced both with 
PRNP shRNA and TCS inhibitor (B, n=5). Levels of pAKT were reduced both 
with PRNP shRNA and TCS (C, both panels, lighter bars) but levels of total AKT 
were unaffected (C, both panels, darker bars, n=5). Levels of both total and 
phosphorylated FAK are reduced upon reduction of PrPC (D, n=6). P53 
expression increases as a result of PrPC reduction in schwannoma cells (E, 
n=6). Ns p>0.05, *p<0.05, **p<0.01, ***p<0.001. GAPDH was used as a loading 
control.  
 
The PI3K/AKT pathway and its downstream effector protein mTOR, have 
previously been shown to be upregulated in schwannoma (367) and contribute 
to increased schwannoma cell proliferation and survival (368). Reduction of 
PrPC via both PRNP shRNA (Fig.25C, left panel) and TCS prion inhibitor 13 (Fig. 
25C, right panel) reduces levels of activated AKT phosphorylated at serine 473 
(darker bars), but expression of total AKT is unchanged (lighter bars).  
FAK is a protein kinase localised mainly to membrane focal adhesions. As its 
name suggests it has a role in cell matrix adhesion (368) but, via its 
translocation to the nucleus  can also play an important role in cell proliferation 
(369). It also binds to and inhibits the tumour suppressor activity of p53 (369) 
which is mutated in at least 50% of all human cancers and has been shown to 
be reduced in schwannoma tumours (359). I show that phosphorylation of FAK 
at tyrosine 397 may be dependent on PrPC expression as reducing PrPC both 
with PRNP shRNA and TCS prion inhibitor 13 reduced activation of FAK at this 
phosphorylation site (Fig. 25C right and left panel, darker bars). Levels of total 
FAK protein are reduced using shRNA and at high levels of prion inhibitor 
treatment (Fig. 25C right and left panel, lighter bars).   
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Finally, levels of p53 which are very low in schwannoma are significantly 
increased using PRNP shRNA (Fig. 25D, left panel) and at high levels of TCS 
prion inhibitor 13 (Fig.25D, right panel). 
3.4.5 PrPC in schwannoma proliferation, survival and adhesion – Discussion 
PrPC has been shown to protect human neurons from Bax-mediated apoptosis 
(125) and from oxidative stress in neuroblastoma SH-SY5Y cells (113). 
Resistance to oxidative stress has been previously demonstrated in 
schwannoma and has been linked to high expression levels of JNK due to their 
role in suppressing the accumulation of superoxides in the mitochondria 
(370,371). My data show that treatment of schwannoma cells with PrP peptide 
is able to protect them from oxidative-stress-induced apoptosis (Fig. 23A) but 
not from Bax-mediated apoptosis (Fig. 23B) suggesting that the mechanisms 
via which PrPC exerts its neuroprotective effects may differ between different 
cell types.  
As well as influencing schwannoma pathological proliferation and survival, it 
appears that PrPC also plays a role in schwannoma cell matrix adhesion as 
knockdown of PRNP expression leads to reduced numbers of adhered cells in 
culture (Fig. 24). There are several well-documented mechanisms via which 
PrPC affects cell adhesion including N-CAM (372), integrin β1 (175), laminin 
(373), and E-cadherin (reviewed in (374)), proteins known to be expressed in 
Schwann cells, therefore it makes sense to see adhesive properties of 
schwannoma cells diminish as PrPC levels decreased.  
The pathways via which PrPC signals to affect proliferation, survival and 
adhesion are plentiful, so I investigated only a handful of pathways which have 
been previously shown to be important for schwannoma development 
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(67,68,183,213,359,368,375-377). I show that PrPC likely affects schwannoma 
cell proliferation by acting via several of these pathways; the PI3K/AKT pathway 
and its downstream effector cyclin D1 are all downregulated upon reduction of 
PrPC (Fig. 25 A and C), two pathways previously linked and shown to contribute 
to cancer cell proliferation and tumourigenesis (378), also ERK1/2 appears to 
be regulated by PrPC to contribute to increased schwannoma pathological 
proliferation. 
 
Figure 26. PrPC acts via several key signalling pathways to promote 
schwannoma survival, proliferation, cell matrix adhesion and 
tumorigenesis. 
My results show that PrPC acts to enhance schwannoma survival by blocking 
the damaging effects of free radicals as well as causing a reduction in caspase-
3 and an increase in AKT activation. PrPC also acts via cyclin D1 and ERK1/2 to 
increase schwannoma proliferation and FAK, and p53 to increase cell matrix 
adhesion and tumorigenesis.  
 
Proliferation of schwannoma cells was also likely affected by the reduced 
ERK1/2 signalling seen upon PrPC knockdown and inhibition (Fig. 25B) and 
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also reduction of autophosphorylated FAK (Fig. 25D) known to be involved  in 
cell proliferation and tumour development as well as adhesion (379). Levels of 
total ERK and FAK, but not AKT, were also significantly decreasued upon 
PRNP knockdown. This shows that there is reduced production of these 
proteins upon PrPC depletion which may account for the reduction in 
phosphorylation seen, suggesting that PrPC promotes the transcription of 
ERK1/2 and FAK. The fact that the same result is seen using TCS 
demonstrates that the reduction in total protein is not an off-target effect of the 
shRNA (Fig. 25B-D, light grey bars). Reduction of PrPC likely reduced cell 
survival by decreasing signalling via the same PI3K/AKT pathway as well as 
increasing levels of pro-apoptotic cleaved caspase-3 (Fig. 22). Finally reduction 
of PrPC affects increases levels of the tumour suppressor protein p53 (Fig. 25E) 
that is inherently decreased in schwannoma tumours due to FAK signalling 
leading to its proteasomal degradation (15,183). These results suggest that a 
treatment that focuses on reducing PrPC in schwannoma would likely have 
significant impact in reducing schwannoma pathological proliferation, adhesion 
and survival (for overview see Fig. 26).  
 
3.5 The effect of PrP treatment and overexpression in Schwann cells 
3.5.1 Treatment with PrP increases proliferation, expression of c-Jun and alters 
Schwann cell morphology 
To check the importance of PrPC in schwannoma development I wanted to look 
at the effects of treating Schwann cells with the central portion of the PrP 
peptide (aa 105-120). My initial investigation was to see whether it would induce 
signalling pathways similar to those shown to be activated in schwannoma.  
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Figure 27. Long-term treatment of Schwann cells with PrP peptide 
increases proliferation and causes a schwannoma-like phenotype. 
Treatment of Schwann cells with a synthetic human prion protein peptide (Abd 
Serotec) significantly increased the number of Ki67-positive cells (Ai and ii, n=3) 
and the number of cells staining positive for the master regulator of de-
differentiation, c-Jun (Bi and ii, n=3). Long-term treatment of Schwann cells with 
the PrP peptide also altered cell morphology to that of a more schwannoma-like 
shape, visualised using immunostaining of cells with phalloidin (C). Long-term 
treatment of both Schwann and schwannoma cells with PrP peptide was 
insufficient to transform the PrPC within these cells to PrPres and render it 
resistant to degradation by proteinase K (PK) (D). *p<0.05. GAPDH was used 
as a loading control. 
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Due to extremely limited numbers of control human Schwann cells I looked only 
at the effects on proliferation (via Ki67 staining) and c-Jun, a proto-oncogene 
and marker of de-differentiation, shown to be overexpressed in schwannoma 
(380). 
Results show that treating Schwann cells with PrP 105-120 peptide for six days 
significantly increases the number of Ki67-positive cells (Fig. 27A, red staining, 
bottom panel) when compared to untreated Schwann cells (Fig. 27A, top panel), 
cell counts have been quantified in Fig. 24Aii. Treatment of Schwann cells with 
PrP peptide also increases the number of cells staining positive for c-Jun (Fig. 
27Bi) andthis difference is statistically significant (Fig.27Bii). 
PrP 105-120 treated Schwann cells alters cell morphology after both six (Fig. 
27C, central panel) and 14 days (Fig. 27C, right panel) and cells begin to lose 
their polarity, become more spread and show signs of altered actin cytoskeleton 
(phalloidin, green staining) compared to cells cultured only in GFM (Fig. 27C, 
left panel). The cell shape after treatment with PrP 105-120 is more similar to 
that of schwannoma cells with more membrane ruffles and increased cell 
spreading (Fig. 27C), suggesting that overexpression of PrP may be an early 
event in the pathogenesis of schwannoma tumours.  
Finally, several papers have suggested long-term treatment of cells with PrP 
aa105-120 peptide can cause the PrPC expressed to turn to PrPres (381,382). 
Therefore, it was essential that we checked whether the PrPC expressed by 
Schwann cells after PrP 105-120 treatment was still able to be degraded by 
proteinase K. I show that treatment with PrP 105-120 for six days both in 
Schwann and schwannoma cells does not affect the ability of PrPC to be 
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degraded by proteinase K, nor does it affect the endogenous PrPC levels within 
the cells (Fig. 27D). 
3.5.2 Overexpression of PrPC increases expression of cyclin D1 and c-Jun  
To further back up the results found using the PrP 105-120 peptide, I made a 
PRNP overexpressing virus by cloning the coding section of PRNP into a 
pLenti6.2 vector that uses a CMV promoter to overexpress the gene (full 
structure of the plasmid can be seen in Fig. 8). I then continued to make 
lentiviral particles using 293FT cells that were able to effectively and stably 
deliver the PRNP overexpressing clone into primary human Schwann cells. I 
followed a lentiviral infection protocol to infect Schwann cells with the PRNP 
overexpressing virus before checking protein expression within cell lysates via 
Western blotting.  
 
Figure 28. Overexpressing PRNP in Schwann cells leads to increased 
cyclin D1 and c-Jun expression. 
Overexpression of PRNP in Schwann cells using a homemade PRNP-
containing lentivirus significantly increased expression of both cyclin D1 (A and 
C, n=3) and c-Jun (B and C, n=3) compared to cells infected with scramble-
control containing lentiviral particles, mirroring the effects seen with treatment 
using PrP peptide 105-120 (Fig. 27). **p<0.01, ***p<0.001. GAPDH was used 
as a loading control. 
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I show that overexpression of PrPC in Schwann cells increases expression of 
cyclin D1 (Fig. 28A and C) a key marker of proliferation suggesting that the 
increase in proliferation of Schwann cells upon treatment with PrP 105-120 (Fig. 
27A). This complements my earlier findings where PRNP knockdown in 
schwannoma caused a reduction of cell proliferation (Fig. 22A and G).  Levels 
of c-Jun were increased (Fig. 28B and C) as demonstrated using the PrP 
peptide (Fig. 27B).  
 
3.5.3 The effect of PrP treatment and overexpression in Schwann cells – 
discussion 
In order to fully understand the effects of PrPC overexpression in schwannoma I 
investigated the effects of overexpressing PrPC in healthy Schwann cells (Fig. 
28). I show upregulation of two key proteins known to be involved in 
schwannoma proliferation. Cyclin D1, a protein that marks the transition 
between G1 and S phases of the cell cycle, known to be overexpressed in 
schwannoma tumours alongside many other cancers (383) and Ki67 which is 
expressed in all active phases of cell division. Upregulation of both of these 
proteins upon overexpression of PrPC confirms our earlier findings of PrPC’s role 
in schwannoma proliferation (Fig.22).  
Moreover, upregulation of c-Jun, regulator of Schwann cell dedifferentiation and 
myelination, is seen in schwannoma (218) and thought to contribute to 
schwannoma development and pathology (384). The fact that overexpression 
and treatment of cells with PrPC leads to overexpression of c-Jun (Fig. 27 and 
28), suggests that PrPC-induced upregulation of c-Jun upon Merlin loss may be 
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a key initiating stage in the development of schwannoma tumours. An overview 
of these findings can be seen in Fig. 29.  
 
Figure 29. PrPC also acts via c-Jun to increase proliferation and 
tumourigenesis in schwannoma cells. 
As well as the previously discussed pathways (PI3K/AKT, FAK, cyclin D1 
ERK1/2, cleaved caspase-3 and p53), it appears that c-Jun may also be 
regulated downstream of PrPC in schwannoma and contribute to 
tumourigenesis and dedifferentiation in these cells.  
 
3.6 LR/37/67kDa as a receptor for PrPC in schwannoma 
3.6.1 LR/37/67kDa is not differentially expressed between Schwann and 
schwannoma cells 
Next, I looked at potential receptors via which PrPC could interact with on the 
schwannoma cell membrane in order to cause the increases in proliferation, 
adhesion and cell survival that we have thus far demonstrated. Laminin receptor 
(LR/37/67kDa or LR) is a promising target as it has been shown previously in 
several different studies to act as a cell surface receptor for PrPC (128,248). I 
first checked whether there was and differential expression of the LR/37/67kDa 
 
131 | P a g e  
 
between Schwann and schwannoma cells. I show that LR is expressed in both 
Schwann and schwannoma cells (Fig. 30A) but that expression of LR /37/67kDa 
does not significantly differ between the two cell types.  
3.6.2 LR/37/67kDa co-localises and physically interacts with PrPC in schwannoma  
 
 
Figure 30. PrPC physically interacts with LR/37/67kDa in schwannoma 
cells. 
LR/37/67kDa (LR) is not differentially expressed between Schwann and 
schwannoma cells as seen using Western blotting (A, n=3). PrPC and 
LR/37/67kDa co-localise both throughout the cytosol (B, n=3) and in membrane 
ruffles at the cell surface (C, white arrowheads, n=3). PrPC and LR/37/67kDa 
directly interact in schwannoma seen by co-immunoprecipitation both when 
LR/37/67kDa is pulled down (D, n=5) and when PrPC is pulled down (E, n=4). 
Ns p>0.05. GAPDH was used as a loading control.  
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Using immunofluorescence visualised with z-stack confocal microscopy and co-
immunoprecipitation, I then looked at whether LR/37/67kDa and PrPC co-
localise and physically interact. It appears that PrPC and LR/37/67kDa do 
localise together intracellularly throughout the cytoplasm (Fig. 30B) and in 
membrane ruffles on the cell membrane of schwannoma cells (Fig. 30C, white 
arrows).  
Upon immunoprecipitation of laminin receptor PrPC was also pulled down (Fig. 
30D) and, likewise, upon immunoprecipitation of PrPC I also found LR/37/67kDa 
in complex (Fig. 30E), suggesting a physical interaction between PrPC and 
LR/37/67kDa in schwannoma that may be as a receptor-ligand pairing. 
3.6.3 Knockdown of LR/37/67kDa significantly affects the ability of PrPC to 
activate several key signalling pathways   
Having shown that PrPC and LR/37/67kDa interact together in schwannoma 
cells, I wanted to ascertain whether LR/37/67kDa does indeed act as a receptor 
for PrPC in these cells. To do this I knocked down RPSA, the mRNA coding for 
LR/37/67kDa before stimulating the cells with synthetic human PrP aa105-120 
(the same PrP peptide as used in previous experiments). I show that treatment 
with PrP peptide increases cyclin D1 levels and activation of ERK1/2, AKT and 
FAK (Fig. 31A-E. light grey bars). Upon knockdown of LR/37/67kDa levels of 
cyclin D1 and activation of ERK1/2, AKT and FAK are not affected but 
stimulation with PrP peptide no longer leads to activation of these pathways or 
increased expression of cyclin D1 (Fig. 31A-E, dark grey bars). This suggests 
that PrPC acts via laminin receptor to stimulate ERK1/2, PI3K/AKT and FAK 
signalling and increase expression of cyclin D1, and could lead to pathological 
proliferation, adhesion and survival seen in schwannoma cells. 
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Figure 31. PrPC signals via LR/37/67kDa to activate key signalling 
pathways in schwannoma. 
Upon treatment with PrP peptide (72h) levels of cyclin D1, pERK1/2, pAKTSer473 
and pFAKTyr397 are significantly increased (A-D, light grey bars). Knockdown of 
LR/37/67kDa using shRNA prevented this increase in expression upon 
treatment with PrP peptide (A-D, dark grey bars) suggesting that LR/37/67kDa 
is key for PrPC’s activation of downstream signalling pathways. Western blot 
images are combined in (E, n=5).  Ns p>0.05, *p<0.05, **p<0.01. GAPDH was 
used as a loading control. 
 
3.6.4 LR/37/67kDa as a receptor for PrPC – discussion 
Although there appears to be no significant difference in LR/37/67kda 
expression between Schwann and schwannoma cells (Fig. 30A) there appears 
to be an important role for this receptor regarding signalling of PrPC. Literature 
has shown in other cancer cell types that LR/37/67kDa acts as a cell surface 
receptor for PrPC including in neuroblastoma N2a cell line  (128) thus fuelling 
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the investigation to see whether it plays the same role in schwannoma. PrPC 
and LR/37/67kDa both co-localise and physically interact in schwannoma cells 
(Fig. 30B-E) as shown by both immunofluorescence and co-
immunoprecipitation suggesting, as previously shown, that PrPC may signal via 
LR/37/67kDa in schwannoma cells.  
 
Figure 32. PrPC signals via LR/37/67kDa in schwannoma cells to activate 
AKT, cyclin D1, ERK1/2 and FAK pathways. 
Data show that PrPC and LR co-localise and physically interact in schwannoma 
cells and that knockdown of LR/37/67kDa affects the ability of PrPC to activate 
AKT, cyclin D1, ERK1/2 and FAK pathways. Taken together this suggests that 
LR/37/67kDa acts as a receptor for PrPC in schwannoma cells. 
 
Moreover, reducing expression of LR/37/67kDa reduced the ability of PrP to 
activate several key signalling pathways involved in schwannoma development 
(Fig. 31), namely Cyclin D1, ERK1/2, AKT and FAK, which strongly suggests 
that LR/37/67/kDa acts as the receptor for PrPC in schwannoma cells and may 
be the mechanism via which extracellular or membrane-bound PrPC signals to 
induce schwannoma proliferation, survival and cell adhesion (see Fig. 32). 
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There are several drugs targetting LR/37/67kDa that have been discovered; for 
example NSC47924 that disrupt the interaction between PrPC and LR/37/67kDa 
(385) or monoclonal antibodies raised against PrPC aimed at inhibiting its 
interactions (386). Further work would have to be done to elucidate whether any 
of these drugs would be effective in reducing schwannoma proliferation, 
adhesion and survival and to check whether the PrPC released in exosomes is 
able to stimulate signalling via LR/37/67kDa. 
 
3.7 P-glycoprotein in schwannoma  
A recent study linked p-gp expression and PrPC in cancer cells, showing a co-
localisation and interaction between these two proteins (264). Moreover, as 
expression of PRNP has been correlated to poor prognosis and decreased drug 
sensitivity in some cancer types (387), it has actually been linked to improved 
survival in other cancer types (388). As of yet, no drug resistance studies have 
been carried out in schwannoma and this interesting link between p-gp and 
PrPC warrants further investigation.  
3.7.1 Different p-gp and CD44 antibodies identify different patterns of p-gp 
expression in schwannoma cells 
Similarly to the PrPC antibodies (Fig. 9), I had to use different antibodies to p-gp 
and CD44 depending on the experimental technique used. After several 
experiments I discovered that, whereas all CD44 antibodies showed very similar 
staining patterns, different p-gp antibodies showed very different 
immunocytochemical staining (Fig. 33). One antibody raised to aa1-50 of p-gp 
displayed nuclear staining of p-gp whereas a p-gp antibody raised to a part of 
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the protein located on the third extracellular loop did not show much nuclear 
staining and instead showed p-gp to be localised more the the cytosol.  
 
Figure 33. Different p-gp antibodies show different staining patterns. 
Two different p-gp antibodies used in various experiments show very different 
staining patterns in schwannoma cells. The rabbit antibody from Abcam (A, 
aa1-50 of p-gp) shows mainly nuclear staining with only slight cytoplasmic p-gp 
expression whereas the mouse antibody from Sigma (third extracellular loop) 
shows mainly cytoplasmic staining with only a small amount of p-gp localisation 
in the nucleus (B).  
 
Table 5 outlines the various different p-gp and CD44 antibodies used, the 
applications in which they were used and their staining pattern, based on 
immunofluorescent tests. Once again, any antibodies used for experiments 
other than those outlined below will be described next to the appropriate results.  
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Table 5: Table of p-gp and CD44 antibodies used and their staining pattern 
Experiment Antibody Recognition site Observations 
IP (as bait)  P-gp (Abcam) aa1-50 of human p-
glycoprotein 
Nuclear staining 
determined by ICC 
 HCAM (CD44, 
Santa Cruz) 
Exon v6 in variable 
region of human 
CD44 
Cytosolic and 
membrane staining in 
ICC 
IP (blot) P-gp (Abcam)  aa1-50 of human p-
glycoprotein 
Nuclear staining 
determined by ICC 
 CD44 (Novus 
Biologicals) 
Central region 
(unspecified) 
Membrane, cytosol and 
small amount of nuclear 
staining in ICC 
ICC/ Immuno-
fluorescence 
P-gp (Abcam (R)) aa1-50 of human p-
glycoprotein 
Nuclear with only a little 
cytosolic staining 
 P-gp (Sigma (M)) 3rd extracellular 
loop  
Mainly cytosolic, some 
membrane and nuclear 
staining  
 HCAM (CD44, 
Santa Cruz (M))  
Exon v6 in variable 
region of human 
CD44 
Cytosolic and 
membrane staining 
 CD44 (Novus 
Biologicals (R)) 
Central region 
(unspecified) 
Membrane, cytosol and 
some nuclear staining 
IHC P-gp (Sigma (M)) 3rd extracellular 
loop 
Mainly cytosolic, some 
membrane and nuclear 
staining.  
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3.7.2 P-gp is over-expressed and localises to the nucleus of schwannoma cells 
Using a blocking peptide alongside a p-gp-specific antibody (anti-p-glycoprotein, 
Sigma) I show that there are several isoforms of p-gp present in schwannoma 
(20kDa, 35kDa, 57kDa, 72kDa and 85Kda) but the main, fully glycosylated 
170kDa isoform does not appear to be present (Fig. 34A). I show, using 
Western blotting (Fig. 34B) that most isoforms of p-gp are more highly 
expressed in schwannoma compared to Schwann cells, part from the 72kDa 
isoform.  
This is mirrored in immunocytochemistry where not only is it clear that p-gp is 
more highly expressed in schwannoma (Fig. 34C, right panels) compared to 
Schwann cells (Fig. 34C, left panels) but also that, in schwannoma, p-gp is 
localised mainly to the nucleus. This has previously been described as being 
indicative of drug-resistance as it is seen in drug-resistant cells to protect the 
nucleus from doxorubicin and other chemotherapeutic agents (389). This is also 
seen using immunohistochemistry where in normal nerve sections the nuclei 
are mostly unstained (blue in colour, Fig. 34D, top panel, blue arrows) whereas, 
in schwannoma tumours, many of the nuclei are also stained brown with DAB, 
depicting the presence of  p-gp (Fig. 34D, bottom panel, brown arrows).  
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Figure 34. P-gp is overexpressed and localises to the nucleus of 
schwannoma cells. 
P-gp blocking peptide was used to determine which of the multiple p-gp 
Western blot bands are specific as the main 170kDa isoform is not present. 
Blocking peptide experiments demonstrate only 20kDa, 35kDa, 57kDa, 72kDa 
and 85kDa to be specific. All p-gp isoforms apart from 72kDa are 
overexpressed in schwannoma (NF2-/-) compared to Schwann cells (NF2+/+) 
(B, n=3). Overexpression of p-gp in schwannoma can also be visualised using 
immunofluorescence (C, n=3), where it is apparent that the p-gp in 
schwannoma localises mainly to the nucleus and weakly to the cytosol (C, NF2-
/-, right panels). Immunohistochemical staining of normal nerve and 
schwannoma sections also shows increased p-gp expression in schwannoma 
(D, bottom panel) compared to normal nerve (D, top panel). IHC also 
demonstrates more p-gp in the nucleus as well as cytosol of schwannoma (D, 
brown arrows) compared to normal nerve (D, top panel, blue arrows). Ns 
p>0.05, *p<0.05. GAPDH was used as a loading control for Western blots. 
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3.7.3 P-gp overexpression in schwannoma is Merlin-dependent 
I show that the overexpression of p-gp seen in schwannoma is due to loss of 
Merlin as reintroduction of the NF2 protein decreases expression of many of the 
isoforms of p-gp seen in schwannoma (Fig. 35A) apart from the 85kDa band. 
These results suggest a potential endogenous or intrinsic drug resistance of 
schwannoma tumours that may help explain why they are unable to be targeted 
using traditional chemotherapeutic agents but also flags up as a warning that 
any future drug could cause further drug resistance in these cells.  
 
 
Figure 35. P-gp expression in schwannoma is Merlin-dependent. 
Adenoviral reintroduction of the NF2 protein into schwannoma cells leads to a 
significant increase in the expression of all p-gp isoforms (72kDa, 57kDa, 
35kDa and 20kDa) but not the 85kDa isoform (A, n=3). Western blot bands can 
also be visualised (B). Ns p>0.05, *p<0.05. GAPDH was used as a loading 
control. 
 
3.7.4 LR/37/67kDa and p-glycoprotein co-localise in schwannoma but not 
Schwann cells  
There is evidence to suggest a role for LR/37/67kDa in multi-drug resistance 
(390), particularly as the laminin receptor precursor LRP, also known as MGr1-
Ag, an MDR-associated protein, is involved in adhesion-mediated drug 
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resistance through activation of several key pathways I show to be activated by 
PrPC/LR interaction in schwannoma including FAK/PI3K and MAPK (269). I 
show, in schwannoma, that LR/37/67kDa seems to co-localise with p-gp in 
membrane ruffles (Fig. 36B).  I also demonstrate the absence of this co-
localisation between p-gp and LR/37/67kDa in human primary Schwann cells in 
culture (Fig. 36A), suggesting that this interaction with LR could be acquired by 
p-gp upon loss of Merlin from the cells.   
 
Figure 36. P-gp co-localise with LR/37/67kDa in schwannoma but not 
Schwann cells. 
Immunofluorescent staining shows that p-gp (Sigma) and LR/37/67kDa do not 
co-localise in Schwann cells (A, NF2+/+, n=3) but do co-localise in membrane 
ruffles of schwannoma cells (B, NF2-/-, white arrows, n=3), suggesting a 
possible interaction between the two proteins. DAPI was used to visualise 
nuclei.  
 
To confirm it I would need to reintroduce Merlin into schwannoma cells and 
again check for p-gp and LR/37/67kDa interaction as well as using co-
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immunoprecipitation to determine whether a physical interaction between 
LR/37/67kDa and p-gp takes place in schwannoma cells. 
3.7.5 P-gp in schwannoma – Discussion  
PrPC overexpression has been linked to multi-drug resistance (MDR) in several 
different cancer types including gastric cancer (184) and has been referred to 
as an MDR-associated protein via its interaction with the major MDR protein p-
gp (264). Interestingly, there are also links between LR/37/67kDa and drug 
resistance; as laminin receptor precursor (LRP) is also known as MGr1-Ag, an 
MDR-associated protein that has been shown to interact with PrPC (268). This 
evidence suggests a role for both LR/37/67kDa and PrPC in MDR. MGr1-Ag 
promotes cell adhesion-mediated drug resistance via interaction with laminin 
(LA) which, in turn, results in Bcl-2 upregulation and thus protection from 
chemotherapy-induced apoptosis (391).  
I first of all wanted to explore the possibility of intrinsic MDR in schwannoma 
cells before going on to investigate whether any drug-resistance could be 
caused by an interaction of PrPC with LR/37/67kDa or not. Initially I investigated 
endogenous levels of the key MDR protein p-glycoprotein between Schwann 
and schwannoma cells and show, using a variety of methods, that p-gp 
expression is upregulated in schwannoma but at various isoforms and not the 
complete 170kDa peptide (Fig. 34). I speculate that the upregulation of p-gp in 
schwannoma could be the reason that drug interventions fail in these patients, 
for example in a recent study investigating the treatment of NF2 with 
Bevacuzimab, a VEGFR inhibitor (392). By targeting p-gp expression in 
schwannoma it would be interesting to see whether these tumours become 
more susceptible to drug treatments.  
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I show that overexpression of p-gp in schwannoma is linked to loss of Merlin as 
re-introduction and overexpression of the NF2 gene leads to a significant 
reduction in the majority of the isoforms of p-gp (Fig. 35). No link between the 
expression of these two proteins have been shown before, this could prove 
interesting to investigate within more malignant NF2-related tumours including 
grade III meningiomas (393), for which chemotherapy is sometimes used as a 
last resort treatment option when resection or radiosurgery are inefficient, 
although itself is not very effective (394).  Finally, in this section, I show a 
potential interaction, between LR/37/67kDa and p-gp in schwannoma (Fig. 36) 
as previously predicted by the fact that LRP/MGr1-Ag is a MDR-associated 
protein. This relationship requires further investigation as immunofluorescence 
cannot confirm direct interaction but it could suggest that PrPC may act via 
LRP/LR/37/67kDa to affect MDR in schwannoma cells, a very tentative 
prediction at this stage but something that could greatly impact schwannoma 
therapeutics and provide an even bigger role for PrPC/ LR/37/67kDa interaction 
inhibitors in schwannoma.  
3.8 Control of p-glycoprotein expression by PrPC  
Using immunofluorescence visualised by z-stack confocal microscopy, I show 
that there is a slight peri-nuclear co-localisation between PrPC (Santa Cruz,N-T 
antibody) and p-gp (Abcam aa1-50 of human p-glycoprotein) in schwannoma 
cells (Fig. 37 A)  However,  no apparent interaction between PrPC and p-gp in 
schwannoma was found  using immunoprecipitation and  pull down of PrPC (Fig. 
37B).  
Although this seem to rule out any direct interaction between the two proteins, 
at a perinuclear location, there could be an indirect mechanism by which PrP 
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and p-gp interact that is yet to be elucidated. Additionally, I will need to repeat 
co-IP experiments using antibodies targeting the third extracellular loop of p-gp 
and the N-terminal of PrP which I show detect both proteins at the membrane 
and the cytosol (Fig. 9 and Fig. 33). A co-IP using antibodies targeting the aa1-
50 of p-gp and C-terminal of PrP both detecting nuclear proteins would also 
need to be carried out in order to fully understand whether PrPC/p-gp interact in 
schwannoma cells. 
 
 
 
Figure 37. PrPC and p-gp co-localise in the peri-nuclear region of 
schwannoma cells but appear not to directly interact. 
Immunofluorescent staining of schwannoma cells with both p-gp (Abcam) and 
PrPC (Santa Cruz) suggests a small amount of co-localisation in the peri-
nuclear region of schwannoma cells between these two proteins (A, right hand 
panel, white arrows, n=3). However, upon immunoprecipitation of PrPC, p-gp 
was unable to be detected (B, n=3). 
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3.8.1 PrPC regulates p-gp expression in schwannoma cells 
Initially I used the PRNP overexpressing virus from previous experiments to 
look at the effects of overexpressing PRNP on p-gp levels in Schwann cell 
cultures. I found that overexpressing PrPC led to an increase in expression of 
most p-gp isoforms but strangely led to a decrease in levels of p-gp 72kDa (Fig. 
38A).  
I then performed the reverse experiment, treating schwannoma cells with both 
PRNP shRNA (Fig. 38B) and TCS prion inhibitor 13 (Fig. 38C) before checking 
p-gp expression. I show that both PRNP shRNA (Fig. 38B) and TCS prion 
inhibitor 13 (Fig. 38C) decrease levels of p-gp in schwannoma cells using 
Western blotting, again with some variability in the effect on specific isoforms.  
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Figure 38. P-gp expression is regulated by PrPC in schwannoma cells. 
Overexpressing PrPC in Schwann cells leads to increased expression of the 
majority of p-gp isoforms, although expression of p-gp 72kDa is significantly 
reduced (A, n=3). Knockdown of PrPC in schwannoma leads to an overall 
reduction in p-gp expression although, again, not all isoforms appear to be 
affected in the same way with the 72kDa isoform again not producing a 
significant result (B, n=5). Reduction of PrPC using TCS prion inhibitor leads to 
a significant reduction in all p-gp isoforms (C, n=4). Ns p>0.05, *p<0.05, 
**p<0.01, ***p<0.001. GAPDH was used as a loading control. 
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3.8.2 Control of p-glycoprotein expression by PrPC – discussion 
Previous research has suggested that PrPC and p-gp act together in complex 
within multidrug resistant cells to promote invasion and resistance to apoptosis 
of breast cancer cells in culture (264). Preliminary experiments show that there 
is a slight perinuclear co-localisation between p-gp and PrPC in schwannoma 
and no direct interaction using co-IP, thus, further work needs to be done with 
immunofluorescence to denote whether C-terminal PrPC co-localises with 
nuclear p-gp and whether cytosolic PrPC and p-gp interact using the various 
antibodies denoted in Table 6. Furthermore, a co-IP specific p-gp antibody to 
nuclear and cytosolic p-gp needs to be used and checked against both C-
terminal and N-terminal PrPC antibodies. This will allow me to fully understand 
the complex interaction between these proteins and their many variants. 
 
Figure 39. Merlin and PrPC modulate p-gp overexpression in schwannoma 
cells. 
Results show that p-gp is overexpressed in schwannoma in a Merlin-dependent 
manner and that p-gp interacts physically with LR/37/67kDa, a known receptor 
for PrPC. The high levels of PrPC in schwannoma also appear to lead to the 
overexpression of p-gp seen in these cells. Targeting PrPC may in schwannoma 
patients produce a secondary effect of contributing to a reduction in p-gp 
expression which could be beneficial in a clinical setting.   
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However, it does appear that p-gp expression is dependent on PrP levels as 
overexpression of PrPC in Schwann cells led to increased p-gp expression (Fig. 
38A) and knockdown of PRNP had the opposite effect (Fig. 38B and C). This 
provides further evidence for PrPC as a potential transcriptional regulator both 
upstream and downstream of several key signalling pathways involved in both 
tumourigenesis (ERK1/2, AKT, FAK, p53) and MDR (p-gp).  
72kDa p-gp is the predicted size of transmembrane domains 1 and 2 of p-gp 
that are de-glycosylated with endoglycosylase H, an enzyme that removed high 
mannose and oligosaccharide chains from N-linked glycoproteins (395) but 
there is little in the literature to prove any significance of this portion of the 
protein in cancer development.  The protein picked up at 72kDa may, in fact, 
actually be breast cancer resistance protein (BCRP) which has been shown to 
be overexpressed alongside p-gp in drug-resistant triple negative breast cancer 
cells (396). This is only speculative, further experiments would be required to 
determine whether BCRP is expressed in schwannoma and, if so, whether it is 
picked up by p-gp antibody in these cells. 
 
3.9 CD44, the magical linker between PrPC and p-gp?  
3.9.1 CD44 is overexpressed in schwannoma and meningioma cells in a Merlin-
dependent manner 
CD44 and its variant isoforms have been shown to be overexpressed in many 
different tumour types including being overexpressed in schwannomas 
compared to Schwann cells (296). Firstly I checked the glycosylation state of 
CD44 present in schwannoma cells to assess whether there was any deficiency 
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in proper glycosylation that could account for some of the pathological features 
of schwannomas; CD44 glycosylation has an important role in cell adhesion, 
particularly via its binding partner hyaluronan (HA) (286), interesting data has 
shown that inhibition of CD44 glycosylation actually enhances HA binding (397). 
Glycosylation of CD44 is also essential in controlling the switch between ‘active’ 
and ‘inactive’ forms of CD44, making it a key post translational modification for 
this protein (398).  
 
 
Figure 40. CD44 is overexpressed in meningioma as well as schwannoma 
but its expression is not Merlin-dependent. 
CD44 is in its fully di-glycosylated state in schwannoma cells as shown using 
PNGaseF de-glycosylation assay (A, n=3). CD44 is also overexpressed in 
primary, Merlin-negative, grade I meningioma cells compared to HMC control 
(B). Upon adenoviral reintroduction of Merlin into schwannoma cells, there is no 
significant difference in CD44 expression compared to GFP control virus (C, 
n=3). Ns p>0.05, **p<0.01. GAPDH was used as a loading control. 
 
Results confirm that the CD44 present in schwannoma cells appear to be in a 
glycosylated state seen by two separate de-glycosylated bands upon treatment 
with PNGaseF (Fig. 40A). In the literature, there is evidence of a minimum of 5 
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N-linked glycosylation sites (286) suggesting that although the CD44 may only 
be partially glycosylated in schwannoma. This lack of full glycosylation may 
influence and participate in the enhanced schwannoma cell matrix adhesion as 
shown previously (58).  
Next, I wanted to look at whether CD44 was differentially expressed in other 
NF2-related tumours, primarily between HMC and grade I, Merlin-negative 
meningiomas. CD44 expression (both standard and several variant isoforms) in 
meningiomas has previously been described as ‘weak’ in immunohistochemical 
staining of tumour sections (399). However, in our cell culture model, I show 
that there is a significant increase in CD44 expression (approximately 1.5-2-fold) 
in Merlin-deficient Grade I meningiomas compared to the HMC control cells (Fig. 
40B).  
To investigate the notion as to whether CD44 overexpression in NF2-related 
tumours is Merlin-dependent I used adenoviral infection to reintroduce and 
overexpress the NF2 gene in schwannoma cells. I show that there is no 
significant difference in CD44 expression between schwannoma cells infected 
with a GFP-control compared to those infected with the NF2-containing virus 
(Fig. 40C) thus, allowing the conclusion that the overexpression of CD44 in 
schwannoma is not Merlin-dependent. This contradicts previous work that show 
knockdown of Merlin in Schwann cells leading to an upregulation of CD44 [300]. 
The same experiment would need to be carried out in the future with primary 
human meningioma grade 1 cells in order to fully understand these results.  
 
 
151 | P a g e  
 
3.9.2 CD44 partly co-localises and interacts with serveral p-gp isoforms in 
schwannoma  
 
Figure 41. CD44 interacts with PrPC and with several p-gp isoforms in 
schwannoma cells. 
Immunofluorescent z-stack technique shows co-localisation of CD44 and P-gp 
(Abcam) in schwannoma both at the membrane and peri-nuclear (A, white 
arrows, n=3). CD44 immunoprecipitation demonstrated a physical interaction 
between CD44 and PrPC (B, n=3) which was also seen using 
immunofluorescence, z-stack confocal microscopy particularly at membrane 
ruffles (C, n=2, white arrows).  
 
To check whether CD44 could be an interaction mediator between p-gp and 
PrPC I investigated whether CD44 and p-gp interact in schwannoma cells. Using 
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immunofluorescence, I show that CD44 and p-gp co-localise in the peri-nuclear 
region and in membrane ruffles of schwannoma cells upon visualisation using z-
stack confocal microscopy (Fig. 41A).  
Pull down of CD44 showed interaction with only two of the bands normally seen 
for p-gp in schwannoma – 35kDa and 85kDa (Fig. 41B), however, pull down of 
p-gp was unsuccessful, thus the results were unable to be confirmed in both 
directions. This suggests an interaction between CD44 and some p-gp isoforms 
within schwannoma cells. 
3.9.3 PrPC and CD44 physically interact in schwannoma cells  
I next wanted to investigate whether CD44 interacted with PrPC to see whether 
PrPC could interact indirectly with p-gp via a CD44-containing complex. 
CD44/PrPC interaction has been demonstrated in several other malignant 
cancer cells (319) but never in schwannoma. Using immunoprecipitation, it is 
clear to see bands for PrPC in the lysate and also in the CD44 IP, suggesting a 
direct interaction between these two proteins (Fig. 41B, n=3).  This gives further 
evidence to my hypothesis that PrPC may be in complex with both CD44 and p-
gp in schwannoma, something suggested in previous reviews to occur in other 
breast cancer and cancer stem cells (CSC’s) (400). To further evidence this 
claim, immunofluorescence staining also shows co-localised staining patterns 
between the two proteins at the cell membrane (Fig. 41C, white arrows). 
Unfortunately, due to limited material and time constraints, I was unable to 
follow up this experiment by repeating the IP using a PrPC pull-down which 
would be required in future work to confidently demonstrate the interaction 
between these three proteins, whilst also investigating the role of the N and C- 
terminals of PrPC within this interaction. 
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3.9.4 Reduction of PrPC decreases expression of CD44 
I then decided to investigate the relationship between PrPC and CD44 further. 
Using PRNP shRNA (Fig. 42A) and TCS prion inhibitor 13 (Fig. 42B), it appears 
that, like p-gp, expression of CD44 is also dependent of PrPC as genetic 
knockdown of PRNP using shRNA decreases expression of CD44 (Fig. 42A). 
Treatment with TCS prion inhibitor 13 (100µM, 72 hours) also causes a 
significant reduction in CD44 expression, visualised using Western blotting (Fig. 
42B). This is in line with previous data (401) suggesting that PrPC may act as a 
transcriptional regulator of both p-gp and CD44. However, more experiments 
would have to be done to confirm the exact mechanism by which PrPC affects 
the expression of these two proteins.  
 
Figure 42. CD44 expression is controlled by PrPC in schwannoma. 
CD44 expression is significantly reduced upon knockdown of PRNP in 
schwannoma cells (A, n=3) and after 72h treatment of schwannoma cells with 
TCS prion inhibitor (B, n=3). *p<0.05, **p<0.01. GAPDH was used as a loading 
control.  
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3.9.5 CD44 acts as a cell surface receptor for PrPC in schwannoma 
Similarly to the experiment investigating whether LR/37/67kDa acts as a cell 
surface receptor for PrPC in schwannoma (Fig. 32), I also investigated the 
possibility that CD44 has a role as a receptor for PrPC as CD44 is known 
already to act as a hyaluronan (HA) receptor on the surface of various cell types 
and also acts to link substrates to the actin cytoskeleton via its ability to interact 
with ERM proteins (398). To investigate the role of CD44 as a PrPC receptor in 
schwannoma cells, I stimulated cells with PrP aa105-120 both before and after 
knockdown of CD44 expression using HCAM shRNA. I conclude, as I showed 
previously (Fig. 32) that stimulation of schwannoma cells with PrP peptide 
aa105-120 activates signalling via cyclin D1, ERK1/2, AKT and FAK compared 
to basal cells cultured in GFM (Fig. 43A-E, light grey bars). Upon knockdown of 
CD44, the basal levels (not treated with PrP peptide aa105-120) of cyclin D1 
and pFAKY397 are unchanged (Fig. 43A and D) whereas levels of both pERK1/2 
and pAKT are significantly reduced (Fig. 43B and C). Additionally, knocking 
down expression of CD44 makes PrP peptide aa105-120 unable to activate any 
of the aforementioned signalling pathways (Fig. 43A-E, dark grey bars), 
suggesting that CD44 does function as a receptor for PrPC in schwannoma to 
activate cyclin D1, ERK1/2, AKT and FAK signalling pathways. The ability of 
CD44 knockdown to significantly decrease basal levels of pERK1/2 and pAKT 
also suggests that CD44 alone may play a role in both ERK1/2 and AKT 
signalling in schwannoma via various other signalling pathways, independently 
of PrPC.  
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Figure 43. PrPC signals via CD44 to activate key signalling pathways in 
schwannoma. 
As shown previously (Fig. 31), treatment of schwannoma cells with PrP peptide 
increases levels of cyclin D1, pERK1/2, pAKT and pFAK (A-D, light grey bars). 
Knockdown of CD44 reduces the ability of PrP to activate each of these 
signalling pathways (A-D, dark grey bars). Changes in activation of the various 
signalling pathways can be visualised using Western blotting (E, n=5). Ns 
p>0.05, *p<0.05, **p<0.01, ***p<0.001. GAPDH was used as a loading control. 
 
3.9.6 CD44, the magical linker between PrPC and p-gp? Discussion 
It has been known for two decades now that CD44 is upregulated in 
schwannoma (296) but, in that time, very few experiments have been carried 
out to look at alternative receptor functions of CD44 other than its primary ligand 
hyaluronan (HA), interaction with which is inhibited by Merlin (402). Work has 
shown that schwannomas, like Schwann cells, normally express CD44s 
(standard isoform) and that schwannomas express only a few of the 17 CD44 
variants (403).  
 
156 | P a g e  
 
There is a large amount of literature on CD44 expression in meningiomas but 
the conclusions drawn are varied, particularly with so many variants of CD44 to 
be investigated. Studies have shown that CD44s is expressed in the range of 
“strong” to “negative” in meningiomas using immunofluorescence (404) whilst 
other studies have shown variants of CD44 to be expressed in line with 
transition of tumour cell differentiation to a more epithelial type such as 
secretory meningiomas (405). I show a high expression of CD44 in grade I, 
Merlin-deficient meningiomas compared to ‘normal’ human meningeal cell line 
HMC (Fig. 40B). Although this is in line with what is seen in schwannoma it 
appears that the cause of CD44 overexpression in these tumours is not due to 
loss of Merlin as re-introduction of the NF2 gene did not lead to a significant 
reduction in CD44 expression in schwannoma (Fig. 40C). Thus, there must be 
an alternative pathway leading to the genetic upregulation of CD44 in 
schwannoma that isn’t Merlin-dependent or due to alterations in glycosylation 
status of CD44 as the CD44 expressed in schwannoma appears to be fully 
glycosylated (Fig. 40A).   
Although CD44 is predicted to be the missing link in the interaction between p-
gp and PrPC having been shown to interact with both p-gp (316) and PrPC in 
cancer cells (319), it appears it might not be quite as simple a relationship as 
previously hypothesised.  Although p-gp and CD44 co-localise in schwannoma 
cells (seen using immunofluorescence Fig. 41A), determining whether a direct 
interaction between the two protein occurs using immunoprecipitation proved 
difficult as p-gp pull-downs were all unsuccessful. This may well be due to the 
fact that low-salt lysis buffer was unable to sufficiently lyse the nuclear 
component of the schwannoma cells where the majority of p-gp is retained. 
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Much more work is required to fully elucidate the relationship between p-gp and 
CD44 in schwannoma cells with further co-IP and immunofluorescence 
experiments required, testing both of the p-gp antibodies against CD44 and 
PrPC.  
 
Figure 44. PrPC can act via CD44 to activate AKT, cyclin D1, ERK1/2 and 
FAK which, in turn, enhance schwannoma survival, proliferation and 
adhesion. 
I show that CD44 expression is controlled by PrPC and that CD44 and PrPC 
physically interact. CD44 also acts as a receptor for PrPC via which downstream 
signalling pathways cyclin D1, AKT, ERK1/2 and FAK can be activated to 
enhance schwannoma proliferation, adhesion and survival. 
 
PrPC and CD44 do appear to interact (co-IP, Fig. 41B) in schwannoma cells, 
suggesting that this still could be a mechanism of reduced therapeutic efficiency 
in schwannoma cells and inhibition of this interaction could be interesting to 
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target therapeutically. Moreover, PrPC appears to be controlling expression of 
CD44 in schwannoma, further complicating the picture of PrPC/CD44 interaction 
and upregulation. These data, taken together, suggest that PrPC lies upstream 
of both p-gp and CD44 but may also interact with both proteins in order to 
mediated tumorigenesis.  
Finally, CD44 is known to act as a cell surface receptor in various cancer cell 
types and has a variety of ligands including other cell adhesion molecules 
laminin and integrin β1 (reviewed in (406)) and is able to transduce extracellular 
stimuli to activate intracellular signalling pathways, with the intracellular domain 
having been shown to interact with various cytoplasmic proteins including ERM 
proteins (of which Merlin is a member) and Fyn kinase (which PrPC has been 
shown to interact with (406)).  
Therefore, I wanted to check whether CD44 acts as a receptor for PrPC in 
schwannoma cells. Results show that PrP aa105-120 is able to act via CD44 to 
activate ERK1/2, PI3K/AKT, cyclin D1 and FAK. This suggests that CD44, like 
LR/37/67kDa, acts as a cell surface receptor for PrPC and may explain the co-
localisation and interaction demonstrated between the two proteins (Fig. 41). As 
well as abolishing the ability of PrPC to activate these key signalling pathways, 
knockdown of CD44 appears to dramatically reduce pERK and pAKT levels, 
even without PrP stimulation (Fig. 43, Fig 44). This mirrors previous findings 
that CD44 signals via ERK1/2 and PI3K/AKT to protect chronic lymphocytic 
leukaemia (CLL) cells from spontaneous and drug-induced apoptosis (407) 
suggesting that the same may be happening in schwannoma cells and that 
targeting CD44 expression alone, as well as CD44/PrPC interaction could 
produce promising therapeutic effects.  
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3.10 Drug resistance in schwannoma  
For the next portion of this study I wanted to investigate the effects of inhibiting 
PrPC using TCS prion inhibitor alongside two drugs that are already clinically 
approved for other conditions. Firstly, Sorafenib (commercially known as 
Nexavar, Bayer), a tyrosine kinase inhibitor that targets several tyrosine kinases 
including PDGFR and VEGFR that is currently in Phase 0 clinical trials for 
schwannoma but has been approved for use in some types thyroid cancer (408), 
advanced renal cell carcinoma (409) and in hepatocarcinoma (410). Secondly, 
PSC833 (commercially known as Valspodar, Amdray), a non-immunorepressive 
cyclosporine-D analogue that acts as a chemosensitizer and multidrug 
resistance modulator to reverse the p-gp efflux pump. Although some studies 
have been successful (411,412) the benefits of its use have yet to be fully 
determined. PSC833 has not been successful in other clinical trials when given 
with a combination of several other chemotherapeutic agents including 
vincristine, doxorubicin and dexamethasone (known as VAD). This was due to 
increased toxicity and lack of improved treatment outcome in 
PSC833/Valspodar-treated patients compared to VAD therapy alone (413). 
3.10.1 MTS assay demonstrates that inhibition of PrP and p-gp can enhance the 
effects of Sorafenib  
I wanted to investigate the effects of inhibiting PrPC and p-gp on Sorafenib 
treatment and cell proliferation and survival in human primary schwannoma 
cells to see whether a multi-pronged approach would be more beneficial as a 
therapeutic intervention. This experiment had two treatment time points (72 
hours, Fig. 45A or 14 days, Fig. 45B) in order to demonstrate both the short and 
long-term treatment effects of these drugs. Cells were pre-treated with PSC833 
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or TCS prion inhibitor 13 (for laboratory use only). PSC833 has been shown to 
be effective in combination with Methotrexane as a treatment to peadeatric 
acute leukaemia. I chose to use a concentration of 4µg/ml of PSC833 to inhibit 
p-gp as a phase I clinical trial in these patients show plasma serum 
concentrations ranging from 1.1-7.8µg/ml with toxicity appearing in some 
patients around 4.4µg/ml serum concentration level (414). Maximum tolerated 
dose of PSC833 in patients was 12.5mg/kg/day for 5 days which resulted in 
varying plasma concentrations of the drug from 1.4µg/ml to 5.2µg/ml.  
Cells were pre-treated with PSC833 or TCS, followed by treatment with 
Sorafenib (1µM). The medium was exchanged and cells were re-treated every 
48 hours to maintain a stable concentration of the drug, as the half-life of 
Sorafenib is 25-48 hours. MTS assay was used to determine cell viability, 
whether that be due to increased cell death or decreased cell proliferation.  
I show that Sorafenib significantly decreases schwannoma cell viability/ 
proliferation by ~30% after 72 hours (Fig. 45A), interestingly, no further 
decrease was seen after 14 days (Fig. 45B) which may either be due to an 
upregulation of p-gp pumps that efflux the drug from cells or simply because the 
concentration used was insufficiently high to cause more cell death than this. 
Treatment with TCS prion inhibitor 13 (20µM) alone significantly decreased 
schwannoma viability after 72 hours (by ~60%) as predicted by the previous 
proliferation and survival assays (Fig. 22), even though this concentration of 
TCS was never enough to significantly decrease PrPC levels (Fig.21).  
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Figure 45. Treatment of schwannoma cells with TCS prion inhibitor or a 
combination of Sorafenib and PSC833 (Valspodar) is more effective at 
reducing cell viability than treatment with sorafenib alone. 
Schwannoma cells were treated with either DMSO, Sorafenib alone, Sorafenib 
in combination with TCS or PSC833, TCS alone, or PSC833 alone for either 72 
hours or 14 days before undergoing an MTS assay to ascertain cell viability. At 
both time points (A and B) Sorafenib treatment significantly decreased 
schwannoma cell viability. Viability was further decreased when Sorafenib 
treatment was combined with either TCS or PSC833 (A and B). Although 
combined treatment of Sorafenib and TCS reduced viability more than TCS 
alone at the 72 hour time point, this difference was abolished by day 14 (A and 
B). Ns p>0.05, *p<0.05, **p<0.01, ***p<0.001.  
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The effects of TCS on schwannoma viability were even more apparent after the 
14 day treatment (~90% reduction in viability) (Fig. 45B), suggesting that this 
drug is even more powerful than Sorafenib at reducing schwannoma viability. A 
combination treatment of both TCS and Sorafenib was only beneficial at the 72 
hour timepoint (Fig. 45A), the addition of Sorafenib had no significant additive 
effect at the longer timepoint due the effectiveness of TCS alone (Fig. 45B).  
Use of the p-gp inhibitor PSC833 alone had no significant effect on viability 
(MTS test) after 72 hours but did significantly decrease viability (~30%) after 14 
days (Fig. 45A and B). However, PSC833 treatment in combination with 
Sorafenib, decreased viability levels dramatically, more that treatment with 
Sorafenib alone, both at 72 hours (~80%) (Fig. 45A) and 14 days (~90%) (Fig. 
45B). The fact that combination therapy of Sorafenib and the PSC833 was able 
to overcome the plateau in viability seen with the Sorafenib treatment alone 
after 14 days, suggests that upregulation of p-gp may have been preventing the 
continual decrease of viability in these cells. 
Nevertheless, treatment with PSC833, even in combination with Sorafenib was 
not as effective as TCS alone after 14 days, suggesting that a monotherapy of 
just TCS (if it were ever approved for human use) may be better than a dual 
therapy intervention that could initiate drug-drug interactions and cause a large 
number of adverse side effects. More investigations need to be carried out to 
investigate the mechanisms of action of TCS before it can even be considered 
for clinical trials, as my work (415) is the only published data available which 
uses this product. Thus, for the time being it may be beneficial to use Sorafenib 
and PSC833 in combination for schwannoma patients as both have been used 
clinically previously and PSC833 has been reformulated to make it more 
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bioavailable and reduce its toxicity profile (414). The reformulation was due to 
reports from a phase III trial in acute myeloid leukaemia (AML) patients show 
that Valspodar (PSC833) was associated with excessive mortality and had no 
beneficial effect on complete remission rates (416), hence has so far been 
unsuccessful in clinical trials. I therefore suggest, for future experiments, trying 
a lower concentration of Valspodar (PSC833, ~1.1µg/ml) to in combination with 
Sorafenib to increase the effects of Sorafenib whilst minimising any residual 
toxicity caused by the reformulated PSC833/ Valspodar.   
 
3.10.2 Treatment with both TCS and PSC833 may also improve inhibition of 
downstream signalling pathways by Sorafenib in schwannoma 
To back up the results shown by the MTS assay, I looked into the effects of the 
combined drug treatments on downstream signalling in schwannoma cells. For 
these experiments I used a single timepoint of seven days (an intermediate 
between the 72 hours and 14 days of the previous experiment) to minimise the 
quantity of primary cells used and due to time restraints on the project. Cells 
were initially pre-treated with PSC833 (p-gp inhibitor, Valspodar) or with TCS 
prion inhibitor before treatment with Sorafenib. Samples were then lysed and 
run on SDS-PAGE to quantify the expression and activation of downstream 
signalling proteins. I show that levels of both pERK1/2 and pAKT are 
significantly decreased upon treatment with Sorafenib (1µM) (Fig. 46A, B and 
C), showing that the drug is effective  
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Figure 46. Combined inhibition of p-gp, PrPC and RTKs in schwannoma 
leads to a reduced signalling through key pathways involved in 
tumourigenesis. 
Sorafenib treatment of schwannoma cells in culture alone significantly reduces 
expression of pERK1/2 and pAKT (A and B). pERK1/2 levels significantly 
reduce upon treatment of schwannoma cells with TCS (20µM) alone and in 
combination with Sorafenib (1µM) (A, n=3), pAKT is also significantly reduced 
when Sorafenib is combined with TCS compared to Sorafenib treatment alone 
(B, n=3). PSC833 (4µM) reduces pAKT (B) but not pERK1/2 (A) levels when 
treated with PSC833 alone. Neither pERK1/2 (A) or pAKT levels are affected 
when treated with PSC833 in combination with Sorafenib compared to sorafenib 
treatment alone. This can be visualised in (C). Upon Sorafenib treatment p-gp 
expression is increased, although not significantly (D, n=4). Ns p>0.05, *p<0.05, 
**p<0.01, ***p<0.001. GAPDH was used as a loading control.  
 
Levels of pERK and pAKT were reduced with TCS (Fig. 46A, B and C), as 
previously described in Fig. 25. Combined treatment of TCS and Sorafenib 
decreased pERK1/2 levels more than Sorafenib alone but not further than TCS 
alone (Fig. 46A-C) and had additive effect on pAKT inhibition (Fig. 46B and C). 
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PSC833 significantly decreased pAKT but not pERK1/2 levels. (Fig. 46A and C). 
Combined treatment of PSC833 and Sorafenib had, however, no significant 
additive effect on the inhibition of any of the pathways (Fig. 46A, B and C) which 
contrasts my previous results on cell proliferation/survival observed in Fig. 45. 
Further experiments must be performed in order to decipher the mechanisms by 
which PSC833 aids Sorafenib in the inhibition of proliferation/survival in 
schwannoma cells.  
P-gp levels were also investigated to see whether Sorafenib was able to induce 
an increase in p-gp levels, thus potentially being able to potentiate basal 
(intrinsic) MDR and/or contribute to acquired MDR in schwannoma cells if the 
treatment ever cleared clinical trials. Sorafenib treatment did increase levels of 
p-gp in most schwannoma cells tested but the variability was high and the result 
insignificant.  
To diminish potential side effects, the next step would be to decrease Sorafenib 
concentration from 1µM to 100nM (plasma concentration, due to risk of 
hypertension, cardiac arrhythmias and bleeding), TCS from 20µM to 1-5µM 
(although there is no pulished data at this concentration, I tested several 
concentrations and found that these were the lowest doses to have a significant 
effect on both PrPC expression and schwannoma viability ) and PSC833 from 
4µM to 1.1µM and find the lowest and most effective dosage and combination 
of the three drugs in schwannoma cells. 
3.10.3 Drug resistance in schwannoma – discussion 
The drug I chose to focus my studies on was Sorafenib, a multi-kinase inhibitor 
that is currently undergoing phase 0 clinical trials in NF2 patients. Previous data 
suggests that p-gp is strongly expressed on the endothelial cells of blood 
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vessels at both the blood brain barrier and also at the blood-tumour barrier (417) 
and prevents cytotoxic agents (including chemotherapy and other anti-cancer 
drugs) from entering the CNS and tumour. My data suggests that p-gp appears 
to help prevent Sorafenib transferring from the bloodstream and into the tumour. 
A recent study shows that although it plays a role, p-gp is not the main culprit 
for reducing brain and/or tumour accumulation of Sorafenib. Instead, it has been 
suggested another ABC-protein - ABCG2 (also known as breast cancer 
resistance protein, BCRP) - causes drug resistance to Sorafenib in mice (418) 
and in human hepatocellular carcinoma (419).  
There is evidently a form of intrinsic drug resistance in schwannoma caused by 
upregulation of p-gp within these cells (Fig. 34). However, it appears that drug 
treatments, such as Sorafenib, may further potentiate p-gp levels (Fig. 46D) 
indicating that some NF2 patients may also develop acquired resistance. Gene 
expression analysis using quantitative real-time polymerase chain reaction 
(qRT-PCR) would be able to quantify MDR1 gene expression between patients. 
The high variability in p-gp expression upon Sorafenib treatment could account 
for individual differences and be the reason why different tumours respond 
differently to treatment, making basal p-gp levels a potential marker for drug 
efficiency. Those patients whose p-gp levels increase dramatically upon 
treatment may be less likely to respond well to the drug treatment for a longer 
period of time. However, we cannot exclude that some patients may have very 
high (‘saturated’) endogenous levels of p-gp which cannot be further potentiated 
by drug treatment and be resistant to the treatment from the very beginning. 
Again, this is something that requires further investigation.  
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Figure 47. Combined treatment of schwannoma cells with TCS prion 
inhibitor, PSC833 and Sorafenib could be more beneficial than a single 
drug treatment approach. 
Results show that single drug treatment of the multi-kinase inhibitor Sorafenib 
alone does not dramatically decrease schwannoma cell viability and may also 
potentiate p-gp levels in these cells. Therefore, a combination or either 
Sorafenib and p-gp inhibitor, PSC833 or TCS prion inhibitor could prevent 
further upregulation of p-gp and allow blockade of downstream signalling 
pathways, ultimately leading to a decrease in schwannoma proliferation, cell 
matrix adhesion and survival moreso than treatment alone with sorafenib. 
 
These findings also sway the evidence to suggest that personalised and multi-
pronged therapeutic approaches may be the best way forward for treating 
schwannoma patients, as well as potentially patients with other NF2-related 
tumours, in the clinic. A potential dual therapy for two drugs already approved 
for clinical trials has been uncovered in the course of this research project – 
Sorafenib and PSC833 (Vaslpodar) which together reduce tumour survival/ 
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proliferation and pERK1/2 and pAKT pathways (Fig. 46 A-C, also outlined in Fig. 
49). A combination of these two drugs and could be of potential therapeutic use 
for NF2 patients, if the dosage can be lowered significantly enough to reduce 
the side effects (including neutropenia (420)) which currently are restricting the 
widespread use of both of these drugs in the clinic.  
4. Conclusions and future work 
4.1 Summary of results 
• Cellular PrP is overexpressed in schwannoma and contributes to 
schwannoma pathological proliferation, adhesion and survival. 
• PrPC is cleaved at the cell surface of schwannoma cells by ADAM10, as 
well as being released via exosomes.   
• PrP signals via both LR/37/67kDa and CD44 receptors to activate 
AKT/PI3K, ERK1/2, FAK, cyclin D1 pathways.  
• P-gp is intrinsically overexpressed in schwannoma and may form a 
interact with CD44 and PrPC 
• Inhibition of PrPC may be beneficical as a treatment option for 
schwannoma patients, either alone or in combination with the multi-
kinase inhibitor Sorafenib.  
• Individuals respond differently to drug treatments suggesting a role for 
personalised medicine in treating schwannoma and other NF2-related 
tumours. 
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4.2 PrPC signalling in schwannoma 
As seen in many other tumours, the di-glycosylated cellular form of PrP is 
overexpressed in schwannoma due to upregulation of the PRNP gene caused, 
in part, by loss of Merlin from these cells. Whereas a similar Merlin-dependent 
overexpression of PrPC is seen in human malignant mesothelioma cells, in 
meningiomas there may be additional genetic mutations that account for 
upregulation of PrPC as opposed to solely the loss of NF2. PrPC is released 
from cells both via exosomes and by α-cleavage from the cell membrane. 
Extracellular PrPC is able to activate key signalling pathways involved in 
schwannoma development including ERK1/2, cyclin D1, PI3K/AKT, FAK and 
p53 to contribute to schwannoma pathological proliferation, adhesion and 
survival via direct interactions with both LR/37/67kDa and CD44 receptors on 
the cell surface (Fig. 48).  
My findings agree with other schwannoma studies from our research group, 
suggesting that inhibitors of common signalling pathways, such as those I have 
demonstrated to be downstream of PrPC, could be used as therapeutic targets 
in these tumours (62,63,67,68,183,213,359,368,375-377).  Previous work has 
shown that targeting only specific isoforms of key signalling molecules such as 
PI3Kδ (via a drug known as Idelisib) can be very effective and also much more 
selective than first-generation pan-PI3K inhibitors (421) although it has only 
currently been approved for treatment of chronic lymphocytic leukaemia, 
indolent B-cell non-Hodgkin’s lymphoma and relapsed small lymphocytic 
lymphoma. Initially, direct inhibition of PrPC appears an ideal therapeutic target 
as most side effects seen in animal trials (upon PRNP knockdown) appeared 
initially to only demonstrate altered circadian rhythms (81). By inhibiting PrPC, 
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expression of neurotoxic Dpl may be increased and PRNP gene knockdown 
may lead to altered myelination, cognitive defecits, increased susceptibility to 
oxidative stress and increased excitotoxicity (81). This suggests that more of an 
indirect approach to inhibiting PrPC or just reducing PrPC levels back to basal 
levels rather than complete abrogation of the protein would, instead, be a more 
beneficial therapeutic option. The MRC Prion Unit have a clinical trial planned 
which utilises humanised anti-prion antibodies as a potential new treatment for 
CJD (422) in a plan to inactivate the PrPC present in patients and prevent it from 
aggregating and causing neurodegeneration.   
Further investigation using PRNP0/0 mice may also be beneficial as no prior 
studies have shown whether mice lacking PrPC have a reduced incidence of 
tumour development. Crossing a PRNP0/0 mouse with an NF2-/- mouse could 
provide extensive insights to whether targeting PrPC is a good option for 
treatment of NF2 and Merlin-deficient tumours in general. Plus, as mentioned 
previously, PrPC could also act more as a biomarker for tumour development, 
load and prognosis due to the fact it is released in exosomes and may be 
detectable in the blood of patients or those individuals susceptible to developing 
NF2. This would make a huge difference in the diagnosis of these patients and 
would allow doctors to measure their prognosis in an easy, cost-effective and 
non-invasive manner.  
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Figure 48. Overview of PrPC signalling in schwannoma and potential 
therapeutic targets. 
Extracellular PrPC acts via both CD44 and LR/37/67kDa at the cell membrane 
of schwannoma cells to activate cyclin D1, pERK1/2, PI3K/AKT and FAK 
pathways, which contribute to schwannoma proliferation, cell matrix adhesion, 
survival and tumourigenesis. It is likely both that released PrPC and intracellular 
or cell membrane bound PrPC may also be able to activate the same response 
to extracellular PrP. Finally, there is evidence to suggest LR/67kDa is able to 
signal to NFκB (423). NFκB is then able to stimulate PrPC expression and 
potentially also CD44 expression (424). Use of antibody fragments and specific 
inhibitors could be of use to prevent signalling of PrPC through both 
LR/37/67kDa and CD44 in schwannoma. Future work may involve looking at 
inhibitors of some of these elements including A6 peptide or F-19848 to inhibit 
CD44, an fv antibody fragment to LR/37/67kDa or NSC47924 which blocks the 
interaction of PrPC with LR/37/67kDa or even NFκB inhibitors dexamethasone, 
bortezomib and BAY11-7083 which all may act as potential therapeutic targets 
in schwannoma patients, particularly those already approved for clinical use.  
 
Further investigation using inhibitors of PrPc receptors would give an even 
better understanding of PrPC interaction with these receptors. Inhibitors of the 
LR/37/67kDa-PrPC such as NSC47924 which alters LR cell surface localisation 
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and interaction with PrPC (385) or use of Fv antibody fragments to inhibit 
LR/37/67kDa which have already been found to have therapeutic effects in 
prion disease mouse models (386). Both of these therapies are yet to go into 
clinical trial and require further testing before they can be used but they both 
provide an interesting therapeutic approach that could translate to treatment of 
schwannoma and other NF2-related tumours.  
The interaction between NFκB and PrPC proved to be interesting, in that NFκB 
positively regulated PrPC expression and appears to be an interesting 
intermediate of PrPC signalling within schwannoma cells. Although it was 
beyond the scope of this project to investigate, other research using human 
hepatoma (Huh-7) and human cervical carcinoma HeLa cells lines shows 
control of CD44 expression to be downstream of NFκB signalling, however only 
in the non-canonical NFκB pathway (424) not the p65 NFκB pathway that was 
investigated here. Other inhibitors of NFκB such as Bortezomib (a proteasome 
inhibitor that is FDA approved for multiple myeloma (425)) or Dexamethasone 
(a synthetic anti-inflammatory corticosteroid shown to reduce NFκB activation 
and in phase II trials for multiple myeloma (426)) could also potentially be re-
profiled to help in the reduction of NFκB and PrPC in schwannoma and other 
Merlin-deficient tumours.  
 
Inhibitors of CD44-PrPC interaction would also be interesting to study with 
potential benefits, not only for reducing PrP signalling but also for resistance to 
drug therapy. The only CD44 inhibitor currently available is F-19848, which 
inhibits binding of HA to CD44 and can inhibit CD44-induced HA degradation 
(427) making it an interesting potential therapeutic target for schwannoma 
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patients as both HA and CD44 are overexpressed in schwannoma (296,297). 
Plus, it would be interesting to see if PrPC/CD44 binding can be altered upon 
treatment with this novel inhibitor. Furthermore, A6-peptide a urokinase-derived 
peptide currently in phase II trials for ovarian cancer, is able to modulate CD44 
activity, providing a promising new therapeutic option to reduce signalling in 
schwannoma cells. This drug  has not shown any dose-limiting toxic effects in 
animal studies, providing us with a new candidate to take forward into the 
schwannoma cell culture model and potentially also into clinical trials in the 
future (428).  
Compensatory activation of proteins upon selective inhibition of signalling 
pathways is a well-known phenomenon in cancer cells where inhibition of one 
signalling pathways leads to an upregulation of signalling through other 
pathways with similar effects to counteract the drug and prevent the cells from 
dying. An example of this cross talk and compensatory activation is the Ras-
ERK and PI3K/AKT pathways which are able to cross-talk and feed into the 
same downstream pathways. Therefore inhibiting only the Ras-ERK arm of the 
pathway to target tumour proliferation and survival may lead to increased 
activity of the PI3K/AKT pathway to counteract this (429). This mechanism is 
another, non-p-gp associated, mechanism of drug resistance that should always 
be considered when developing drugs for tumour cells. Compensatory 
upregulation of receptors and activation of alternative signalling pathways is the 
reason why targeting a single protein at the beginning of a signaling cascade is 
not always effective, therefore potential new therapeutic targets should consider 
a multi-factorial approach to prevent the compensatory upregulation or 
activation of other pathways that will mask any effects of the given drug. Due to 
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the similarities seen with regards to the decrease in signalling via ERK1/2, 
cyclin D1, FAK and AKT upon both LR/37/67kDa and CD44 shRNA knockdown 
it could be that decreased expression of each of these receptors leads to a 
compensatory upregulation of the other receptor, thus masking some of the 
effects of knocking down each receptor separately. A dual knockdown of both 
receptors would be interesting to investigate further in the future and to check 
whether drug treatments show the same decreases in signalling pathways as 
shRNA.  
Unfortunately, it was only towards the end of the project that I discovered that 
C-terminal PrPC existed in schwannoma cells and localised to the nucleus 
(Fig.10). Therefore, I was not able to investigate the importance of this C-
terminal portion of PrP, what it was doing in the nucleus and whether the C- and 
N-terminals of PrPC interact with different proteins within their separate 
locations. To fully understand the role of the C- and N-terminal portions of PrPC 
in schwannoma, I would ideally like to repeat the key experiments looking at 
PrPC levels in schwannoma, particularly investigating whether different PrPC 
terminal proteins interact differently with LR/37/67kDa, p-gp and CD44  and also 
which terminals are involved in signalling and release, these experiments would 
need to be carried out using C- and N-terminal specific antibodies side-by-side. 
The C- and N-terminal PrPC antibodies show the same results when used for 
Western blotting (data not shown) but show distinct differences in cellular 
localisation (Fig. 10). I would want to investigate the effect of TCS prion inhibitor 
13 and PRNP shRNA on cellular localisation of C-terminal PrPC, look at whether 
an N-terminal PrPC antibody would show different tissue staining pattern than 
seen in Figure 11 and, most importantly, check co-localisation and interaction 
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between p-gp and C-terminal PrPC. Once the exact roles of C- and N-terminal 
PrPC have been deciphered, the rest of the results discussed in this thesis can 
be put into context.  Although, the fact that these two segments of PrPC exist in 
schwannoma cells, further backs up the evidence to suggest the occurance of 
α-cleavage, the cleavage process that leads to their formation.  
4.3 Schwannoma resistance to drug treatments 
The data discussed in this report, particularly the data relating to drug 
resistance and potential therapeutic targets, strongly suggests that a multi-
pronged, personalised medicine approach may be the most beneficial way 
forwards towards a drug treatment for schwannoma and other NF2-related 
tumours. By doing this, patients are more likely to respond to treatment, have 
fewer side effects and also have fewer relapses due to drug resistance caused 
by compensatory receptor upregulation. P-gp inhibitors such as PSC833 or 
drugs such as zosuquidar, which sensitises p-gp expressing cells to drug 
treatments, approved for use in AML (430), could be useful aids in the treatment 
of schwannoma or other Merlin-deficient tumours which present with a high p-
gp expression load but, based on my findings, may not benefit patients as a 
sole treatment option. Combined therapy of Sorafenib with a P-gp inhibitor does 
however look like a promising potential therapeutic intervention that warrants 
further investigation (Fig. 45 and 46). 
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Figure 49. Hypothesis of interplay between PrPC, p-gp and CD44 in 
schwannoma. 
From data outlined in this thesis, I hypothesise that CD44 acts to link PrPC and 
p-gp at the cell membrane as p-gp and PrPC do not appear to directly interact in 
schwannoma cells. CD44 may also use this interaction to initiate translocation 
of both p-gp and the C-terminal portion of PrPC to the nucleus in schwannoma 
cells. In the nucleus, it appears that PrPC exherts some control over expression 
of p-gp and CD44, potentially at the transcriptional level. More experiments are 
required to fully understand whether this is the case.  
 
Within this, PrPC looks to be a particularly promising therapeutic target due to 
minimal disturbances caused by its inhibition and its role upstream of many of 
the key pathways involved in schwannoma development and pathology. 
However, unlike some of the other targets discussed during this report, there is 
no currently approved PrPC inhibitor and much more work is needed before any 
PrPC inhibitor is released for clinical trials, it looks to be an interesting molecule 
which deserves further attention within this field of research. Hence why anti-
prion antibody, PRN100, is being considered as a potential future treatment for 
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CJD within the MRC Prion Clinic at University College London.  Furthermore, 
due to the likely interplay between PrPC, p-gp and CD44 within schwannoma 
cells (Fig. 49), a combination of inhibitors targeting one of more of this complex 
of protein could not only help reduce schwannoma signalling by indirectly 
targeting PrPC but also increase the tumour response to any drug treatment 
given due to the reduction of p-gp, this combinatorial approach is a much more 
realistic, short-term goal for schwannoma patients.  
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Appendix 
6. Supplementary data  
 
6.1. Upregulation of autophagy-related proteins in schwannoma compared 
to Schwann cells  
Lysosome-associated membrane protein-1 (LAMP1) is a glycoprotein 
associated, as its name suggests, with lysosomes during lysosomal degradation 
and autophagy (431). LAMP1 expression is significantly upregulated in 
schwannoma compared to Schwann cells (Sup. Fig. 1A). LAMP1 expression 
has previously been correlated with the metastatic potential of tumours 
(432,433). Although schwannomas are mainly benign tumours of Schwann cells, 
overexpression of LAMP1 in these tumours may be contributing to schwannoma 
pathobiology and/or development. 
 
 
Supplementary Figure 1. Upregulation of autophagy-related proteins in 
schwannoma compared to Schwann cells. LAMP1 is significantly overexpressed in 
schwannoma (A) compared to Schwann cells (n=3). Although the antibody detected 
two isoforms of LC3 (I and II) it is LC3-II that is most associated with autophagosomes 
and thus, autophagy, hence only LC3-II expression was quantified (B). However, it 
appeared that both isoforms of LC3 showed increased expression in schwannoma 
compared to Schwann cells, though this increase was not statistically significant (n=3).   
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Whereas LAMP1 is involved both in normal lysosomal degradation and 
autophagy, microtubule-associated protein 1 light chain 3 (LC3) is essential for 
autophagy (434). Increases of LC3 can be seen in schwannoma compared to 
Schwann cells but these increases are not statistically significant (Sup. Fig. 1B).  
The effects and exact roles of increased LAMP1 and LC3 in schwannoma 
require further investigation, far beyond the scope of this project. It can, 
however, be predicted from the high levels of LAMP1 that lysosomal 
degradation and autophagy are not altered in these cells, providing further 
evidence that the increased accumulation of PrPC within schwannoma cells is 
not due to deficits in lysosomal degradation (refer to chapter 3.2.1).   
7. Abbreviations 
Table 6. Table of abbreviations 
Abbreviation Full terminology 
å Angstrom (unit of measurement equivalent to 0.1nm) 
aa Amino acid 
ABC ATP-binding casette 
Act. D Actinomycin D 
ADAM A disintegrin and metalloproteinase domain 
ADM Adriamycin 
ADP Adenosine di-phosphate 
AKT 
V-Akt Murine Thymoma Viral Oncogene-Like Protein also known as 
protein kinase B (PKB) 
AML AcuteMyeloid Leukaemia 
ANOVA Analysis of variance 
ATP Adenosine tri-phosphate 
ATPB1 ATP binding cassette sub-family B member 1, another name for p-
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glycoprotein 
BAX Bcl-2-associated X protein 
BBB Blood brain barrier 
Bcl-2 B-cell lymphoma-2 
BCRP Breast cancer resistance protein 
BenMen Benign meningioma-1 cell line 
bp Base pairs 
BSA Bovine serum albumin 
CAM-DR Cell adhesion-mediated drug resistance 
CD44 Cluster of differentiation 44 
CD44s Cluster of differentiation 44 standard isoform 
CD44v Cluster of differentiation 44 variant 
CD63 Cluster of differentiation 63 
CDA II/ 
HEMPAS 
Congenital dyserythropoietic anemia type II 
CHX Cycloheximide 
cIAP-1 Cellular inhibitor of apoptosis protein-1 
CJD Creuzfeld Jacob Disease 
CLL Chronic Lymphoblastic Leukaemia 
CMV Cytomegalovirus 
CNS Central nervous system 
Co-IP Co-immunoprecipitation 
COX2 Cyclooxygenase 2 
CpG 5'—C—phosphate—G—3' 
CQ Chloroquine 
CRL4(DCAF1) Cullin ring ligase 4 DDB1-CUL4 associated factor 1 
CSC’s Cancer stem cells 
ctm C terminal 
ctrl Control 
DAB Diaminobenzidine 
DAPI 4’,6-diamidino-2-phenylindole, dihydrochloride 
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DMEM Dulbecco’s Modified Eagle Medium 
DNA Deoxyribonucleic acid 
Dpl Prion protein dublet/doppel 
DPX Distyrene, plasticiser, xylene mix 
DTT Dithiothreitol  
ECL Enhanced chemiluminescence 
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
EGFR Epidermal growth factor receptor 
ELISA Enzyme-linked immunosorbent assay 
EMT Epithelial to mesenchymal transition 
ER Endoplasmic reticulum 
ERAD Endoplasmic reticulum associated protein degradation 
ERK Extracellular signalling-related kinase 
ERM Ezrin, radixin, moesin 
FA Focal adhesion 
FAK Focal adhesion kinase 
FBS Foetal Bovine Serum 
FERM 4.1 ezrin, radixin, moesin 
FISH Fluorescent in situ hybridisation 
FFI Fatal Familial Insomnia 
FN Fibronectin 
FOXO3 Forkhead Box O3 
Fv Antibody variable domain  
G5P Gene 5 protein 
GAG Glycosaminoglycan 
GAPDH Glyceradehyde 3-phosphate dehydrogenase 
GBM Glioblastoma Multiforme 
GFM Growth factor medium 
GFP Green fluorescent protein 
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Golgi QC Golgi quality control 
GPI Glysosyl-phosphotidylinositol 
GPI-PSS GPI anchor peptide signalling sequence 
GSS Gerstmann-Sträussler-Scheinker disease 
GTP Guaosine tri-phosphate 
HA Hyaluronan 
HCAM Homing cell adhesion molecule (also known as CD44) 
HGF Hepatocyte growth factor 
HMC Human meningeal cells 
HMM Human malignant mesothelioma 
HRP Horseradish peroxidase 
HSPG Heparin sulphate proteoglycan 
hTERT Human Telomerase Reverse Transcriptase 
IBMX 3-isobutyl-1-methylxanthine 
ICC Immunocytochemistry 
IFU Infectious units 
IHC Immunohistochemistry 
IGF1 Insulin-like growth factor-1 
IGF1R Insulin-like growth factor-1 receptor 
IgG Immunoglobulin G 
IκB 
Nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, alpha 
IκK IκB kinase 
IP Immunoprecipitation 
iPrPC Insoluble cellular prion protein 
JNK c-Jun N-terminal kinase 
Kb/kbp Kilobase/kilobase pairs 
kDa Kilodalton 
KLF4 Kruppel-like factor 4 
LA Laminins 
LAMP1 Lysosomal membrane-associated protein-1 
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LC3 Microtubule-associated protein 1A/1B-light chain 3 
LR/37/67kDa 37/67kDa non-integrin laminin receptor 
LRP Laminin receptor precursor 
LZTR1 Leucine zipper-like trancriptional regulator-1 
mAb Monoclonal antibody 
MAPK Mitogen-activated protein kinase 
MBP Myelin basic protein 
MDR Multi-drug resistance 
MDR1 Multi-drug resistance gene 1 
MEK Mitogen-enhancing kinase 
Merlin Moesin Ezrin Radixin-like protein 
MGr1-Ag MGr1 antigen 
MMP11 Matrix metalloprotease 11 
MN/Men Meningioma 
MOI Measure of infectivity 
MOT Molecular Targets 
mRNA Messenger RNA 
mTOR Mammalian inhibitor of rapamycin 
MTS 
3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt 
NCAM Neuronal cell adhesion molecule 
NF2 Neurofibromatosis Type 2 
NFκB Nuclear factor kappa-light-chain-enhancer of activated B cells 
nt Nucleotide 
ntm N terminal 
nm Nanometre 
O/E Overexpressed/ overexpression 
P75NTR P75 neutrotrophin receptor 
PAK P21-activated kinase 
PARP Poly ADP ribose polymerase 
PBS Phosphate buffered saline 
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PCR Polymerase chain reaction 
PDGFRβ Platelet-derived growth factor receptor β 
PFA Paraformaldehyde 
P-gp p-glycoprotein 
PI3K Phosphatidylinositol 3-kinase 
PI-PLC Phosphatidylinositol phospholipase C 
PK Proteinase K 
PKC Protein kinase C 
PMS Phenazine methosulfate 
PMSF Phenylmethane sulfonyl fluoride 
PNG PNGaseF 
PNS Peripheral nervous system 
PRNP Gene coding for the cellular prion protein 
PRND Gene coding for the cellular prion protein dublet/Doppel 
Pro-PrP Incompletely processed prion protein 
PrPC Cellular Prion Protein 
PrPRes Form of the prion protein resistant to degradation by proteinase K 
PrPSc 
Scrapie form of the prion protein that is responsible for transmission 
of prion disease 
PRT Testes-specific prion protein 
PVDF Polyvinylidene fluoride 
Q-PCR Real-time quantitative PCR 
R&D Research and development 
Rac Ras-related C3 botulinum toxin substrate  
Raf C-Raf Proto-Oncogene, Serine/Threonine Kinase 
REC Research Ethics Committee  
RIPA Radioimmunoprecipitation assay 
RNA Ribonucleic acid 
RNAi RNA interference 
ROS Reactive oxygen species 
RPSA Gene coding for 37/67kDa non-integrin laminin receptor 
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RTK Receptor tyrosine kinase 
scr Scramble gene sequence 
SDS Sodium dodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Sec Secreted 
SEM Standard error of mean 
Sho Shadoo 
shRNA  Short hairpin RNA 
siRNA Short interfering RNA 
SMARCB1 
SW1/SNF-related, matrix associated, actin-dependent regulator of 
chromatin, subfamily B, member 1 
SNP Single nucleotide polymorphism 
Src Proto-oncogene tyrosine-protein kinase Src 
STAT1 Signal transducer and activator of transcription 1 
Sup. Supernatant 
TBS Tris buffered saline 
TBS-T Tris buffered saline with Tween 
TCS Tocris prion inhibitor 13 / TCS prion inhibitor 13 
TM Transmembrane domain 
TNF Tumour necrosis factor 
TRC The RNA consortium 
TRK Tropomyosin kinase 
UPR Unfolded protein response 
VEGFR Vascular endothelial growth factor receptor 
VS Vestibular schwannoma 
WHO World Health Organisation 
wt Wild type 
XIAP X-linked inhibitor of apoptosis protein 
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The following publication has been removed due to copyright restrictions: 
Provenzano. L, Ryan. Y, Hilton. D.A, Lyons-Rimmer. J, Dave. F, Maze. E.A, 
Adams. C.L, Rigby-Jones. R, Ammoun. S, Hanemann. C.O. Cellular Prion 
Protein (PrPC) in the development of Merlin-deficient tumours. 2017. 
Oncogene, 36(44): 6132-6142. DOI: 10.1038/onc.2017.200 
 
 
 
 
 
 
 
